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Abstract
In vitro and in vivo selection of vaccines is time consuming, expensive and the selected vaccines
may not be able to provide protection against broad-spectrum viruses owing to the complexi-
ties of emerging antigenically novel disease strains. A powerful computational model that can
effectively predict antigenically variant strains can minimise the amount of resources spent
on exclusive serological testing of vaccines and make broad spectrum vaccines possible for
many diseases. However, in silico vaccine prediction remains a grand challenge. To address
this challenge, we investigate the use of linear regression, non-linear regression and support
vector machine (SVM) classification models to predict the antigenic similarity between foot-
and-mouth disease virus (FMDV) strains. The parameters of the linear regression model are
estimated using the least squares method and the structure and parameters of the non-linear
model are optimised using a hybrid evolutionary algorithm. We apply semi-supervised classifi-
cation methods i.e. transductive SVM (TSVM) to improve our classification results due to the
availability of limited labelled data. In addition, we examine two different scoring methods for
weighting the type of amino acid substitutions in the classification and regression models in two
different setups i.e. the entire external viral capsid protein or only antigenically important areas
in the capsid proteins are considered.
Statistical analysis of our data confirmed possible correlates of amino acid substitutions in
antigenic areas in capsid proteins of FMDV and influenza. Across all our prediction models, we
achieved the best results when the scoring method based on biochemical properties of amino
acids is employed in combination with regression or classification and models based on substitu-
tions in the antigenic areas performed better than those that took the entire exposed viral capsid
protein. In our regression analysis, the non-linear regression method optimised with the evo-
lutionary algorithm performed consistently better (throughout FMDV and influenza datasets)
than the linear and non-linear models whose parameters are estimated using the least squares
method. In addition, for the best models, optimised non-linear regression models consist of
more terms than their linear counterparts, implying a non-linear nature of influences of amino
acid substitutions. For our classification models we also used Ebola data. Our TSVM models
outperformed our SVM models across all datasets i.e. FMDV, influenza and Ebola, which con-
firmed the benefits of using unlabelled data for boosting generalization performance. However,
including additional antigenic areas in our Ebola TSVM model had no effect on the prediction
ability of the model which we think is because the additional peptides were not biologically
significant in terms of relaying any effect on the antigenic values which we use as our labels.
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Chapter 1
Introduction
1.1 Project Motivation
Vaccines can be effective in preventing viral diseases and improving the health of millions.
However, there are many viral diseases for which vaccine production/deployment is a challenge
because of extensive antigenic variability 1. Infection and/or vaccination by an antigenically-
variable virus does not necessarily confer protection to subsequent exposure of the disease, e.g.,
human immunodeficiency virus (HIV), influenza and foot-and-mouth disease virus (FMDV)
[247]. Hence, upon an outbreak of an antigenically-variable virus, a rapid response to reduce the
spread of the virus is needed. In other words, the rapid selection of the most effective vaccine,
against the particular strain of virus, is imperative. However, the in vitro serological tests that
measure the cross reactivity of vaccines to outbreak-strains are time consuming and expensive.
An in silico predictor that can accurately predict vaccine efficacy would be invaluable.
With the advent of high-throughput sequencing in the late 1990s, it is now possible to obtain
the sequence of a virus a lot more easily and faster than it was in early 1970s when the first DNA
sequence was obtained [272]. The computational exploitation of this sequence information for
vaccine design/selection is therefore attractive. Yet to date, most computational research on vi-
ral vaccines has focussed on developing tools for identifying epitopes 2 [230, 309, 49, 77]. From
our literature search, only three previous studies attempting to predict antigenic variability and
therefore vaccine efficacy, for foot-and-mouth disease and influenza were identified [290, 202].
Foot-and-mouth disease and influenza are both socio-economically important, highly infectious
diseases caused by antigenically-variable viruses. As DNA sequences and associated serologi-
cal test data are available for these viruses, they are obvious candidates for the development of
an in silico vaccine selection predictor.
Thus far, in silico approaches for predicting vaccine efficacy have focussed on the use of
linear and logistic regression3 techniques. Reeve et al. [290] used linear mixed effects models
to relate estimated antigenic differences to sequence variation in FMDV and Liao et al.[202]
1Antigenic variability is the mechanism by which infectious organisms (bacteria, virus or protozoa) alters its
surface protein to evade a host immune system [68]
2Specific areas on antigens that are recognised by antibodies also called epitopes.
3In statistics regression is the process of estimating the relationship between variables.
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used stepwise and logistic regression to predict antigenic variants in influenza). However, as
vaccine efficacy relies on the interaction of amino acid residues within or outside an antigenic
site (loop) [194] that may result in unusual (non-linear) patterns in antigenic distance [191] it
is likely that non-linear models, that can handle complex interdependencies between variables,
will be better suited. Furthermore, as biological data can be noisy and/or viral strains partially
labelled (dataset contains only sequence data but not serological data) [17, 181], a predictor that
can be trained with imperfect data is needed.
1.2 Challenges of Traditional Vaccine Design Process
Vaccine development has played a hugely important role in combating infectious disease. The
successful eradication of smallpox (worldwide cases reduced from 2 million per year in 1959
to zero in 1978) [93], and estimated avoidance of 2.5 million deaths per year from diphtheria,
tetanus, whooping cough and measles through immunization [264], exemplify their power and
significance for global health. Despite this success, there is still a great need for new vaccines
and these are emerging far more slowly than we would wish. Most of our current vaccines were
developed by determining the components that consistently stimulated antibody responses in in-
fected patients, and often without having a very detailed knowledge of the immune mechanisms
required for protection. Even though many of the problems with traditional vaccine design are
gradually being overcome, as new vaccines continue to appear on the market; the scientific and
financial challenges are considerable [383, 384].
There is broad agreement that development of new and effective vaccine products cannot
proceed without a detailed understanding of the immune correlates of protection. This provides
essential information for rational vaccine design, and also guides the parameters to be measured
when evaluating vaccine efficacy [252]. Gathering such data is usually dependent upon having
material from patients, for example those who have recovered from a natural infection, and the
availability of an animal model which responds to the infection and the vaccine formulation in a
very similar manner to humans. Where these are lacking, vaccine development is considerably
more problematic, and this has too often led to disappointing clinical trials results or even
serious safety concerns [296].
The immunodominant antigens recognized, and the mechanisms of protective immunity
exhibited in animal models such as mice, guinea pigs and rabbits, may differ considerably from
humans [69]. A very common model employed in vaccine development is the mouse, yet its
immune system is known to differ quite radically from that of humans [233].
In addition to the physiological differences between animals and humans, the well-controlled
laboratory conditions under which animal studies are conducted represent a potential cause of
disparity when advancing the work to human trials. Several Phase II clinical trials have re-
ported disappointing results, possibly because the vaccine recipients or target population have
a natural tendency for impaired immune responsiveness [69, 307]. For example, this could be
caused by a high prevalence of chronic and/or immunosuppressive infections (e.g. HIV), they
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may be very young or affected by old age, have poor nutrition, suffer from obesity, have pre-
existing immunity to vaccine vectors (such as recombinant adenovirus) or are naturally exposed
to antigenically similar organisms to the target pathogen [298, 244, 92, 161, 158, 315].
The diversity of pathogens, whether based on genotype or phenotype, is astonishing and
poses enormous challenges with respect to treatment and prevention of microbial diseases
[162, 163]. Although the practice of variolation to prevent smallpox dates back many centuries,
vaccines effectively came of age in the late 19th and early 20th centuries, in the golden era of
bacteriology [292, 38]. The germ theory idea that particular species of microbes caused spe-
cific diseases was axiomatic to the successful development of the earliest vaccines, and paved
the way for use of whole organisms (e.g., for pertussis and tuberculosis) or microbial toxins
(e.g., tetanus and diphtheria toxins) to induce protective immunity [38]. For many decades,
microbial diversity did not cause vaccine failure. Early vaccines stood the test of time because
protective immunity was directed to invariant antigens. With the discovery and characterisation
of viruses, such as influenza and poliovirus, the need to consider antigenic variation became
clear [329, 207]. In the early 1950s, Sabin and colleagues [301] showed that immunisation
with each of three distinct variants of poliovirus was needed to induce comprehensive protec-
tion. The antigenic shift and drift of influenza A viruses provided another example of the need
to base effective vaccine strategies on a detailed knowledge of antigenic variation, specifically
the neuraminidase and haemagglutinin antigens [377, 131]. Vaccination against influenza A is
complicated by antigenic variation in the target vaccine antigens [312]. Hence regular changes
in the formulation of the vaccine are needed, but, at any one time-point, few viral variants are
in global circulation so a viable strategy is feasible. The major problem, as recently shown
by the influenza A H1N1 pandemic, is that existing technology to make the vaccine is not fast
enough to keep pace with the rapid spread of a pandemic strain [326, 306]. For many important
pathogens, vaccine development needs to overcome the problem that many of the relevant can-
didate vaccine antigens are present in only a proportion of disease-causing strains of the species
or, because of allelic variation, the chosen antigens induce protective immune responses that
are not cross-protective against all strains [64]. Thus the new generation of vaccines, not only
needs to constantly overcome the challenge of frequently mutating pathogens but also that of
providing multivalent protection against many disease causing strains of a pathogen species.
High costs of vaccine design is another major challenge faced by traditional vaccine devel-
opment processes. Even though the true costs for development of new vaccines are not disclosed
by pharmaceutical companies, common estimates for R&D for a single vaccine are often based
on development costs for new drugs and fall into the 3-5 million range [355] veterinary (re-
viewed by Light et al.[203]). A reason for these high costs that is often given is high failure
rates (it is often cited that only 1 in every 5000-10000 compounds screened is approved by the
FDA). Costs associated with research, development and clinical studies in particular are high,
and the company has to recoup its investment which could have tied up capital for a decade or
more [203]. Thus these high costs of vaccine development result in premature abandonment of
potentially useful products.
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1.3 Advantages of in silico Vaccine Prediction
The integration of computational tools for epitope discovery has enabled the development of
genome-derived vaccines [74, 73, 241]. Compared to conventional strategies, this approach
has the potential to create more effective and safer next-generation vaccines, as carefully se-
lected epitopes focus immune responses on the minimal, essential pathogen-specific antigenic
elements; epitopes directed against conserved “self” (host) antigens are eliminated. This ap-
proach is also well suited to highly variable4 pathogens, as selection of epitopes that are con-
served across multiple strains or subtypes enables development of a broadly applicable, multi-
valent vaccine. The genome-derived vaccine strategy has been applied to a range of pathogens,
including F. tularensis, HIV, Mtb, H. pylori and influenza. These studies demonstrate that
immunoinformatic-predicted epitopes are immunoreactive in vaccinees and survivors of in-
fection, and stimulate de novo protective immune responses in vivo in HLA transgenic mice
[127, 245, 242, 229]. Epitope-driven vaccines offer distinct advantages over traditional subunit
vaccines. Multiple epitopes derived from several antigens can be packaged together. Thus,
a broad-based immune response directed against several different antigenic proteins can be
elicited without manufacturing and administering the entire protein, much of which will be im-
munologically irrelevant. This may reduce formulation challenges, cost, and safety risk. The
use of epitopes also mitigates safety concerns arising from the use of intact recombinant pro-
teins that may have undesired biological activity.
1.4 Challenges of in silico Vaccine Prediction
In spite of the above advantages of in silico prediction, in theory, many practical challenges
exist in the design and deployment of in silico vaccine design. Once a panel of candidate
antigens has been selected by computational prediction, they need to be tested in preclinical
animal models. The challenge here is that for many pathogens the correlates of protection are
not clear. In other words, the animal experiments may not be reliable indicators of protection
in humans, and following wrong or too few metrics, like immunogenicity only, can misguide
antigen selection [218].
Several lines of evidence indicate that most epitopes are conformational [364], and pre-
diction of discontinuous or conformational epitopes presents further challenges as they require
as a prerequisite the antigen structure. Indeed, all discontinuous epitope prediction methods
currently available require the 3D structures of the antigen, which may in some cases be very
difficult or impossible to obtain [388]. Despite continuous incremental advances in computa-
tional tools for the in silico prediction of 3D protein structures [145], the prediction of discon-
tinuous epitopes still preferentially requires the experimental 3D structure to increase reliabil-
ity. Some of the earlier approaches to conformational epitopes prediction used correlations of
known epitopes with crystallographic temperature factors, protrusions from the protein globular
4Antigenic variation is a mechanism by which pathogenic organisms alter their surface proteins in order to
evade host immune response.
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surface, solvent accessibility, and flexibility. Also, both protein-protein binding site prediction
tools [154] and docking algorithms [132] were introduced and tested for epitope prediction.
Pathogen-derived epitopes that are presented to T cells, or T cell epitopes, are linear and pos-
sess distinct signatures, making it possible for computational algorithms to rapidly scan and
identify epitopes in protein sequences. B cell epitopes, in contrast, are considerably more diffi-
cult to predict because they are often non-linear or discontinuous in a protein sequence.
It has been recently estimated that the accuracy of continuous B-cell epitope predictions
methods can reach 60-66% [280]. Importantly, recent computational and experimental valida-
tion of both continuous and discontinuous epitope predictions made with the most well estab-
lished methods currently available show that they all still perform rather poorly [31].
Another challenge of in silico vaccine prediction is its reliance on extensive biological
knowledge of the virus and immunology. Advances in computational prediction is possible
with progress in the understanding of genetic structure and pathogenesis of many infectious
pathogens that are currently not understood very well. Moreover, unlike, physics and chem-
istry, there are few universal models that explain the fundamentals in biology and thus there
are significant ’gaps’ in the knowledge. Physics and chemistry are by no means complete, how-
ever much progression in these fields come from fundamental understanding, from classical and
quantum mechanics, electromagnetism, the structure of the atom, chemical bonds and reaction
conditions. Biology has been hindered by the complexity of the subject and and has been de-
layed by the progression of technology. There has been a significant increase in the amount
of available data due to improvements in experimentation, data collection and technology. One
such advancement has been the availability of next generation sequencing data which has set the
path of data intensive studies based on genetic data. However, computational modelling based
on these large genomic data still need in depth understanding of the biological relationships and
mechanisms that explain such data.
Vaccine informatics still faces many challenges. Although extensive progress has been made
towards the genetic structure and pathogenesis of many infectious pathogens, significant gaps
in our understanding of host-pathogen interactions still remain [332, 273]. These gaps are
attributable to imperfect and non standardized animal models, the absence of precise immuno-
logical correlates of protection, and the prohibitive cost of confirmatory clinical trials. While
many vaccine adverse events are likely genetically determined (and thus predictable), it remains
challenging to predict possible vaccine adverse events with available genotype data and possibly
design personalized vaccine. These challenges will undoubtedly be met with improved ratio-
nal vaccine design and a better understanding of fundamental protective immunity mechanisms
obtained with improving vaccine informatics technologies.
1.5 Main Achievements
This investigation ranges from the study of the fundamental mechanism of a viral pathogen-
esis, traditional vaccine design, statistical analysis of viral antigenicity data to computational
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prediction of cross creativity against a vaccine strain using experimental data.
The main achievements of this research is implementation of linear and non-linear regres-
sion models to improve the prediction accuracy of previously reported in silico models in foot-
and-mouth disease (FMD) and influenza [202, 290]. We also implement a multi-objective op-
timisation approach to improve our results. In addition, to alleviate the problem of limited
labelled data, we implement a semi-supervised classification5 algorithm which was able to out-
perform the best regression model. This demonstrates a significant step forward for prediction
of cross reactivity of a field virus strain 6 against a vaccine strain 7, when conventional labora-
tory generated antigenic data is limited.
1.5.1 Statistical Analysis of Antigenic Data
Here we present the descriptive statistics of our datasets and also the results of statistical analysis
of our viral antigenic data with sequence data.
The foot-and-mouth disease virus (FMDV) datasets were seen to have positively skewed
distributions, positive kurtosis values and small standard deviation values compared to the in-
fluenza datasets which shows better spread of data in the influenza datasets. In addition, we saw
that the FMDV SAT1 datasets had a better representation of data points in the different r1 value
ranges and also exhibited lower intertypic antigenic variation which probably indicate a better
range in the SAT1 data and hence comparatively better modelling results than SAT2 data (refer
to Sections 3.5.1 and 3.5.2 for details).
The results of our correlation analysis showed that antigenic similarity correlated negatively
to the count of amino acid substitutions in epitopes on their capsid proteins for both FMDV and
influenza. Whether we considered the substitutions in the entire capsid protein or only in the
epitopes on the capsid proteins, it made no significant difference to the degree of correlation
that we observed. And also, specific substitutions show no clear correlation with antigenic
similarity probably because we considered substitutions across the viral sequence. The results
of the correlation analysis confirmed that antigenic similarity negatively correlated to amino
acid substitutions in capsid proteins, and thus can be confidently applied as variables for further
modelling work to understand how inter and intratypic genetic variation in virus effect their
cross reactivity (refer to Section 3.5.3 for details).
1.5.2 Regression Analysis for Predicting Viral Antigenicity
In silico approaches for predicting vaccine efficacy have focussed on the use of linear and logis-
tic regression techniques (Reeve et al.[290] used linear mixed effects models to relate estimated
antigenic differences to sequence variation in FMDV and Liao et al.[202] used stepwise and lo-
5In statistics and machine learning, classification is the problem of identifying to which category a new obser-
vation belongs to based on a training set of data.
6In experimental setup, field virus strain is the virus isolate used in neutralisation experiment
7Vaccine strain is the virus strain against which each animal has been previously vaccinated or with which it
has been infected
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gistic regression to predict antigenic variants in influenza). However, as vaccine efficacy relies
on the interaction of amino acid residues within or outside an antigenic site (loop) [194] that
may result in unusual (non-linear) patterns in antigenic distance [191] it is likely that non-linear
models, that can handle complex interdependencies between variables, will be better suited.
We investigate the use of linear and non-linear regression models to predict the antigenic
similarity in foot-and-mouth disease virus strains and in influenza strains (refer to Section 4 for
details). We also present a Genetic Algorithm (GA) optimised quadratic non-linear regression
model that is able to accurately (98 % accuracy) predict the vaccine efficacy for foot-and-mouth
disease virus (FMDV) and influenza A strains taking amino acid sequences as input. We show
that our model is an improvement to the approaches previously taken.
Furthermore, to examine whether there are differences in the influence of amino acid changes
in different capsid proteins on the Virus Neutralisation (VN) titre/Haemagglutination inhibition
(HI) assay value we compare two approaches for calculating amino acid changes, one reporting
the total number of changes across all capsid proteins (three capsid proteins in FMDV and one in
influenza), while the other reporting specific-capsid changes. Finally, we study two methods for
weighting the importance of amino acid changes, one based on the characteristics and structure
of amino acids and the other based on amino acid substitution scores. where the structure and
parameters of the non-linear model are optimised using an evolutionary algorithm. In addition,
we examine two different scoring methods for weighting the type of amino acid substitutions in
the linear and non-linear models.
Our results show that better prediction accuracy is achieved when amino acid changes in
the capsid(s) were treated as different independent variables. Models with substitutions in the
antigenic areas performed better than ones that took the entire exposed viral capsid protein(s)
i.e. only the specific antigenic regions on the capsid protein(s) are most relevant for modelling.
When substitutions in the capsid(s) are summarised, important information for prediction may
be overlooked resulting in poor results.
We found that, of the three scoring methods, the grouping method performed best, which
is probably because the grouping method classifies amino acids based on their biochemical
properties that enhances the models. The non-weighted approach did not perform as well as
the grouping method perhaps because it considers all substitutions regardless of structural rel-
evance, thereby including frequent substitutions of little significance to the model. The predic-
tion power of the scoring method was unexpectedly low which is probably because a significant
amount of biological data was lost when the substitution matrix was normalised to penalise only
the non-frequent substitutions. Overall, the models that combined the scoring method based on
biochemical properties of amino acids with non-linear regression for the specific antigenic areas
on the capsid protein(s) gave best results.
GA is a much more robust optimisation method than least squares method (LSM) as LSM
cannot find the optimal solution of coefficients if the initially guessed solution is not sufficiently
close to the ideal solution (refer to Section 4.3 for details of the GA and the LSM methods).
Hence, GAs are able to work well with noisy biological data, which is reflected in our results
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as the non-linear regression models using the GA performed consistently better than the linear
and the non-linear models whose parameters are estimated using the LSM. We set up the GA
model as a single objective (SO) and a multi-objective (MO) (refer to Section 4.3.2 for more
details of the SO and the MO methods) and got better results (refer to Section ?? for details of
how models were selected) with the two objective set-up rather than the single objective one.
The MO set-up achieves better generalisation than in SO case because of a more diverse search
space.
1.5.3 Classification Models for Vaccine Prediction
Here we define our vaccine prediction problem as a classification problem (refer to Section 5
for details). As prediction of cross reactivity does not need the exact value of the label (anti-
genic value) to be labelled, the above regression problem could be converted to a classification
problem to check for any improvement in results. We retained the same scoring methods and
looped/unlooped variations with the classification models as we did with the regression models
for better comparison and results. We used support vector machines (SVMs) for the super-
vised classification modelling and our results for the grouped looped model was the best of
the variants which confirmed that when we considered antigenic substitutions only in the outer
capsid areas and scored/weighted them based on their biochemical properties, they enhanced
the prediction power of our models.
Serological data is difficult and expensive to obtain and remains a bottleneck in obtaining
robust and accurate classifiers using such data. Our labelled datasets being quite small, we
used available unlabelled data to build a semi-supervised model implementing a transductive
support vector machine (TSVM). An inductive SVM with a small dataset finds it difficult to
create a global model (function) that would be valid for the whole problem space. Thus the
use of additional information in iterative retraining of the TSVM, greatly enhances the model
performance of a TSVM compared to an SVM particularly when labelled data is limited which
is reflected in our results as the TSVM model outperforms the SVM. The SVM models perform
worse than the TSVM models because of the small training data which can result in over-fitting
as model variance has been seen to be inversely proportional to sample size [45].
Our three and five epitope TSVM models perform almost identically, as the substitutions
in the additional two epitopes in the latter model provide no additional information for better
prediction. These two epitopes were seen to be non-binding in in vitro tests even though they
were predicted as antigenically relevant in in silico prediction. Even though the results of TSVM
were promising for Ebola, further in vivo studies in non-human primates are needed to confirm
their ability to confer protection.
1.6 Study Flowchart and Layout of This Report
Fig. 1.1 shows the flowchart of our project, methods and results of which we present in Chapters
3, 4 and 5.
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We begin this report by providing the background information for this entire project in
Chapter 2. We discuss viruses, their structure, mode of infection and the three viruses (FMDV,
influenza and Ebola) that we study in this project in Section 2.1. In Section 2.2 we discuss vac-
cines, their types and the three relevant laboratory procedures that are used to detect antibodies
and we refer to in this report. In Section 2.3 we discuss the various approaches that exist for
vaccine selection including in silico methods. Section 2.4 presents a literature review of all the
current bioinformatics used for epitope prediction. In Section 2.5 we describe the measures of
prediction that we use throughout this report and in Section 2.6 we describe how we constructed
the three scoring methods that we used throughout the project.
In Chapter 3, we present and analyse our data statistically to understand the distribution
and trends present in our data. Section 3.1 to 3.4 introduces, defines and discusses the statistical
analysis in the later sections. In Section 3.5 we discuss the descriptive statistics of our data, what
it says about our data and how it might effect our modelling results in the following chapters. A
significant part of this section is correlation analysis of antigenicity and amino acid substitutions
since this is the relationship that we repeatedly explore through the various modelling methods
in the later chapters.
In Chapter 4, we explore the relationship between antigenic similarity and amino acid sub-
stitutions in sequences by using linear and non-linear regression models. We
describe linear regression, non-linear regression, parameter estimation methods and evolu-
tionary algorithms in Section 4.1 to 4.3. We discuss the experimental setup of this part of the
project in Section 4.4. Here, in addition to our linear and non-linear models using least squares
estimation, we also discuss a hybrid single and multi objective optimisation setup, results of
which we discuss in Section 4.5.
In Chapter 5, we investigate amino acid substitutions in the capsid proteins for correlates
to antigenic data as a classification problem and also use unlabelled data in a semi-supervised
learning algorithm to check for any prediction improvement over our supervised models. In
Section 5.1 we describe Inductive and Transductive SVMs and in the following section we
discuss the experimental setup of this part of the project. Here we compare the results of our su-
pervised and semi-supervised models with each other and also with the best regression model.
In addition, we also explore whether adding extra features, makes any difference to the perfor-
mance.
This report concludes with a discussion of the results obtained in this study and areas for
future work in Chapter 6.
1.7 Publications and Presentations
• Rahman, T. , Mahapatra, M. , Laing, E. , and Jin, Y. , (2015). Evolutionary Non-linear
Modelling for Selecting Vaccines Against Antigenically-variable Viruses. Bioinformat-
ics, 31(6),834-840.
• Rahman, T. , Laing, E. , and Jin, Y. Modelling for Predicting Antigenic Variability in Foot-
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Figure 1.1: Flowchart of our study. The three dashed lined boxes represent the three analysis
chapters while the common methods (connecting them) are represended in solid boxes.
and-Mouth Disease Virus. Presented at: Parallel Problem Solving from Nature Workshop
on Modelling Biological Systems; 2012 Sept 1; Taormina, Italy.
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Chapter 2
Background
2.1 Viruses
Viruses were discovered in the 1890s when a Russian botanist Dmitri Ivanovsky’s article about
a non bacterial pathogen infecting plants [148] led to the discovery of the Tobacco Mosaic Virus
by Martinus Beijerinck in 1892 [26]. Closely following this was the discovery of the FMD virus
by Friedrich Loeffler and Paul Frosch in 1897 [294].
They were called ‘filterable viruses’ due their very small size and their size ranges between
5 and 300 nanometer. Although they are minute organisms they are able to cause a wide range
of illnesses in humans, animals and plants [260]; they may cause milder infections like cold
and/or flu or more severe illnesses like Rabies, Hepatitis, AIDS, etc.
It is debatable whether viruses by themselves are alive [361] since they cannot grow or
multiply on their own. They enter the plant, animal or bacterial cell and take over their cell
machinery to carry out their own life processes. Thus, the infected host cells produce viral
products enabling the viral community to multiply and grow [260]. Even though we often
focus more on the detrimental effects of viruses on other living organisms, it is important to
remember that viruses play a crucial role in balancing nature’s ecosystem by controlling the
number of other microbes [205] and by increasing genetic diversity through horizontal gene
transfer [53].
2.1.1 Viral Structure and Infection
Viruses have evolved many structure based strategies for invading cells. Viruses are either en-
veloped or non-enveloped. Influenza, HIV, rabies, Ebola and Dengue are some of the pathogenic
enveloped viruses that have a major impact on human and animal health. Enveloped viruses
contain the viral genome and the core proteins wrapped within one or more membranes. They
use membrane fusion to penetrate a cell [374]. During the fusion of the viral membrane with the
host cellular membrane, the genome containing viral capsid or core is transferred to the cytosol.
These fusion reactions of enveloped proteins are mediated by specific virally encoded enve-
lope proteins [375]. The following organisation governs the structural transition and stability of
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enveloped viruses and are important concepts for the development of in silico predictors.
1. The outer protein net that has a well-defined structure. These structures have protein units
that maintain connectivity with specific nearest-neighbour units to display the structure
[330]. This suggests a complex combined effect of these interactions on the function of
the protein.
2. A subsystem of genomic RNA or DNA complexed with proteins where the nucleotides
maintain a connectivity between them but lack a well defined structure [393]. These
nucleotides are prone to frequent substitutions which can result in a change in the protein
structure and consequently its function.
Developing a quantitative understanding of enveloped and non-enveloped viruses will help
us understand the structure-function dynamics of their capsid proteins which will be of great
global economic importance. For the purpose of this study, we focus on two enveloped viruses
namely influenza and Ebola and one non-enveloped virus namely foot and mouth disease virus
(FMDV).
Although viruses vary greatly in size and complexity, all species of virus have three common
parts. Figure 2.1 shows the structure of a virus [112, 115].
Figure 2.1: Viral structure. Source: [350].
Nucleic acid forms the core of the virus. It is either DNA or RNA (deoxyribonucleic acid
and ribonucleic acid respectively) but not both and this determines how the virus replicates. The
DNA or RNA is the genetic material and holds all of the necessary information for the virus to
multiply and replicate. Replication for DNA viruses is easier since they can use the host’s RNA
polymerase to make mRNA which is then translated to viral proteins.
Protein capsid encloses the genetic material and thus forms a protective covering over the
nucleic acid. It is made up of one or more protein subunits called protomers which form a
symmetrical crystal structure. Capsids are broadly classified based on their structure which are
mostly helical or icosahedral [119], but can also evolve into unusual shapes like an elongated
icosahedron as in the case of bacteriophages [360]. The helical structure assumes a cylindrical
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shape (example Ebola, influenza, tobacco mosaic virus, etc) while the icosahedral takes the
form of a sphere (example FMDV, bluetongue virus etc) [46]. The capsid may consist of one or
more proteins aligned on them like FMDV has three proteins VP1, VP2 and VP3 [225].
Viral envelope is a coat that covers the capsid. This envelope is generally acquired by
the virus from the host cell and are made up of phospholipids or proteins. The viral envelope
also involve glycoproteins which help the virus to identify and bind to receptor sites on the
host during the process of viral entry and infection [209]. They also help the virus to avoid
the host immune system. Examples of enveloped viruses are herpes simplex, chickenpox virus,
influenza virus, Ebola virus etc. Viruses might not have this coating in which case they are called
naked viruses [320]. Examples of non-enveloped viruses are adeno virus, FMDV, poliovirus etc.
Compared to the non-enveloped viruses, the enveloped viruses have limited survival outside the
host because their lipid bilayer envelope is usually sensitive to external agents and factors such
as heat, detergents and dessication. Thus, they are more easily destroyed by a process such as
sterilisation than non-enveloped viruses. Enveloped viruses try to make up for this by being
very adaptable and being able to change in a short period of time to evade the host immune
system and cause persistent infection [209].
2.1.2 FMDV
FMDV is an aphthovirus of the family Picornviridae and is the etiological agent of the economi-
cally devastating foot-and-mouth disease (FMD) in cloven-hoofed animals. Although mortality
associated with FMD is usually low, it negatively effects livestock productivity and interna-
tional trading of animal and animal products from effected countries is prohibited [85]. Hence,
research into FMDV vaccine production is of economic importance. FMDV exhibits high ge-
netic variability [225] (we also discuss this further when we discuss the structural proteins
below) and moreover traditional vaccine development processes are expensive in terms of time
and costs involved in production. This means that by the time a vaccine is out for circulation,
the strain might have already muted making it hard to predict for long the vaccine would be
effective. This makes FMDV a good candidate for the application of in silico predictors for
vaccine development. Figure 2.2 shows the prevalence of FMDV outbreaks caused by SAT (1,2
and 3) serotypes from 1931 to 2010. As can be seen from the figure, FMD outbreaks in cattle
in southern Africa have increased in frequency since the turn of the 21st Century. In the period
1981-2000 there was a significant decrease in the occurrence of FMD outbreaks in Botswana
and South Africa but in the period 2001-2010 the situation deteriorated significantly. The rea-
sons for this pattern of events are understood to be multifactoral and the details can be found
in the report by Thomson (2012) [344]. This also highlights the need for furthering vaccine
research for FMDV.
The FMDV genome is a single stranded positively charged RNA molecule of about 8500
nucleotides that occurs in seven immunologically distinct serotypes1 namely O, A, C, South
African Territories (SAT)-1, SAT-2, SAT-3, and Asia-1. These are a direct consequence of an
1Serotypes are distinct variations in species of micro-organisms determined by its constituent antigens [222]
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Figure 2.2: Prevalence of FMDV outbreaks caused by SAT (1,2 and 3) serotypes from 1931
to 2010 in three countries (Botswana, Namibia and South Africa) of Africa as obtained from
[344].
observed lack of cross-protection between vaccination or infection [85]. Of the seven serotypes,
SAT types 1, 2 and 3 exhibit greatest intra-typic variations [362, 363, 305]. Figure 2.3 shows
a neighbour joining phenetic2 tree of SAT1, SAT2 and SAT3 whole genome sequences while
Figure 2.4 shows a maximum likelihood phylogenetic3 tree of the SAT1 and SAT2 sequences
that have been included in this study. The highly variable nature of SAT type viruses (the intra
and inter typic variations of SAT viruses both phynotypically and genotypically can be seen in
the two types of trees) requires the development of broad-spectrum vaccines and the ability to
accurately test cross-reactivity as currently determined through in vitro or in vivo approaches.
Structural Proteins Involved In Viral Antigenicity: Antigenic diversity is a direct con-
sequence of genetic variations. Studies on genetic variability of FMDV have reported 33%
intra-serotypic and 53% inter-serotypic variability in its antigenically important external cap-
sid proteins VP1, VP2 and VP3 [174, 290]. The outer capsid proteins VP1, VP2 and VP3
(see Figure 2.5) are directly involved in antigenicity and a large proportion of residues are ex-
posed on the virion surface. Amongst the exposed residues are epitopes recognised by the
host immune system. All serotypes are believed to share the major antigenic site on the flex-
ible G-H loop (antigenic area in a capsid protein) of the VP1 protein, which is seen to be
highly variable between even closely related strains [223]. While this is the only site that
has been identified in serological tests for SAT1, none have been identified for SAT2 yet
[66] even though at least four others have been serologically mapped for type O, A and C
[300, 341, 303, 226, 189, 40, 22, 172, 65, 18]. There are three further loops (HI and CT loops
in VP1 and BC loop in VP2) reported in SAT1 and SAT2 through in silico predictions [290]
that have not yet been identified serologically but we have considered in this study to check for
correlates with antigenicity. Figure 2.5 shows the capsid and their antigenic regions (loops).
2In biology, phenetics is the study of classification of organisms based on their overall morphological and
observable characteristics without taking into consideration their evolutionary relation.
3In biology, phylogenetics is the study of evolutionary relationships and history of organisms.
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Figure 2.3: A Neighbour-joining tree showing the classification of SAT1, SAT2 and SAT3
isolates from different regions (indicated by eastern, western and southern) of South Africa
based on overall morphological traits. The numbers on the inner side of the nodes represent
a topotype of the serotype. All sequences were obtained from NCBI http://www.ncbi.
nlm.nih.gov/gquery/gquery.fcgi for multiple alignments and the phylogenetic tree
was generated by the ClustalW algorithm in Mega version 7.0. Bootstrapping values on a 1000
replicates are indicated at the nodes. Scale bar indicates a 5% amino acid change.
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Figure 2.4: A maximum likelihood tree showing the phylogenetic distance between SAT1 and
SAT2 sequences that are used in this study. All sequences were obtained from NCBI http:
//www.ncbi.nlm.nih.gov/gquery/gquery.fcgi for multiple alignments and the
maximum likelihood tree was generated by the ClustalW algorithm in Mega version 7.0. The
numbers on the branches indicate the branch lengths.
2.1.3 Influenza
Influenza viruses belong to the family Orthomyxoviridae [182] that cause zoonotic infectious
diseases in birds and mammals. The symptoms can range from mild to severe. The most
common symptoms of the disease are chills, fever, sore throat, muscle pains, severe headache,
coughing, weakness/fatigue and general discomfort [108]. There are three types of influenza
virus (A,B and C) distinguishable on the basis of antigenic differences between their matrix and
nucleoproteins (M and NP). It is difficult to distinguish influenza A and B viruses by electron
microscopy, there are differences. Influenza B virions have four proteins in the envelope i.e.
HA, NA, NB and BM2. Like the M2 protein of Influenza A virus, the BM2 protein is a proton
channel that is essential for the uncoating process. The NB protein is an ion channel but is not
required for viral replication in cell culture. The influenza C segment contains seven RNAs
while the influenza A and B segments contain eight RNAs. Influenza A, B and C viruses also
differ with respect to host range, variability of the surface glycoproteins, genome organization
and morphology [182]. Out of the three types only A and B are human pathogens. The influenza
A viruses are responsible for pandemic outbreaks of influenza and for most of the well-known
annual flu epidemics [385]. Although influenza pandemics are rare [208], the virus has caused
yearly epidemics resulting in severe illness in three to five million and about 500,000 deaths
worldwide[263]. Severe cases resulting in deaths mostly occurs in the young, the old and those
with other underlying health problems [263]. While pandemics are not frequent, three influenza
pandemics, each resulting in more than a million fatalities have occurred in the 20th century;
Spanish influenza in 1918, Asian influenza in 1958, and Hong Kong influenza in 1968 [170].
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Figure 2.5: The FMDV capsid and antigenic sites (loops). (A) FMDV viral capsid. A pentamer
is magnified showing the relative positions of the three structural proteins VP1, VP2 and VP3
which are partially exposed to the virion surface (Adapted from [1]). (B) A linear representation
(not drawn to scale) of VP2, VP3 and VP1 in the FMDV genome showing the antigenic areas
(we refer to them as loops here) BC, GH and C terminus. The BC loop is magnified to show its
amino acid sequence.
Influenza is an enveloped negatively charged, single stranded RNA virus. The influenza
virion (the infectious particle) is roughly spherical consisting an outer layer i.e a lipid membrane
which is taken from the host cell in which the virus multiplies. The spikes in the lipid membrane
are made of glycoproteins, which are proteins linked to sugars known as HA (hemagglutinin)
and NA (neuraminidase) [380]. HA and NA proteins induces protective antibody response and
influenza A is subtyped based on these antibody responses while B viruses are currently only
categorised into two genetic lineages but not subtyped[103].
The yearly influenza epidemics and occasional pandemics of influenza respiratory disease
are as a result of their extreme genetic and antigenic diversity [325]. Several wild avian species
are the natural reservoirs of the influenza A viruses where they are at evolutionary equilib-
rium, but occasionally viruses or viral genes get transferred from their natural reservoir to mu-
tate/evolve into new influenza virus strains which results in the infection of mammals, including
humans [144, 371, 164]. All three influenza pandemics that occurred in the 20th century and
killed millions of people, were caused by the appearance of a new strain of the type A virus in
humans [266]. Sometimes, the infection in human can also be caused when an existing human
strain picks up new genes from a virus that usually infects birds or pigs.
The influenza A/H5N1 avian flu strain that emerged in Asia in 1990s raised concerns of
a new influenza pandemic, even though it has not evolved to a form that spreads easily be-
tween people. The "swine flu" (also known as influenza A/H1N1) pandemic of April 2009 that
emerged in Mexico, the United States, and several other nations was caused by a novel flu strain
that evolved through acquiring genes from human, pig, and bird flu [168].
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Extreme genetic diversity caused by mutations in the genetic code of the influenza virus
makes it a huge challenge to design vaccines that are broad spectrum as well as those that
would provide protection against quickly evolving virus strains. Influenza A/H1N1, A/H3N2
and B viruses have been in circulation in the world since 1977. Current vaccines contain these
three strains but it wouldn’t for example protect against the influenza A/H5N1 strain if it did
spread in humans. An in silico predictor of vaccines would be a quick and efficient way in
checking the efficacy of an existing vaccine against a newly evolved strain and as well as in the
design of new broad spectrum vaccines.
Figure 2.6 shows the incidence of influenza A and B cases in Simcoe Muskoka, Ontario
from 2006-2015. We can see from the figure that the number of cases of influenza A and B
have been on the rise in the last two to three years. We can also see that it is influenza A which
have resulted in the majority of the influenza cases. Due to the social and cultural impacts of the
influenza virus, this is another virus that we considered for our in silico prediction of vaccines
although all the analyses in this work will be limited only to influenza A viruses.
Figure 2.6: Number of influenza A and B cases in Simcoe Muskoka, Ontario from 2006-
2015 as obtained from http://www.simcoemuskokahealthstats.org/topics/
infectious-diseases.
Structural Proteins Involved In Viral Antigenicity: HA protein contains three identical
subunits each containing two chains of HA1 and HA2 of which HA1 mutates more frequently
[50]. Accumulation of mutations on HA protein give rise to immunogenically distinct strains
which are produced continuously. The HA1 polypeptide mutates more frequently than the
HA2 polypeptide and plays a major role in natural selection [379, 382]. Figure 2.7 shows a
phylogenetic tree of all subtypes of hemagglutinin (HA) of influenza A and influenza B viruses.
We can see from the figure that there is a huge amount of genetic diversity even within the type
A of influenza virus due to accumulation of mutations on the HA protein. Figure 2.8 shows the
phylogenetic tree of hemagglutinin (HA) of H3N2 sequences that are used in this study. Even
within H3N2 we can see a large amount of genetic diversity and can see how new strains of
the virus have evolved geographically over decades (most new strains that emerge in various
parts of the world within a period on one to two years are clustered together in the tree) by
accumulating mutations or acquiring genes from other strains.
Even though NA also undergoes rapid substitutions, it is not considered an antigenic deter-
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Figure 2.7: Phylogenetic tree of all subtypes of hemagglutinin (HA) of influenza A and in-
fluenza B viruses. The scale bar represents a 10% amino acid change, and the bootstrap values
for 100 replicates are given at each node. Details of the methods of tree generation can be found
in Jang and Lin (2014) [151].
minant due to its relatively small occurrence on the surface [275].
Currently used inactivated vaccines provide essential protection when the vaccine antigens
and the field viruses (a viral strain that is circulating in a population) share high degree of sim-
ilarity in the HA protein. Frequent accumulation of point mutations (i.e. antigenic drift) in the
HA protein results in the emergence of antigenic variants of the virus and thus influenza vac-
cine antigens need to be updated frequently, based on the results of global influenza surveillance
[134], which includes clinical, virologic, and immunologic surveillance. An in silico vaccine
predictor will greatly enhance the speed of at which vaccines are updated.
The three-dimensional structure of the HA protein of A/Aichi/2/68 (H3N2) proposes five
antigenic sites on the HA1 polypeptide [379, 382, 169] but the importance of these amino
acid positions in terms of antibody cross-reactivity is still unclear. These five positions were
effectively used by Lee and Chen[191] for predicting antigenic variants of influenza A/H3N2
viruses and obtained the best results compared to four other models that were in their study. Of
the 329 amino acid positions on HA1, 131 lie on or near the five antigenic sites [50, 214]. In
the further sections of this work we look at the effect of substitutions in these regions on the
antigenicity of the virus.
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Figure 2.8: Maximum Likelihood tree of hemagglutinin (HA) of influenza A H3N2 that are
used in this study. The rooted phylogenetic tree was generated based on a full-length amino
acid sequence comparison of hemagglutinin (HA) of the influenza A viruses. All sequences
were obtained from Influenza Virus Resource of NCBI http://www.ncbi.nlm.nih.
gov/gquery/gquery.fcgi for multiple alignments using ClustalW and the maximum
likelihood tree was generated in Mega version 7.0. The scale bar represents a 2% amino acid
change.
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2.1.4 Ebola
Genus Ebolavirus, family Filoviridae has five viral species [180] of which four species Zaire
Ebolavirus (ZEBOV), Sudan Ebolavirus (SEBOV), TaÃ¯ Forest Ebolavirus formerly CÃ´te
d’Ivoire Ebolavirus (TAFV) and Bundibugyo Ebolavirus (BEBOV) cause the Ebola hemor-
rhagic fever in humans and other primates. In large outbreaks due to ZEBOV, SEBOV and
BEBOV, case fatalities have ranged from 32 − 90% [101, 51, 107, 167, 111, 120, 365, 215].
The fifth species Reston Ebola virus (REBOV) causes severe disease in non-human primates
[239, 136, 110] and can infect swine [20]. Figure 2.9 shows the number of fatalities caused by
Ebola Zaire, Sudan and Bundibugyo between 1976 and 2014. As we can see from the figure,
the number of fatalities in the latest outbreak (2014) has been by far the largest in the last four
decades. And we can also see that Zaire Ebolavirus strains were the causative agents in majority
of the outbreaks.
Figure 2.9: Number of death by classification (in order they are Ebola Zaire, Sudan, Bundibu-
gyo) by year and ordered from most impacted to least impacted year. Due to the severity of
the latest outbreak in 2014, it has been shown separately. Source: http://www.who.int/
csr/disease/Ebola/situation-reports/archive/en/.
Results of earlier attempts to develop protective EBOV vaccines in guinea pigs and non-
human primates have been inconsistent [212, 237]. No human disease has been associated
with REBOV species even though human infection with the species has been documented
[20, 240, 109]. Even though the severe pathogenic disease caused by the different species
in humans and non-human primates are very similar, there is 30 − 45% nucleotide differences
in their genomic sequences [347, 155]. Figure 2.10 shows a neighbour joining tree of 60 Zaire
Ebolavirus genomes. We can see from the figure that the viral stains that caused outbreaks in
certain periods of time are genetically quite different from those that caused an outbreak at an-
other time. This again implies that the strains accumulate mutations and/or gather genes from
other strains before they cause an outbreak again. Due to these extreme (and not yet well under-
stood) genetic variations and the socio-economic impact of Ebola, it is another good candidate
for in silico vaccine prediction.
The Ebola virus (EBOV) contains a linear, single-stranded, negative-sense RNA genome. It
encodes seven structural proteins and a non-structural protein. Structural proteins are nucleo-
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Figure 2.10: A neighbour joining tree of 60 Zaire Ebolavirus genomes. The tree shows a
model rooted by a clade of the 1976 outbreaks. The asterisk identifies a clade of 1994-1996
isolates from Gabon. All sequences were obtained from NCBI http://www.ncbi.nlm.
nih.gov/gquery/gquery.fcgi for multiple alignments and the tree was generated by
the ClustalW algorithm in Mega version 7.0. The bootstrap values for 1000 replicates are given
at each node.
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protein (NP), polymerase cofactor (VP35), (VP40), glycoprotein (GP), transcription activator
(VP30), VP24, and RNA polymerase (L). It is an enveloped virus with a lipid bilayer and with
anchored GP forming the viral spikes on the surface [190]. Figure 2.11 shows the arrangement
of the seven structural proteins in the Ebola genome.
Figure 2.11: Arrangement of the seven structural proteins in the Ebola genome.
Structural Proteins Involved In Viral Antigenicity:
Most studies of EBOV epitopes have been on mice [370]. Despite the encouraging results
of the these studies aimed at developing candidate EBOV vaccines, none of the strategies that
protected mice or guinea pigs from lethal infection with this virus have been shown to provide
similar protection in nonhuman primates [118]. Sullivan et al. [333] reported the development
of an accelerated vaccine for Ebola where a single immunization with adenoviral (ADV) vectors
encoding the Ebola GP and NP was able to induce highly effective protection against lethal
challenge in non-human primates. Warfield et al. [370] described the production of virus-like
particles (VLPs) of Ebola by coexpressing GP and VP40 proteins. Mice vaccinated with Ebola
VLPs developed virus-specific antibodies including neutralizing antibodies and these mice were
100% protected against lethal field virus strain. While these investigations provide insights into
the genetic markers of EBOV that stimulate murine effector T cell activation in the context of
specific MHC4 haplotypes, the information derived from such studies may not be applicable
to human MHC determinants. Sundar, et al. used a combination of computational prediction
methods together with in vitro and in vivo assays to identify three human HLA-A2.1-restricted
CTL (Cytotoxic T lymphocytes) 5 epitopes for the nucleoprotein of EBOV. They were able to
predict five MHC class I-binding NP peptides within the structural proteins of EBOV, namely,
FLS, RLM, KLT, AMN and YQG (first three letters of the peptides that were nine amino acids
long) [337]. These EBOV-NP peptides induced CTL responses in HLA-A2-transgenic mice and
hence these could be useful in the development of protective immunogens for this hemorrhagic
virus. In the absence of any confirmed epitopes for vaccine production in Ebola, we look at
these five epitopes, to check for any correlates with antigenicity.
4The major histocompatibility complex (MHC) is a set of cell surface proteins essential for acquired immune
system to recognize foreign molecules in vertebrates, which in turn determines histocompatibility. The main
function of MHC molecules is to bind to peptide fragments derived from pathogens and display them on the cell
surface for recognition by the appropriate T-cells. [150]
5Cytotoxic T lymphocytes are lymphocytes that kill other “target” cells. Targets may be virus-infected cells,
cells infected with intracellular bacterial or protozoal parasites, allografts such as transplanted kidney, heart, lungs,
etc. and cancer cells.
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2.2 Control of Viruses
The spread of viral diseases has been greatly altered by the introduction of vaccines. Vaccination
is one of the most effective tools for controlling infectious diseases. Many viral vaccines have
been very successful, particularly the smallpox vaccine, as a result of which the disease has been
completely eradicated since 1980s [27]. However, several challenges exist for viral vaccine
design. Some viruses in circulation are less understood than others while a bigger problem
being that newer strains of viruses constantly emerge [188].
2.2.1 Vaccines
The word ‘vaccine’ is derived from the term ‘vaccination’ (root Latin word vacca meaning
cow) which was used by the English physician Edward Jenner in 1796 while performing the
first successful vaccination against a disease(smallpox) using cowpox virus.
A vaccine is a biological preparation intended to provide immunity to a host against a partic-
ular disease by causing the host to produce antibodies against that disease. Vaccines typically
include suspensions of killed or attenuated forms of the microbe, its products or derivatives.
The microbial agents introduced triggers the host immune system to produce antibodies which
destroys the foreign bodies. Antibodies form an immunological memory, meaning that the
pathogen can be recognised and eliminated by the host immune system if encountered in the
future.
Vaccines can be either used to prevent (prophylactic) or to cure (therapeutic) a disease
caused by a micro-organism. While all vaccines that are currently available in the market are
preventative vaccines, there are considerable research ongoing to find therapeutic vaccines for
diseases like cancer [231] and AIDS [251]. They are the second most effective agents (after
safe water) in reducing mortality and boosting population growth [262]. However, the efficacy
of a vaccine is dependent on various factors:
• Adherence to the vaccination schedule.
• Some vaccine strains are more effective than others for a given disease.
• Some individual hosts do not generate antibodies for certain vaccines even after being
vaccinated correctly. Some of the causes for such non-response could be age, ethnicity or
genetic disposition [258].
Types of viral vaccines: Vaccines are dead or inactivated micro-organisms or purified prod-
ucts derived from them. Different strategies are used during vaccine production to minimise
the risk of illness whilst maintaining the vaccine’s ability to induce the necessary immune re-
sponse [258]. Below are listed the types of vaccines for viral infections.
Attenuated: These vaccines contain live but reduced virulence microbes. Most attenuated
vaccines are viral although some may be bacterial. These may be live viruses whose virulent
properties have been disabled by certain conditions induced during its culture [23]. In many
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cases, less virulent strains may also be used to induce a wider immune response. Attenuated
vaccines are the preferred choice as they provide more prolonged protection due to their capac-
ity for transient growth and thus no booster vaccines are required. However, there can also be
disadvantages too whereby they can revert to their virulent form and cause the disease. Exam-
ples of some attenuated viral vaccines are for yellow fever, measles, rubella, influenza (oral)
and mumps [278].
Inactivated: These vaccines contain previously virulent microbes that have been killed us-
ing antibiotics, heat or other chemicals. These vaccines are much more stable and safer than the
attenuated vaccines as they cannot mutate back to a disease-causing state [23]. Although inac-
tivated vaccines are safe, they stimulate a weaker immune system response than the attenuated
vaccines. Hence, several additional doses or booster shots maybe needed to provide continuous
protection to an individual. This could be a major disadvantage in areas where people do not
have the required access to health care which might result in not getting booster shots on time
[323]. Rabies vaccine, FMDV vaccine and hepatitis A vaccine are some examples of viral killed
vaccines.
Subunit: These vaccines only contain a part of the pathogen that they protect against rather
than an inactivated or attenuated whole micro-organism. These vaccines use a piece of the target
pathogen (for example a protein subunit) to induce the immune response of the host [323].
Subunit vaccines can be produced using genetic engineering. This is achieved by introduc-
ing a gene encoding for a vaccine protein into another virus or culture, so that when the carrier
reproduces or the culture grows, the vaccine protein is also produced. This is a recombinant
vaccine and will be recognised by the immune system. These vaccines are safe and stable as
they no have live components but the immune response may be weaker than live attenuated
vaccines as the combination of antigenic properties that are used in the vaccine is very impor-
tant to produce an effective immune response with the correct pathway. Moreover, an immune
response may be elicited, but there is no guarantee that memory will be formed for future re-
sponses. For example, the Hepatitis B vaccine is a recombinant vaccine in the United States
and the influenza vaccine (injection) are recombinant subunit vaccines [277].
As seen above, for the three viruses that we use in our study (FMDV, influenza and Ebola)
either inactivated or subunit vaccines are used and they have their disadvantages. While they are
both safe and stable to use, they may for different reasons stimulate a weak immune system re-
sponse. In the case of inactivated vaccines which use killed antigens, the immune response may
not be for long enough needing several doses of vaccine while in the case of subunit vaccines
which use purified antigens, the immune response depends on the combination of antigenic
properties that are used to produce the vaccine. To develop both types of vaccines, there is
a need for identification of the antigenically most relevant epitopes which is time consuming
and can be a real deterrent in efficient vaccine development specially when the viruses show
extreme genetic variability.
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2.2.2 Laboratory Procedures for Detecting Antibodies
Determination of the virus type/subtype/serotype involved in field outbreaks has to be estab-
lished before within laboratories to permit proper control/ vaccination programs to be followed.
Various techniques have been used to diagnose viral disease and to ascertain the serotype of
the virus. These techniques are used for identification and screening of relevant antigens which
is the first stage of pre-clinical development of vaccines followed by creation of the vaccine
concept i.e. the mode or type of vaccine that is used to deliver the protection (discussed in the
previous section) in the next stage. Below we discuss three methods that are used for identifica-
tion of antibodies in FMDV (Virus Neutralisation Test), influenza (Hemagglutination Inhibition
Test) and Ebola (Enzyme Linked ImmunoSorbant Assay) since they will be referred to in the
following chapters.
2.2.2.1 Virus Neutralisation Test (VNT)
Neutralisation of a virus is defined as the loss of infectivity through reaction of the virus with
specific antibody. Virus and serum are mixed under appropriate conditions and then inocu-
lated into cell culture, eggs or animals. The presence of unneutralised virus may be detected
by reactions such as cytopathic effect (CPE 6),haemadsorption/haemagglutination (refer to Sec-
tion 2.2.2.2 for details), plaque formation or disease in animals. The VNT is carried out as a
two dimensional checkerboard titration in microtitre plates as described previously by Booth
et al. [42]. This test uses an antiserum raised against a vaccine strain. The titres of this serum
against a 50% tissue culture infective dose (100 TCID50) of the homologous vaccine strain and
the same dose of a field isolate are compared to determine how antigenically ‘similar’ the field
virus is to the vaccine strain, where similarity leads to neutralisation.
The procedure is as follows:
1. The viral field isolates are grown on cell cultures until adapted to give 100% CPE in
24 hours. Once adapted, the virus titre (log10 TCID50/ml) is determined by end-point
titration.
2. A chequerboard titration [358] of virus against vaccine serum and along with a back-
titration of virus alone is performed. Cells are added and incubated at 37◦C for 2-3 days
after which they are assessed for CPE.
3. At each virus dose tested the corresponding antibody titres of the vaccine serum against
the vaccine strain is determined by the method of Spearman-Karber [238]. Regression is
then used to estimate the titre of the vaccine serum against each virus. The relationship
between the field isolate and the vaccine strain is then expressed as an r1 value as:
r1 =
reciprocal arithmetic titre of reference serum against field virus
reciprocal arithmetic titre of reference serum against vaccine virus
6The degeneration of cells which may be as a result to viral infection [247]
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The reference serum in the above equation is a standard bovine serum (for details refer
to the OIE “Manual of standards for diagnostic tests & vaccines” [94]). An r1 value is
accepted only after achieving at least two consistent results.
4. Interpretation of the results: r1 values between 0.4 and 1.0 are indicative of reasonable
levels of cross protection, whilst values below 0.2 indicate the need for a new vaccine for
the isolated field virus [305]. A value of 0.3 has also been proposed as a conservative
threshold [19] indicating the need for a new vaccine for a value below that.
5. The number of times that the examination is repeated [299] decides the confidence with
which r1 values can be taken to indicate the antigenic relationship between strains. And
thus these tests are repeated at least three times.
2.2.2.2 Hemagglutination Inhibition Test (HIT)
The nucleic acids of various viruses encode surface proteins that agglutinate the red blood cells
(RBC) of a variety of species. For example; influenza virus particles have an envelope protein
called the hemagglutinin, or HA, which binds to erythrocytes , causing the formation of a lattice.
This property is called hemagglutination. Hemagglutination (HAI) assay apply the process of
hemagglutination reaction of viral hemagglutinins with the sialic acid receptors on the surface
of RBCs results in a lattice of agglutinated cells which settle irregularly in a tube or microtiter
well. Unagglutinated cells settle in a compact button.
The basis of the HAI assay is that antibodies to that particular virus (for example-influenza
virus) will prevent attachment of the virus to RBC. Therefore hemagglutination is inhibited
when antibodies are present.
The procedure is as follows [376]:
1. RBCs from an appropriate species (Chicken, goose, guinea pig, etc.) is collected in Al-
sever’s solution or heparin solution.
2. Diluent (e.g. bovine albumin veronal buffer) at appropriate pH, solutions to remove non-
specific hemagglutinins from serum and infected cultural fluid or standard antigen (e.g
preparation of influenza virus) for serology are also needed.
3. A preparation of virus (e.g. influenza viruses) with known HA titer or its HA titer is
obtained.
4. Two-fold dilutions (e.g. from 1:4 to 1:1024) of patient/test serum are prepared for testing.
5. A fixed amount of virus is added to every well of a 96-well plate, equivalent to 4 HA units
(varies according to virus), except for the serum control wells.
6. The plate is then allowed to stand at room temperature for 60 minutes (time varies ac-
cording to specific requirements).
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7. RBCs are added and incubated at 40◦C for 30 minutes.
8. The wells are then read (for details of how the wells are read, refer to Grimes [128]).
The highest dilution of serum antibody that prevents hemagglutination is called the HAI
titer of the serum. A smooth or jagged shield of cells or an irregular button indicates
agglutination.
9. If the serum contains no antibodies that react with virus, then hemagglutination will be
observed in all wells. Likewise, if antibodies to the virus are present, hemagglutination
will not be observed until the antibodies are sufficiently diluted.
2.2.2.3 Enzyme Linked ImmunoSorbant Assay (ELISA for Ebola)
The purpose of an ELISA is to determine if a particular antibody (or protein) is present in
a sample and if so, how much. ELISAs are performed in 96-well plates which permits high
throughput results. To obtain the elisa values for the Ebola dataset used this study, the following
method was used [337]:
1. The bottom of each well is coated with one of the six structural proteins to which the
primary antibody (HLA-A2) to be measured will bind.
2. TAP-deficient T2 cells expressing HLA-A2 were supplemented with 20% fetal bovine
serum.
3. The serum is incubated in wells, and each well contains a different serum. A positive
control serum and a negative control serum were included among all the samples being
tested.
4. After some time, the serum is removed and weakly adherent antibodies are washed off
with a series of phosphate buffered saline rinses.
5. To detect the bound antibodies, a secondary antibody (HLA-A2.1) was added to each
well. The secondary antibody binds to the primary antibodies and and in this case was
produced in a six to eight week old transgenic mice. Attached to the secondary antibody
is an enzyme such as peroxidase or alkaline phosphatase. These enzymes can metabolize
colorless substrates (sometimes called chromagens) into coloured products.
6. After incubating the wells overnight at 37 degree centigrade, the secondary antibody so-
lution is removed and loosely adherent ones are washed off with serum-free medium and
then incubated with individual peptides at 37 degree centigrade for 18 hours.
7. The final step is the addition the enzyme substrate and the production of coloured product
in wells with secondary antibodies bound.
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8. When the enzyme reaction is complete, the entire plate is placed into a plate reader and
the optical density (i.e. the amount of coloured product) is determined for each well. The
amount of color produced is proportional to the amount of primary antibody bound to the
proteins on the bottom of the wells.
9. The HLA-A2.1 epitope comprising of the peptide GILGFVFTL derived from influenza
matrix antigen, was used as a positive control [234] and the HLA-A2.1 nonbinder com-
prising of the peptide IAGNSAYEY was used as a negative control [37].
2.3 Selection of Vaccines
Conventional methods of vaccine selection are time consuming and have failed to provide a
solution for many pathogens. Availability of genome sequencing data has enabled the use of
genetic information for vaccine development in silico.
2.3.1 Experimental Approach
The conventional method of vaccine selection comprises of growing the pathogen in laboratory
conditions, dissecting them into individual components and then testing the components for
ability to induce immunity. Once the suitable antigen is identified it is produced on a large scale
and often the gene encoding the antigen is cloned for better characterisation and identification
of the antigen(s). The vaccine then enters vaccine development [288].
The disadvantages of this approach are:
• It is very time consuming (5-15 years)[342].
• Limits identification of antigens only to those that can be purified in quantities essential
for testing.
• Antigens expressed during infection in vivo are not expressed in the culture environment.
• Fail to provide a vaccine for those pathogens that did not have easily identifiable immun-
odominant antigens.
• Non-cultivable micro-organisms are completely omitted from vaccine development.
2.3.2 Computational Approach
The rapid growth in high-throughput technologies and the availability of complete genome se-
quences has led to the rise in new vaccine development techniques. Pan-genomic reverse vac-
cinology, has increased the chances of identifying novel vaccines by enabling sequence com-
parison of multiple isolates of the same species of a pathogen. These recent developments in
genomics will provide a unique opportunity for combining in silico procedures of sequence
analysis (genome mining) and the knowledge from structural and functional genomics to aid
vaccine design.
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2.3.2.1 The Genomics Effect
Through genome mining it is now possible to predict genes encoding potentially pathogenic
substances. This is done by sequence comparison of an unknown gene with that of a gene which
is present in a database and whose functions are already known. Combining comparative and
experimental knowledge from genome mining with reverse vaccinology, will provide a quick
and attractive means of identifying conserved putative antigens. In addition, the development
of postgenomic approaches has also aided new vaccine design by its discovery factors leading
to pathogenesis.
The rapid increase in the availability of genomic data has also driven comparative genomics
studies in the inter and intra species level providing new opportunities and insights for biological
prediction [392, 117]. Comparison of genome sequences of closely related pathogenic and
non-pathogenic microbes using bioinformatics and microarray technology are being used for
identifying virulence determinants, vaccine candidates and drug targets [16].
2.3.2.2 Reverse Vaccinology
‘Reverse vaccinology’ is an in silico vaccine selection method that uses the genome sequence
of a pathogen of interest to start the process of antigen identification rather than the pathogen
cell itself. Obtained results are subsequently confirmed by experimental biology [288]. The
aim of this gene mining technique is to computationally identify genes potentially encoding
pathogenic factors or other associated proteins.
The advantages of this approach are:
• The micro-organisms do not need to be cultivated.
• The only requirement for this approach is a computer. It happens in in silico and so there
is no requirement of a laboratory setup.
• Dangerous pathogens can be studied without being physically exposed to them.
• Applicable to cultivable as well as non-cultivable micro-organisms.
• In the presence of high throughput data and techniques, all genes of a pathogen genome
can be tested without any bias.
• Allows the identification of all antigens whether or not they have been discovered by
conventional methods although those computationally identified antigens will need to
verified in the laboratory before they can be become candidates for a vaccine.
Table 2.1 compares the two approaches. However, there are a few limitations too, as follows:
• Since the process starts by looking at all possible protein antigens, a vital question that
remains unanswered is whether any of the potential antigens can induce immunity without
knowing whether the antigen is abundant, immunogenic during infection or expressed in
vitro.
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Table 2.1: Comparison of conventional and reverse vaccinology approach to vaccine selec-
tion [206].
Conventional vaccinology Reverse vaccinology
Essential features Essential features
Cultivable microorganism Cultivable and non-cultivable microorganisms
Most abundant antigens purifyable All antigens identifiable
Antigens expressed in vitro Antigens expressed in vitro and in vivo
Based on structural proteins microorganisms Non structural proteins searchable
Animal models essential Animal models essential
Correlates of protection useful Correlates of protection very important
High throughput expression/analysis important
Non-protein components may be used as antigens Non protein antigens cannot be used
Antigens which are not immunogenic during infection
can be identified
Takes 5-15 years Takes 1-2 years
• Cannot identify non-protein antigens which are important components of many successful
vaccines.
Pizza and coworkers in collaboration with The Institute for Genomic Research (TIGR) first
reported a successful application of the reverse vaccinology approach [274, 340]. They reported
the identification of vaccine candidates against a sepsis and meningitis causing pathogen, Neis-
seria meningitidis serogroup B. Empirical approaches to vaccine identification for this serotype
had repeatedly failed as the capsular polysaccharide used to make conjugate vaccines against
other serotypes induced a poor immune response as they resembled components of the human
tissue [293]. In addition, conjugate vaccines being based on variable antigens do not provide a
wide spectrum protection.
Some viruses, like the human immunodeficiency virus (HIV), are difficult candidates for ef-
fective vaccine development due to the high antigenic diversity of the pathogen. Computational
methods are being used to develop polyvalent (contains antibodies for more than one pathogen)
vaccines by identifying sequences encoding short peptides representing the antigenic diversity
using a mining approach [104].
2.3.3 Reverse Vaccinology for Viruses
Even though virus genomes have been available to vaccine developers for many decades, the re-
verse vaccinology approach was applied to virus genomes later than bacteria and other pathogens
[288]. Conventional vaccine development approaches work on the assumption that only struc-
tural proteins like the capsid and core proteins confer protective immunity. And when reverse
vaccinology was applied to available virus genomes, this assumption still stood true. As a re-
sult, even though new virus genomes were available, the vaccine candidates that were tested
were ones that were already identified using conventional methods.
Reeve et al. have used a linear mixed effects approach [389] to identify antigenically sig-
nificant areas in the exposed part of the FMDV capsid discussed more in depth later [290].
Although these epitopes were not previously discovered by conventional matching methods,
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the above study focussed their search only on the exposed structural proteins. Similar studies
on influenza viruses have identified potential immunodominant positions in the haemagglutinin
(HA) surface proteins [192].
In the case of HIV vaccine research, a couple of decades were spent expressing the en-
velope proteins like gp120, gp140, gp160 and gp55 which had already been identified by the
conventional methods. It was as recent as 1999 when genome analysis revealed that there might
be potential antigens which are either not a part of the final viral particle or are in such low
quantities that they cannot be purified and identified by conventional approaches. The promis-
ing results achieved with non-structural antigens like Tat, Rev, Nef and Pol [270, 52, 265] has
opened up the opportunity for many more vaccine search possibilities for viruses with reverse
vaccinology.
As we can see, epitopes identified by reverse vaccinology need to be subsequently verified
by conventional vaccinology and often these conventional method are time consuming which is
costly in terms of funding and also when it comes to the implications it has on public health.
One way to approach this problem could be to use another in silico predictor to verify the results
of one in silico predictor as there is a wide range of mathematical and statistical methods to
choose from. Thus in this approach we are not computationally predicting epitopes, but we are
verifying potential epitopes by modelling correlated of biologically relevant information that we
mine from these epitopes with laboratory generated data of antibody reaction tests that would
have been used in the identification of the epitopes. This also has the advantage of being able to
build potentially better predictors. In silico prediction can exploit a certain training method or
algorithm that has been seen to improve a certain problem. For example, application of semi-
supervised learning methods when training data, to improve the performance of the predictor.
In this project, we have focussed on those aspects of in silico prediction i.e. verifying potential
epitopes and implementing new modelling approaches to improve the current models. So far,
we havent come across any work that has focussed on in silico prediction to verify potential
epitopes and use the approaches that we have to improve existing in silico predictors.
2.4 Bioinformatics Tools Currently Used for Epitope Predic-
tion
The ’omics’ technologies that explore the functions, interactions and relationships of various
molecules making up an organism, produce a wealth of data to contribute to vaccine develop-
ment. With high throughput data comes a need for bioinformatics tools to analyse and interpret.
It has identified nucleotide sequences from which all protein products can potentially be de-
rived. Although this information is extensively used in functional genomics7, it might not be
enough to allow for the identification of the subset of proteins that are expressed at any particu-
lar stage of the life of an organism and in this case, the pathogen. Proteomics plays an important
7A field of molecular biology that makes use of data produced by DNA/RNA sequencing projects to annotate
functions and interactions of genes and proteins.
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role in this field as it can apply genomic based approaches to immunomics techniques to iden-
tify and characterize immunogenic proteins. Vaccinomics is to do with characterization of host
response to immunization and this information is invaluable in studying pathogen-host cell in-
teraction to validate candidate antigens. Advances and research in these fields also facilitate the
identification and characterization of new antigens [2]. advances in bacterial proteomics which
have been verified with data obtained from genome sequencing and bioinformatics analyses
have lead to the discovery of new proteins, which could be potential candidates for future vac-
cines [2, 173, 99]. Adamczyk-Poplawska has published a comprehensive review on the impact
of proteomics on the development of antibacterial and antiviral vaccines [2]. In the following
sections we present currently used bioinformatics tools for prediction of viral epitopes although
these tools are not enough for detailed analysis of whole genomes. Immunoinformatics which
has evolved from application of genomics to immunology studies, applies computational and
mathematical approaches on large-scale immunological data, organises them to obtain immuno-
logically meaningful interpretations [48, 178]. These tools are based on statistical and machine
learning methods and models antigen interactions along with proposing hypotheses that can
help us understand mechanisms of the host immune system [346, 345]. This review gives a
summary of some of the immunological tools currently available for genomes analyses, and
provides an outlook on how these tools have been used for prediction of epitopes.
Based on Vaccine Prediction: Epitopes are vital for vaccine design, disease prevention,
diagnosis, and treatment. Hence, they are of great interest to both the fields of biomedical
and clinical research. Even though specific epitopes can be produced using rDNA technolo-
gies, which can replace the whole pathogen in a vaccine, not all of the epitopes8 identified,
even those that seem to be highly immuno dominant, are guaranteed to exhibit the ability to
elicit antibody production [254, 13, 334]. rDNA technologies using entire genomes in addition
to producing particular immunogens has made possible the production of chimeric 9 proteins.
This enables exploring a number of possibilities for immunogen application in vaccine design
such as the conception of multiepitopic vaccines which will have advantages such as several
immunoprotective epitopes included in a single molecule, non-protective epitopes even though
immunodominant are discarded, and epitopes such as T cell epitopes will be included to en-
hance immunogenicity [4]. Design of such multiepitopic vaccines could offer the possibility of
multitarget, highly efficient vaccines being a reality. However design of such a vaccine requires
the discovery of the immunoprotective epitopes, that would guarantee protection even when ge-
netic variability is of relevance for a particular pathogen. A large amount of research effort has
gone into epitope-driven vaccine research in variable or rapidly mutating pathogens and have
been successful in identifying immunodominant epitopes [147, 121]. Our approach of in silico
verification of these potential epitopes and use of various machine learning techniques predic-
tions of previous predictors is a new direction in in silico vaccine prediction and will contribute
to this effort where conventional verification of epitopes is time consuming and serological data
8Part of an antigen that is recognised by the immune system and hence to which an antibody attaches.
9A genetic chimerism or chimera is a single organism composed of cells from different zygotes. This can result
in male and female organs, two blood types, or subtle variations in form.
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are limited [284]. For a selected epitope to be used in a vaccine to provide protection against
wild type strains of the pathogen, it should be conserved across different stages of the pathogen’s
life cycle, its variants and it should elicit the desired immune response. In the case of cytotoxic
T cell-mediated response which is elicited by a pathway comprising intracellular antigen pro-
cessing with linear epitopes as predominant targets [334], the selected epitopes for a vaccine
must be able to bind to more than one major histocompatibility complex (MHC) allele covering
a large population [105, 204]. These proteins containing many epitopes that bind to common
MHC alleles and hence are recognized by them are known as promiscuous binders [204]. The
human leukocyte antigen (HLA) supertype is a set of HLA alleles with overlapping peptide
binding regions and these alleles represent the same epitope which indicates to a region on the
surface of an antigen that is capable of eliciting a T cell mediated immune response [105, 282].
In the case of humoral immunity, recognition of linear and conformational epitopes is neces-
sary for the elucidation of the immune response, which presents as an obstacle for chimeric
vaccine design as the epitopes must retain their native conformation to be successful as a func-
tional candidate [357]. Thus, to design a rational vaccine design that targets conformational B
cells requires knowledge of the whole antigen structure [282] where bioinformatics methods
can contribute to the design of such epitope derived vaccines. Many of these tools summarised
below have successfully accomplished selecting epitopes computationally [137, 76].
Tools that predict potential epitopes for T cell mediated immunity
Differentiating epitopes that are potentially immunoprotective from non-immunodominant
epitopes is the starting point of bioinformatics application in vaccine development. In T-cell
mediated immunity, the connection between ligands and T-cells can be accurately modelled as
T-cell epitopes and MHCs form a linear ligand [82]. This linear linkage is seen as, epitopes
using interactions between their R group side chains and pockets located on the floor of the
MHC to bind to MHC Class I and Class II molecules [397, 100, 295]. This knowledge has been
used to design a large number of T-cell epitope identifying algorithms to build tools to identify
potential T-cell epitopes [82, 228, 75]. The current MHC-I binding predictors have a predic-
tion accuracy in the range of 90-95% positive prediction value [137, 143, 211]. RANKPEP,
predicts peptide binders to MHC-I and MHC-II molecules from protein sequences or sequence
alignments using Position Specific Scoring Matrices (PSSMs). It offers users the widest allelic
coverage to MHC-I (118) and MHC-II alleles (67) for human and mouse. PSSMs uses a dy-
namic algorithm implemented in Python; that scores all protein segments based on the PSSM
width before sorting them.
The IEDB Analysis Resource database which uses NetMHCpan [143] as prediction method
generates a mapping of HLA-A and HLA-B for humans as well as non-human primates, mouse,
pig and cow and is one of the few databases that include such a variety of organisms for
reference[143]. nHLAPred also covers MHC-I binding peptides for 67 MHC alleles and uses
Artificial Neural Networks (ANNs)10 to predict the alleles. It uses proteasomal matrices to scan
the predicted MHC binders to identify potential CTL epitopes. The server offers two options,
10An ANN is an information processing model containing an interconnected group of nodes inspired by the way
the brain/nervous system process information.
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ANNPred and Compred, the first uses ANNs to predict binding of peptides to a number of dif-
ferent HLA alleles the latter uses a hybrid of artificial neural networks and quantitative matrices
[36]. The ANNs have been trained for 78 different human MHC (HLA) alleles representing all
12 HLA-A and B Supertypes. It also provides predictions for 41 other animals [211].
Kernel-based Inter-allele peptide binding prediction SyStem (KISS) uses a support vector
machine (SVM) (refer to Section 5.1.1 for details.) multitask Kernel to predict whether 9-mer
peptides will bind an MHC-I molecule for 64 alleles. The SVM improves the accuracy of iden-
tifying alleles with few known epitopes by using available allele wide training information. It
uses epitopes from databases SYFPEITHI, MHCBN, LANL, and IEDB for training the pre-
dictor. Among all servers that provide predictors to identify MHC-I binding epitopes, KISS
provides the most complete allelic coverage in terms of identifying alleles in other organisms
other than humans [149].
MHC-I restricted antigen processing is associated with a class of transporters called TAP.
The transporter is composed of two proteins named TAP-1 and TAP-2. The subset of this trans-
ported peptide binds to MHC-I molecules and these complexes are loaded on the surface of
antigen presenting cells (APCs), which might trigger a T cell immune response [183, 140].
TAPPred predicts peptides that have a binding affinity toward the TAP transporter. These pep-
tides are crucial in identifying the MHC-I restricted T cell epitopes. This online tool uses a
cascade SVM, using sequence and properties of the amino acids [186, 271, 35].
EpiJen server predicts TAP binding peptides and also provides a proteasome cut off. It is
based on the assumption that each substituent independently contributes to a biological activity
and uses this information in an additive method. They factor in the interaction between specific
amino acids and the binding site for additive method [88].
The Whole Antigen Processing Pathway (WAPP) server provides a tool for predicting pro-
teosomal cleavage and MHC-peptide binding. They use a weighted matrix that is constructed
from sequences around experimental cleavage sites, while TAP affinity is predicted using a
regression based SVMs [87]. It was seen that predictions of the MHC class I pathway were im-
proved by the by integrated approach used for predicting proteasomal cleavage, TAP transport
efficiency, and MHC class I binding affinity [331, 185].
Even though historically, good performance results have been achieved for predicting MHC-
I epitopes, tools designed to predict MHC-II epitopes have had limited success [366, 125] due
to poor quality of training data, difficulty on identifying 9-mer binding regions within training
peptides and the limited permissiveness of the binding groove of MHC-II molecules which
limits binding [137, 366].
ProPred1 is a server that uses quantitative matrices to predict MHC Class-II binding regions.
It locates promiscuous binding regions to select vaccine candidates covering 51 alleles [322].
The SVMHC can predict both MHC class I and MHC class II11 binding peptides. The user can
11MHC class I molecules are present on the surface of all nucleated cells and they mainly interact with cytotic T
cells to signal when the cell is under attack and hence clearance of andogenous antigens. MHC class II molecules
are present on the surface of antigen presenting cells such as macrophages, B cells etc and mainly interact with
helper T cells to destroy exogenous antigens. [150]
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also visualise the promiscuous epitopes in the graphical output provided by this software. The
software uses the matrices developed by the TEPITOPE software [87].
The MHC2Pred used an SVM for predicting promiscuous MHC-II binder and average ac-
curacy of SVM based method for 42 alleles was reported as 80%. The relatively smaller size of
the dataset meant poor performance for few alleles. This server finds uses in cellular immunol-
ogy, vaccine design, immunodiagnostics and immunotherapeutics [322].
CTLPred and NetCTLPan are servers that predict CTL epitopes, that are crucial in subunit
vaccine design. CTLPred uses ANNs and SVM to predict the T cell epitope patterns and pro-
vides consensus and combined prediction based on these two methods [34]. NetCTLpan server
uses ANNs to predict CTL epitopes in protein sequences. The method has been updated to
include the newest MHC allele releases for non-human primates and pig.
The epitope discovery tools described above can be applied to most pathogens, although
certain approaches are more suitable than others depending on their characteristics and limita-
tions. These predictions are indicators of a potential epitope but is not a guarantee of a vaccine
candidate. Consequently these kind of in silico analyses need to be backed up by experimental
data for validation of the predictions.
Tools that predict potential epitopes for B cell mediated immunity
B cell epitopes are recognised by B cell antibodies and hence in principle prediction of B cell
is very similar to prediction of T cell. Like T cell prediction, continuous B cell predictions have
also been based on the amino acid properties such as hydrophilicity, charge, exposed surface
area and secondary structure while a 3D structure of the antigen is required for discontinuous B
cell epitope prediction [336, 126].
The Bcepred tool predicts linear B cell epitopes and uses physicochemical properties such
as hydrophilicity, flexibility and polarity on a non-redundant dataset. The prediction accuracy
of this tool has been reported to be between 52.92% and 57.53% [388].
The ABCpred server, is based on neural networks and has slightly better estimated accuracy
of 65.93% [336]. Another server, BepiPred uses a hybrid of Hidden Markov Models (HMM)
and a propensity scale method to predict the location of linear B-cell epitope[302].
Below, we list some tools used to predict discontinuous B cell epitope. DiscoTope, uses
three dimensional protein structure to determinate the surface accessibility and an amino acid
score for epitope propensity. This server also predicts multiple chain epitopes[184].
SEPPA, scores each residue in the query protein based on the information from residues in
its vicinity. The residue with the highest probability of being involved in an epitope is assigned
the higher score [335].
The ElliPro server predicts linear and discontinuous epitopes based on a protein antigen’s
3-D structure (from a protein sequence unlike the above two that require a 3D structure of
the antigen). ElliPro defines a PI (Protrusion Index) value which is a score that it assigns to
a predicted epitopes. A 3-D structure is predicted for the input protein sequence by homol-
ogy modelling based and then linear and discontinuous epitopes are computed based on the
predicted protein structure [279].
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These tools provide an opportunity for development of new vaccines special those that aim
at the elicitation of humoral responses, but the predictions results still do need to be verified
by other methods (eg. further in silico or serological experiments). Hence, our work takes on
a new approach of in silicoverification of potential epitopes in FMDV and influenza and also
uses a novel evolutionary optimised algorithm to build a vaccine predictor that improves the
results of previous predictors [284]. In this project, we also further that work by exploring other
supervised and semi-supervised machine learning techniques.
2.5 Statistical Methods Used For Testing Models
We have used the following methods to evaluate the performance of our models in this work.
2.5.1 Hypothesis Testing and Types of Error
We have used hypothesis testing to compare our various classification and regression models.
We also use hypothesis testing and the types of error to optimise our regression models. While
we will present the details of the specific hypotheses and the error calculations in the model
setup and results sections, here we present some background information for those sections.
A hypothesis test is a statistical test that is used to determine whether there is enough ev-
idence in a sample of data to infer that a certain condition is true for the entire population. A
hypothesis test examines two opposing hypotheses about a population; the null hypothesis and
the alternative hypothesis.
Null hypothesis (H0): The null hypothesis is the statement being tested. It is often an
initial claim that researchers specify using previous research or knowledge. Usually the null
hypothesis is a statement of “no effect” or “no difference”.
Alternative Hypothesis (H1): The alternative hypothesis states that the population parame-
ter is different than the value of the population parameter in the null hypothesis. The alternative
hypothesis is what one might believe to be true or hope to prove true.
While doing a hypothesis test, two types of errors are possible: type I and type II. The risks
of these two errors are inversely related and determined by the level of significance and the
power for the test. Therefore, depending on the specific problem/situation, one type of error
would have a more severe consequences than the other.
No hypothesis test is 100% certain. Because the test is based on probabilities, there is always
a chance of drawing an incorrect conclusion.
Type I error: When the null hypothesis is true and the null hypothesis is rejected, a type I
error is committed. The probability of making a type I error is α, which is the level of signifi-
cance of the hypothesis test. An α of 0.05 indicates that one is willing to accept a 5% chance
that one is wrong when the null hypothesis is rejected. This risk can be reduced by using a
lower value for α . However, using a lower value for alpha means that the test will be less likely
to detect a true difference if one exists.
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Type II error: When the null hypothesis is false and is not rejected, a type II error is
committed. The probability of making a type II error is β, which depends on the power of the
test. The risk of committing a type II error is decreased by ensuring that test has enough power.
This is done by ensuring that the sample size is large enough to detect a practical differences
that exists.
The probability of rejecting the null hypothesis when it is false is equal to 1− β. This value
is called the power of the test.
Below is a representation of our problem case in terms of hypothesis testing and Figure 2.12
presents the two error scenarios.
H0: The vaccine strain is not antigenically similar enough to the field virus strain and hence
the vaccine will not work against the viral strain.
H1: The vaccine strain and the field virus strain are antigenically similar enough for the
vaccine to work against the viral strain.
Figure 2.12: Hypothesis Test for Vaccine Selection.
If U, σU , PU is the probability space, where U ⊆ Rn is the set of elementary events, σU is
the sigma measurable subsets in U , and PU is a probability measure of σU . If we assume that the
measure PU plays a role of vacuous information about the experiment and can be chosen. If we
describe it with a random variable ρ : U → R and corresponding probability measure Pρ with a
density function pρ : U → [0,∞. Thus the probability of any A ∈ σU can be computed by the
formula Pρ(A) =
∫
A
pρ(u)du. For any random variable ρ, the values of typical and non-typical
one are divided using the set of typical events Bρ ∈ σu. This separation heuristically can be
described by the following postulates:
1. Let pρ(u1) > pρ(u2) for u1,u2 ∈ U , then u1 is more typical than u2.
Since the proceeded experiment changes the probability distribution over the U , the re-
gions with a high degree of outcomes, tend to contain a lot of posterior probability. In
this case the following should be true:
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2. The value of PU(Bρ) should be close to 0.
3. The value of Pρ(Bρ) should be close to 1.
To formalise the above, consider an arbitrary elementary event u ∈ U . If we introduce a pair
of hypothesis that are collectively exhaustive, the null hypothesis H0 states that the elementary
event u is typical for the random variable ρ,
H0 = U ∈ Bρ (2.1)
The alternative hypothesis H1 says the opposite, i.e, u is not typical for the random variable
ρ
H1 = U /∈ Bρ (2.2)
If X is a random variable such that its probability density function depends on the choice
between the hypotheses H0 and H1, i.e. pX(u;H0) 6= pX(u;H1).
If we consider postulate I, the optimal statistical criterion to classify elementary events
should have the critical region
Sρ,y = u ∈ U |Pρ(u) < y (2.3)
where y ≥ 0 is the parameter.
If the probability of type I error is α(y) and the probability of type II error is β(y), for the
parametrised criterion with the critical space Sρ,y:
α(y; ρ,X) =
∫
Sρ,y
pX(u;H0)du, (2.4)
β(y; ρ,X) =
∫
U\Sρ,y
pX(u;H1)du, (2.5)
Postulate II can be formalised as the minimisation of the following function∫
U\Sρ,y
dPU → miny (2.6)
and postulate III can be formalised as the minimisation of the following function∫
Sρ,y
dPρ → miny (2.7)
If pX(u;H0) = pρ(u) then Eq. 2.7 minimises the probability of type I error α(y). Analo-
gously, if pX(u;H0)du = dPU , then Eq. 2.6 minimises the probability of type II error β(y).
Thus, the null H0 and alternative H1 hypothesis are presented. The critical region for the
optimal statistical criterion to check the main hypothesis belongs to the parametrised family Eq.
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2.4. The optimal criterion should minimise probabilities of type I and type II errors that can be
presented as the system of conditions
{
α(y; ρ) =
∫
Sρ,y
dPρ → miny,
β(y; ρ) =
∫
U\Sρ,y dPU → miny.
(2.8)
2.5.2 Measures of Prediction Accuracy
Throughout this work different techniques are used to assess the accuracy of any procedures
undertaken; in this section the definitions and calculations are described. These simple matrices
are widely used in bioinformatics to assess the merits of different approaches to the prediction
of discrete states of biological phenomena, such as secondary structure states of amino acids in
proteins [60]. The prediction assessments covered in this thesis are briefly presented here in the
context of vaccine prediction.
First, it is important to define what true positives (TP), true negatives (TN), false positives
(FP) and false negatives (FN) are with regards to this project. Predictions of antigenicity (pres-
ence or absence) are made by either noting whether the predicted output variables/labels match
the actual VNT, HI or Elisa value (refer to Section 2.2.2.1 for details). The substitutions in
various chosen antigenic loops (refer to Sections 4.5.1 and 5.3.1 for details) are used as input
variables/features along with serologically obtained VNT, HI or Elisa values to construct regres-
sion and classification models. A predicted output variable/label can then be compared with the
actual labels and can then be classified as TP, TN, FP or FN, such that:
1. TP: If a viral strain is known to be antigenically similar enough (positive example) to the
vaccine strain (hence the vaccine will work against the viral strain) and correctly predicted
to be antigenically similar as the vaccine strain.
2. TN: If a viral strain is known to be antigenically not similar enough (negative example) to
the vaccine strain (hence the vaccine will not work against the viral strain) and correctly
predicted to be antigenically not similar as the vaccine strain.
3. FP: If a viral strain is known to be antigenically not similar enough (negative example) to
the vaccine strain (hence the vaccine will not work against the viral strain) and incorrectly
predicted to be antigenically similar as the vaccine strain.
4. FN: If a viral strain is known to be antigenically similar enough (positive example) to
the vaccine strain (hence the vaccine will work against the viral strain) and incorrectly
predicted to be antigenically similar as the vaccine strain.
From the total number of TPs, FPs, FNs and TNs, it is then possible to calculate the sensi-
tivity and specificity of a model by : Sensitivity=TP/(TP+FN) and Specificity=TN/(TN+FP).
The accuracy of prediction of a model is given by: Accuracy=((TP+TN)/(TP+TN+FP+FN)).
And Error Rate is given by: Error Rate=1-Accuracy.
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Thus, models that had a better trade off between sensitivity and specificity (both high with-
out compromising on the score of either) along with high model accuracy compared to the others
were considered better performers and hence were the ones selected over the less performing
ones.
2.6 Scoring Methods
Previous studies on FMDV have been based on the raw counts of amino acid changes between
sequences [290]. In this study, we have introduced a weighting method to score the type of
amino acid changes taking into consideration their polarity, structure and side chain charge.
The 20 amino acids were divided into seven groups, namely, non-polar aliphatic, non-polar
aromatic, polar, positively charged and negatively charged. Cysteine and Glycine were placed
separately due to their ability to form disulfite bridges12 [98]. Details of the members in each
group are listed in Table 2.2.
Table 2.2: Grouping of amino acids
Group No. Properties amino acids
1 Non-polar aliphatic A,G,I,L,M,V
2 Non-polar aromatic F,W,Y
3 Polar N,Q,S,T
4 Positively charged H,K,R
5 Negatively charged D,E
6 C
7 G
Using this scoring approach based on the groups, substitutions between groups are assigned
‘1’ and within a group are assigned ‘0’. The additive value of all these substitutions is taken as
the score for a particular antigenic area or the capsid region.
The other scoring approach employs the PAM-12013 matrix that is a 20 by 20 matrix of the
20 amino acids, where each element of the matrix is the probability at which one amino acid is
substituted by another [72]. We chose a PAM-120 rather a PAM-250 since FMDV sequences
are quite closely related within serotyes [174]. The matrix was modified by setting the diagonal
values to ‘0’ so that identical amino acids in the two sequences are not scored. The positive
values were changed to zero and the negative values to positive so that frequently occurring
substitutions are not scored while the rare substitutions are scored. In addition, all elements
in the matrix were normalised between ‘0’ and ‘0.5’. The scores using this approach were
12A disulfite bond is a covalent bond between two thiol (an organic sulfur compound that contains a carbon
bonded sulfhydryl (-C-SH or R-SH) group) groups [68].
13Point accepted mutation (PAM) matrices were introduced by Margaret Dayhoff in 1978 to score sequence
alignments based on 1572 observed mutations in 71 families of closely related proteins [72]. For example the
sequences in PAM-120 matrix have undergone 120 mutation events for every 100 amino acids, although only 80
out of the 100 amino acids are affected. Thus, higher the suffix of the PAM matrix, greater is the evolutionary
distance between the sequences
41
calculated by totalling the values of all elements corresponding to substitutions between pairs
of sequences.
For simplicity we will refer to the models obtained by the former scoring approach to
grouped models and the latter as scored models in the rest of this document.
2.7 Discussion
Bioinformatics tools have enabled the capability of selecting potential epitopes without running
the risks involved in cultivating the pathogen of interest. These techniques present considerable
advantages such as faster output and lower cost over conventional vaccine design techniques.
The application of ‘omics’ technologies to this field has also revolutionized the way in which
potential vaccine candidates can be identified. Proteomics and transcriptomics have been used
as complementary approaches to genomics and are often more useful in identifying surface
proteins during host-pathogen interaction. Despite that numerous epitope prediction methods
are available, developing a systematic assessment of different methods on standard benchmark
datasets is still needed. It is necessary to develop standardized data representations that will
enable the evaluation of different prediction methods on a standardized benchmark dataset in
order to compare the methods and develop the predictions of multiple prediction tools.
Underperformance (even the best set of parameters performed only marginally better than
than random) of in silico epitope prediction was identified in a number of reports [39]. The
appropriate combination of several algorithms, and critical evaluation of the information gen-
erated, are essential for the successful selection of antigenic epitopes. Therefore vaccinologists
should be aware of the fact that outputs are highly dependent on the criteria used for tool se-
lection. This fact highlights the complexity of the task and motivates the development of more
sophisticated and specific tools to improve performance. The MHC-II prediction tools did not
perform as well as noted for class I predictions, which can be due to the fact that MHC-II
requires a highly specific match.
In conclusion, the extensive research accomplished on developing tools useful on vaccine
rational design are considerable but further improvements in in silico analysis along with ex-
perimental evaluations will be critical to advance the vaccine development field to eventually
introduce to the market new vaccines derived from these technologies, especially for highly
variable viral pathogens.
From the previous sections it is clear that an approach that incorporates both experimental
(serological vaccine detection) data and sequence information is needed to further understand-
ing of identification and selection of viable epitopes (from the large pool of epitopes identified
using current bioinformatics tools) for vaccine design. This project hopes to contribute towards
filling that gap in the current in silico vaccine research initiatives.
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Chapter 3
Statistical Analysis of Data
3.1 Introduction
The word ‘statistics’ has been derived from the Latin word ‘status’. In the singular form i.e.
‘statistic’ it is used to denote a collection, classification, presentation, analysis, comparison,
a meaningful interpretation of a feature of ‘raw data’. In its plural form i.e. ‘statistics’ it
is used to describe a set of numerical figures called ‘data’ that can be obtained by counting,
or, measurement of ‘raw data’. Different authors have defined it in different ways. Croxton
and Cowdon (1939) defined it as ‘the science which deals with the collection, analysis and
interpretation of numerical data’ [67] According to Dodge (2006), statistics is to do with “all
aspects of data including the planning of data collection in terms of the design of surveys and
experiments” [84]. Some consider statistics to be a mathematical body of science that pertains
to the collection, analysis, interpretation or explanation, and presentation of data [281] or as
a branch of mathematics[378], while some consider it to be a distinct mathematical science
[243, 55].
When statistics is applied to a financial, scientific or social problem, it usually starts by
applying a statistical model to a statistical population and populations can be diverse entities
like the citizens of a country or all genes in a genome. Statistical data related to a problem helps
us to understand the problem. For example, in economics it helps us understand disparities of
income and wealth, national income accounts, supply and demand curves, inflation, deflation,
living and whole sale price index numbers, production, consumption, etc. In whatever field they
are applied, they can help formulate theories and test old hypotheses. It also helps in planning,
forecasting and hence is regularly applied to prediction and extrapolation of data whether it is
in forecasting weather, stock market trends or geographical disease models.
3.2 Statistics and Biology
Statistics plays a major role in biology. It is often used to express relations that describe corre-
lations between a cause and effect in a biological model or system. For example, the effect of
a drug on a medical condition, the health implications of personal habits, population genetics,
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enzyme kinetics, etc. However, knowledge of causality (what results from what) is a different
study which requires studying the mechanisms of the underlying properties and is not the result
of this numerical analysis/description.
If we consider to ask whether biology is a statistical science, we have to first understand
the underlying mechanisms of a biological system. Living systems behave very differently
from inanimate objects and while science describes the state and behaviour of systems, Er-
win Schroedinger has outlined the difference by asking the question “What physical principles
govern the stability of biological systems?”. He describes the behaviour of a large number of
inanimate objects in terms of similar atoms such as temperature of a gas or liquid using laws
of physics, while he says that biological systems are composed of small numbers of rather dis-
similar atoms whose behaviour cannot be described statistically [311]. At an organism level,
biological systems follow non-random patterns and can be described using statistical methods
such as kinetics and thermodynamics [232]. However, at the molecular level, the randomness
or lack of pattern in many of the biological behaviours is still not well understood. These ran-
dom events while forming a major part of biological functions also provides the opportunity for
applying mathematical tools like statistics to understand them better.
When we apply statistics to biology it is perhaps also important to understand another differ-
ence between biological and other physical/chemical systems. Physics and chemistry, are dis-
ciplines that have a strong foundation in statistics and defines systems as being in equilibrium.
Biological systems on the other hand are made of cells that are never in chemical equilibrium,
or at least not in the way that physics or chemistry defines a system, i.e. a state that follows
statistical laws, with average and variation that are well characterized. Their functions can be
explained in terms of their cells, which are more complex in their behaviour than particles of
non-living matter.
However, formal study of biology is a statistical science as much of what is known in modern
biology has been obtained through statistical analysis by studying biological systems under
much simplified conditions. While this approach is powerful in extrapolating and estimation,
its ability to explain biological mechanisms is limited. For example, biochemical pathways like
glycolysis have been studied experimentally by isolating the components and then replicating
each individual step to study the chemical equilibrium in diluted solution. Hence, formal study
of biology is a statistical science as it relies on large numbers, millions and billions of units in a
population to explain how a single molecule in our collective aggregate behaves in average.
Knowing how to distinguish between the average behaviour of a population (of molecules)
and the behaviour of a specific individual (molecule) is very important while studying mecha-
nisms of a biological system. The behaviour or the random effect of a small molecule or a very
small number of molecules can effect the outcome of a whole process or reaction. Thus, we
cannot always consider the average behaviour of many small biological units as being represen-
tative of a unit behaviour [21].
Biological systems are truly dynamic systems. And with the availability of computational
tools that are becoming ever more sophisticated, biologists are entering this world where com-
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plex molecular interactions and numbers together bring to us a better understanding of the world
that we live in. And with advances in computer science, even though these biological interac-
tions that were not possible to observe before, can now be simulated and studied. In this chapter
we aim to mine some those biologically relevant information from our datasets of sequence and
serological data to understand and facilitate the process of building in silico vaccine predictors.
3.3 Data Analysis
Two main statistical methodologies exist in data analysis; exploratory methods and inferential
statistics.
Exploratory analyses are also called “descriptive analyses”. Their objectives are to sim-
plify and clarify a situation or pattern not known, summarize the information contained in the
data and make apparent the relationships between variables. Examples are mean, median, stan-
dard deviation, etc. They are expressed mostly graphically through histograms, correlation
plots, factorial maps, etc. Thus exploratory statistics describe patterns or typologies. They do
not assume any distribution among variables and they do not allow numerical testing of hy-
potheses.
Inferential analyses, on the contrary, aim at predicting rules based on existing data, i.e. to
infer from the sample to the population. Generally speaking inferential methods consist in quan-
tifying a dependent variable as a function of driving independent variables. It draws conclusions
from data that are subject to random variation such as observational errors and sampling varia-
tion etc. Examples are various parametric, non-parametric tests, hypothesis testing,etc [291].
Statistical tests are complementary tools often used to assess the difference or similarity
between samples. Parametric tests are used for data that follow a standard distribution (e.g.
normal, binomial, hypergeometric, etc.), and use the parameters of that distribution, such as av-
erage or standard deviation. They require a fairly high sample size (>60). Non parametric tests,
on the contrary, do not assume any distribution in data but are less powerful than parametric
tests in detecting differences; however they are often used by biologists since they require much
less data than parametric tests.
Converting biological data to a form that can be used for statistical analysis may involve a
few steps as follows:
1. detailing the biological question in clear and concise terms and converting the biological
questions into statistical questions (hypothesis testing, testing correlation, etc);
2. describing precisely the data gathered so that any noise (bias) related to the process can
be factored in when transforming the data or preprocessing the data before analysis;
3. coding and formatting data so that they are software-compatible (i.e. meeting the numer-
ical analysis requirements);
4. processing enough data (statistically significant for the chosen method) to answer the
questions asked.
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3.4 Dataset and Sequence Analysis
In this study we use seven FMDV (SAT1, SAT2 and A) datasets and four influenza A datasets.
For the dependent variables we use antigenic distance values between the pair of viral sequences
and for the independent variables we use the count of amino acid differences between the pairs
either on along the entire viral capsid or only specific epitope regions on those capsid proteins.
FMDV data: All seven datasets for FMDV; three for SAT1 (SAR/09/81, KNP/ 196/91
and NIG/05/81 as vaccine strains) and four for SAT2 (ZIM/07/83, KNP/99/89, ERI/ 12,89 and
RWA/02/01 as vaccine strains) containing 21 and 22 pair-wise antigenic distances respectively
were taken from Reeve et al. [290]. One dataset containing 52 outbreak-vaccine strain pairs for
FMDV A (Tur 20/06 as vaccine strain) was taken from Upadhyaya et al. [352]. The antigenic
distance between two virus strains is recorded using ‘r1’ values. These values are generated by
VN tests (VNT)1 and is a ratio of the serum titre of the heterologous virus (e.g. outbreak strain)
to the serum titre of the homologous virus (e.g. the vaccine strain) [354]. r1 values between 0.4
and 1.0 are indicative of reasonable levels of cross protection, whilst values below 0.2 indicate
the need for a new vaccine for the newly isolated virus [305]. A value of 0.3 has also been
proposed as a threshold [19] indicating the need for a new vaccine for a value below that. For
more details on serological measure of r1 value please refer to Section 2.2.2.1.
Influenza data: All the four datasets for influenza A H3N2 (A/PORTCHALMERS /1/1973,
A/VICTORIA/1/1973, A/PHILLIPINES/2/1982 and A/SHANGHAI/11/1987 as vaccine strains)
containing 21, 54, 29 and 32 pair-wise antigenic distances were taken from Liao et al. [202].
The antigenicity of influenza viruses is characterized based on ferret serum HI antibody cross-
reactivity (for more details on HIT refer to Section 2.2.2.2). The antigenic distance between
two viruses is defined as the reciprocal of the geometric mean of two ratios between the heterol-
ogous and homologous antibody titers [171]. The “antigenic relatedness” between two viruses
(presented as a percentage) is a geometric mean of two ratios between the heterologous and
homologous antibody titers and is calculated using the method proposed by [11, 171]. Since
this study investigates the relationship between antigenic difference and amino acid changes,
the antigenic similarity values were modified to calculate “antigenic distance” (i.e., reciprocal
of antigenic relatedness). For example, if homologous titers of two viruses are 480 and 480 and
two heterologous titers against each other are 240 and 240, the antigenic relatedness between
these two viruses is ([240X240]/[480X480])1/2 = 50%, and the antigenic distance between
these two viruses is ([480X480]/[240X240])1/2 = 2%. Antigenic distance <4 indicates similar
antigenicity while antigenic distance >4 is indicative of antigenic variants [310].
Amino acid sequences for FMDV serotypes SAT1 and SAT2 and for influenza A H3N2
were downloaded from GenBank [29] and for FMDV serotype A was provided by The Pirbright
Institute. The sequences of a particular viral serotype were harmonised to the same length (714
residues for SAT2 comprising viral proteins (VP) 1-3, 655 residues for A similarly comprising
(VP) 1-3 and 329 residues for HA1 gene of H3N2) by obtaining a multiple sequence alignment
1VNT is a standard test for cross reactivity and provides the most definitive serological results for virus identi-
fication [259]
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using ClustalW [343]. This alignment was used to identify substitutions between the pairs of
sequences for which the serological data was available. We have used two different approaches
to build the models. In one we have used substitutions only from specific antigenic regions,
two regions in VP1 and one in VP2 [290] for FMDV (SAT1, SAT2 and A) and three regions
in H3N2 HA1 [192]. In the other setup, we have used substitutions in all three capsid proteins
(VP1, VP2 and VP3) for SAT1, SAT2 and A, and the entire HA1 sequence for H3N2.
3.5 Analysis
Raw data is usually difficult to interpret, and hence arises the need to represent this raw data in
an organized way. This process of organising and summarizing raw data in a compact format
yields meaningful information concerning the data. Here we use a combination of graphical
and tabular representations to present our datasets mentioned above and also present the results
of the statistical analysis we have performed on them to understand our datasets and look for
any hidden patterns or correlates in our data that we use in our modelling work that we present
in the later chapters of this document.
We use the language R version 3.2.4 [146], the statistical analysis tool SPSS version 22
[255] and the MATLAB version 8.1.0.604 (R2013a) toolbox [227] to analyse and present our
data.
3.5.1 Sample Statistics
Here we present the characteristics of our FMDV and influenza datasets using a number of
parameters. We summarise the distribution of the data and also look at the spread of the data
which tied up with the results in the later chapters (4 and 5) have helped us understand and
analyse those results better.
Distribution fitting uses random sampling to generate a dataset and then selects a statistical
distribution that best fits the dataset. Probability distributions are used to deal with uncertainty
by helping to develop valid models. Such models find application in various real life problems
in science, business, engineering, etc. Thus it can protect us from potential time and money loss
which can arise due to invalid model selection [389]. In practice, probability distributions are
applied in diverse fields such as risk analysis, market research, business and economic research,
customer support, mining, reliability engineering, game design, biology, physics, medicine etc
[62, 217, 381, 287, 70, 135, 390, 372].
We present the data distributions in the form of histograms that gives a general idea of
the shape of the distribution and we also use two numerical measures of shape to give a more
precise evaluation: skewness, which tells us the amount and direction of skew (departure from
horizontal symmetry), and kurtosis which tells us how tall and sharp the central peak is, relative
to a standard normal curve.
We also present the descriptive statistics of our datasets in terms of measures of central
tendency such as mean (the average of all the values), median (the middle number such that 50%
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(a) (b)
(c)
Figure 3.1: Frequency distribution of the FMDV SAT1 when (a) NIG/05/81 (b) KNP/196/61
and (c) SAR/09/81 were used as vaccine strains.
lies above and 50% lies below the mean) and mode (the most commonly occurring value) and
measures of dispersion or variability such as range (arithmetic difference between highest value
and lowest value; and highly dependent on sample size and outliers), standard deviation (is a
measure of how spread out the numbers are around the mean and is calculated as σ =
√∑
(x2−µ)
n
where µ is the sample mean and n is the sample size) and variance (average of the squared
deviations from the mean i.e. σ2).
Figures 3.1a to 3.2d show the frequency distributions of FMDV SAT1 and SAT2 datasets
compared to a normal distribution. And Table 3.1 presents the descriptive statistics of the
FMDV datasets.
From the frequency histograms of the seven FMDV datasets we can see that only two
datasets (SAT1 NIG//05/81 and KNP/196/61) out of seven show a roughly symmetric distri-
bution which show an even distribution of data points on either side of the sample mean and
hence indicates a better spread of data than the other datasets. These datasets could probably
display a smoother distribution or even be normally distributed in the presence of more data.
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(a) (b)
(c) (d)
Figure 3.2: Frequency distribution of the FMDV SAT2 when (a) KNP/99/89 (b) ZIM/07/83 (c)
ERI/12/89 and (d) RWA/02/01 were used as vaccine strains.
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Out of the remaining five, three datasets (SAT2 KNP/99/89, ERI/12/89 and RWA/02/01) are
clearly positively skewed while SAT1 SAR/09/81 shows a weak positive skew which means
that mass of the distribution is concentrated in the left of the histogram and hence to the left of
the population mean. The SAT2 ZIM/07/83 dataset shows a slight negative skew. These skews
are indicative of non-uniform data spread where most of the titre values (r1) in these datasets
are clustered in one group (low or high r1 value) which could lead to a less specific model. The
skewness of the datasets can also be seen in the ‘skewness statistic’ in the summary table in
Table 3.1. From the sample statistic Table 3.1 we can see that the standard deviations for all the
seven FMDV datasets are quite small (between 0.186 and 0.211) which indicates that that most
of the data points are very close to the average which means that the data is not very spread out.
In addition to that we also see that all the seven FMDV datasets show positive kurtosis values
(between 7.512 and 19.516) which indicates a distribution that is more peaked than normal and
more values close to the mean than in the normal. The high positive kurtosis values also show
a poor spread of data.
Table 3.1: Descriptive sample statistics of FMDV SAT1 and SAT2 r1 datasets used in the study.
The left most column correspond to the names of SAT1 and SAT2 datasets of r1 values for
different vaccine strains.
Dataset N Range Mean Std. Dev Variance Skewness Kurtosis
Statistic Statistic Statistic Statistic Statistic Statistic Std. Err Statistic Std. Err
SAT1
SAR 21 0.90 0.2886 0.19208 0.037 2.768 0.501 9.489 0.972
KNP 21 0.90 0.3419 0.18656 0.035 2.222 0.501 7.512 0.972
NIG 21 1.00 0.2800 0.20057 0.040 2.557 0.501 8.457 0.972
SAT2
ZIM 22 0.98 0.1323 0.19969 0.040 4.250 0.491 19.156 0.953
KNP 22 0.97 0.1632 0.21009 0.044 3.347 0.491 66912. 0.953
ERI 22 1.00 0.1668 0.20402 0.042 3.457 0.491 14.270 0.953
RWA 20 1.00 0.1945 0.21120 0.045 3.155 0.512 11.889 0.992
Figures 3.3a to 3.3d show the frequency distributions of I influenza A H3N2 datasets com-
pared to a normal distribution and Table 3.2 presents the descriptive statistics of the influenza
datasets.
From the frequency histograms of the four influenza datasets, we can see that all the four
datasets are slightly positively skewed with skewness values between 0.834 and 1.424 (refer
to the ‘skewness statistic’ in the summary table in Table 3.2). The right tailed distributions
for all datasets are indicative of most of the data being clustered to the left of the mean and
thus a non-uniform spread of data. From the sample statistic table in Table 3.2 we can see that
the standard deviations for all the four influenza A datasets are quite large (between 17.17 and
53.97) which indicates that most of the data points are very spread out and far away from the
average which means that the data is very sparse. In addition to that we also see that two of
the datasets show positive kurtosis values (0.046 and 2.181) while the other two show negative
kurtosis values (-0.631 and -0.746). Both the positive and the negative values are quite low
which is probably because the antigenic distances (rather than similarity) that we use are quite
small. The weak positive skew, high values of standard deviation, low kurtosis values together
with a small sample size are indicative of a non-uniform but spread out sparse dataset which
could result in model over-fitting.
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(a) (b)
(c) (d)
Figure 3.3: Frequency distribution of influenza A when (a) A/SHANGHAI/11/87 (b)
A/PHILLIPINES/2/82 (c) A/VICTORIA/3/73 and (d) A/PORTCHALMERS/1/73 were used
as vaccine strains.
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Table 3.2: Descriptive sample statistics of influenza A r1 datasets used in the study. The left
most column correspond to the names of influenza A datasets of r1 values for different vaccine
strains.
Dataset N Range Mean Std. Dev Variance Skewness Kurtosis
Statistic Statistic Statistic Statistic Statistic Statistic Std. Err Statistic Std. Err
PORT 21 0.67 0.6349 0.29487 0.087 0.019 0.501 -2.094 0.972
VICT 22 2.01 1.8530 0.85563 0.732 -1.110 0.491 -0.833 0.953
PHIL 54 1.14 1.0104 0.40371 0.163 -0.441 0.325 -1.275 0.639
SHAN 32 3.11 0.9395 0.59213 0.351 2.738 0.414 9.691 0.809
3.5.2 Measure of Spread of Data
While in the previous section we looked at the general spread of the antigenic similarity and
distance values for FMDV and influenza, here we present the spread in specific classes based on
the cut-off value for antigenic similarity which is relevant to the modelling work in the following
chapters.
Figure 3.4 shows the number of samples within three categories/levels of antigenic similarity
(r1) values i.e. 0 ≤ r1 ≤ 1.9, 2 ≤ r1 ≤ 3.9 and r1 ≥ 4 for all the seven datasets of FMDV.
From the compound bar chart, we can see that the SAT1 datasets have a better representation
of data in all the three ranges of r1 values than the SAT2 datasets. We see that of the four SAT2
datasets, only one dataset has data in all the three ranges of r1 values while the majority of the r1
values in the SAT2 datasets are in the range 0 ≤ r1 ≤ 1.9. This clearly supports the observation
that intratypic antigenic variability is much higher in SAT2 than in SAT1. From the statistical
point of view, the relative poor spread of r1 values across the three ranges in SAT2 compared
to SAT1 means that predictive models trained on SAT1 datasets will be of a higher quality than
for SAT2.
Figure 3.4: Spread of r1 values for FMDV SAT1 and SAT2 datasets classed into three levels of
r1 values i.e. 0 ≤ r1 ≤ 1.9, 2 ≤ r1 ≤ 3.9 and r1 ≥ 4.
Figure 3.5 shows a comparison of all the SAT1 and SAT2 datasets with respect to the dis-
tribution of the middle 50% of the data in each of the seven FMDV datasets. From the figure
we can see that between SAT1 and SAT2, SAT1 has a better range of data than SAT2, indicated
by the wider range of data for SAT1 SAR/09/81 and KNP/196/91 than the other datasets (lower
minimum and higher maximum values for both datasets than the other datasets). The ‘box’
in each case shows the middle 50% of the values of that dataset. Comparing the ’boxed’ area
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across all datasets, it can be seen that 50% of data in all SAT1 datasets have higher r1 values
compared to SAT2 datasets. Out of the four SAT2 datasets, only one (RWA/02/01) has a range
of r1 values that indicate antigenic similarity high enough to provide protection to antigenically
divergent viral pairs. The ’boxed’ areas in SAT2 datasets show that majority of the data in the
SAT2 datasets have low r1 values. This is again indicative of the SAT2 datasets not representing
a wide range of data points which would effect the quality of a model trained on it.
Figure 3.5: Comparison of distribution of r1 values for FMDV SAT1 (SAR/09/81, KNP/196/91
and NIG/05/81 as vaccine strains) and SAT2 (ZIM/07/83, KNP/99/89, ERI/12,89 and
RWA/02/01 as vaccine strains) datasets. The “box” shows the middle 50% of the data, the
horizontal line is the r1 splits the data into 2 equal parts - 50% less than and 50% greater than.
(the“median”). The circles and asterisks show r1 values that were outside this distribution since
their values were much lower or higher than the ones in the “box”. The numbers alongside the
circles and asterisks denote the sample number.
Figure 3.6 shows a comparison of the four influenza datasets with respect to the spread
of the middle 50% of the data. We can see that A/VICTORIA/3/73 has the widest range of
the four datasets (lower minimum and higher maximum values than the other datasets). The
‘box’ in each case which shows the middle 50% of the values of that dataset, in the case of
A/VICTORIA/3/73 shows the values are more spread out (longer ‘boxed’ area) than the other
three datasets. The ‘boxed’ areas for all the datasets also show that a mass of the data is in the
lower quartile which in line with our previous observation of most of the data lying on the left
of the median.
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Figure 3.6: Comparison of distribution of r1 values for influenza A datasets
when A/PORTCHALMERS/1/1973, A/VICTORIA/1/1973, A/PHILLIPINES/2/1982,
A/SHANGHAI/11/1987 were taken as vaccine strains. The “box” shows the middle 50%
of the data, the horizontal line is the r1 splits the data into 2 equal parts - 50% less than
and 50% greater than. (the“median”) and the asterisks show r1 values that were outside this
distribution since their values were much lower or higher than the ones in the “box”. The
numbers alongside the asterisks denote the sample number.
3.5.3 Correlation between r1 Values and Amino Acid Substitutions
In this part of the analysis we explore the presence of any correlation between antigenic simi-
larity and amino acid substitutions between pairs of viral sequences.
In FMDV, the outer capsid proteins VP1, VP2 and VP3 are directly involved in antigenicity.
There were three loops (HI and CT loops in VP1 and BC loop in VP2) reported in SAT1 and
SAT2 through in silico predictions [290] that have not been identified serologically which we
have considered in this study to check for correlates with antigenicity.
In influenza, accumulation of mutations on HA protein give rise to immunogenically distinct
strains which are produced continuously. We consider three epitope regions reported by Liao et
al. [202] to look for correlates with antigenicity.
We correlate the antigenic similarity values (r1) with substitutions either in the entire capsid
proteins or the epitopes in the capsid proteins and report the results below.
3.5.3.1 Correlation between r1 Values and Substitutions in Entire Capsid Proteins
Here we present the results of correlation analysis between antigenic similarity (r1 values) and
total count of amino acid substitutions across the entire capsid protein for FMDV and influenza.
Figures 3.7a to 3.8d show the correlation plots for SAT1 and SAT2 data. We can see from
the plots that in the SAT1 plots the points form a more negative slope (a diagonal line from
the bottom right corder towards the top left corner can be drawn through the points) than the
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SAT2 datasets. Of the three SAT1 datasets KNP/196/91 and SAR/09/81 show a clear negative
correlation between r1 values and the total raw count of amino acid substitutions in the three
capsid proteins (VP1, VP2 and VP3). Even though the SAT2 datasets also show negative cor-
relation between the r1 values and the amino acid substitution raw counts, it is more difficult to
visualise it as most of the data is clustered in a small area due to the small range of r1 values
for SAT2. Hence small patterns (like a slight negative slope) in the data is hard to identify in
the plot. However, if we note the Pearson’s Correlation [327] coefficients in Table 3.3 we can
see that all the seven FMDV datasets show a negative correlation between the r1 values and the
count of amino acid substitutions in the three capsid proteins. Six out of seven datasets show
a strong negative correlation (correlation coefficient values between -0.566 and -0.786) while
the seventh has a coefficient value of -0.461 which shows moderate negative correlation i.e. as
the count of substitutions increase between a pair of sequences in their outer capsid proteins,
their antigenic similarity reduces. Table 3.3 also reports the minimum p value at which the test
is significance (pt) and the p value of each Pearson’s correlation coefficient (p); from which we
can see that all the coefficients reported are statistically significant.
Figures 3.9a to 3.9c are correlation plots for three influenza A datasets to show the cor-
relation between r1 values and raw count of amino acid substitutions along the HA1 protein
sequence. From the three plots, we can see that all the three datasets show a clear negative
correlation between r1 values and the total count of amino acid substitutions across the outer
capsid protein. The negative correlation in the influenza datasets is more visible due to the more
diverse range of r1 values compared to the FMDV datasets. From Table 3.3 we can also see
that the Pearson’s correlation coefficient values are higher for influenza datasets than the FMDV
datasets (between -0.645 and -0.897). Since the range of r1 values in the influenza datasets is
wider than the FMDV datasets, the correlation between amino acid substitutions in the outer
capsid proteins and r1 is more pronounced.
Table 3.3: Pearson’s correlation coefficients for r1 Values and Amino Acid Substitution Count in Entire Capsid Pro-
tein in FMDV and influenza A. Key: SAR-vaccine strain SAR/09/81, KNP (for SAT1)-vaccine strain KNP/196/91,
NIG-vaccine strain NIG/05/81, ZIM-vaccine strain ZIM/07/83, KNP (for SAT2)-vaccine strain KNP/99/89, ERI-
vaccine strain ERI/12/89, RWA-vaccine strain RWA/02/01, A/PORT-vaccine strain A/PORTCHALMERS/1/1973,
A/VIC-vaccine strain A/VICTORIA/3/1973, A/PHIL-vaccine strain A/PHILLIPINES/2/1982, A/SHAN-vaccine
strain A/SHANGHAI/11/1987, PC coeff.-Pearson’s correlation coefficient, p-significance value of the coefficient,
pt-test significance level
Virus Strain PC p pt
Type coeff.
FMDV SAR -0.593 0.005 0.01
SAT1 KNP -0.566 0.007 0.01
NIG -0.610 0.003 0.01
FMDV ZIM -0.633 0.002 0.01
SAT2 KNP -0.461 0.031 0.05
ERI -0.786 0.000 0.01
RWA -0.677 0.001 0.01
INF A/PORT -0.727 0.000 0.01
A/PHIL -0.645 0.000 0.01
A/VIC -0.897 0.000 0.01
A/SHAN -0.479 0.000 0.01
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(a) (b)
(c)
Figure 3.7: Correlation between the raw count of substitutions in the three outer capsid proteins
and their respective r1 values in SAT1 when (a) KNP/196/61 (b) NIG/05/81 and (c) SAR/09/81
were used as vaccine strains.
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(a) (b)
(c) (d)
Figure 3.8: Correlation between the raw count of substitutions in the three outer capsid proteins
and their respective r1 values in FMDV SAT2 when (a) ZIM/07/83 (b) KNP/99/89 (c) ERI/12/89
and (d) RWA/02/01 were used as vaccine strains.
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(a) (b)
(c)
Figure 3.9: Correlation between the raw count of substitutions in the three outer capsid proteins
and their respective r1 values in influenza A when (a) INF/A/PORT (b) INF/A/VICTORIA and
(c) INF/A/PHILLIPINES were used as vaccine strains.
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In summary, we can say that a strong correlation between antigenic similarity (r1 value) and
count of amino acid substitutions in the outer capsid proteins was seen in 80% of the data (8 out
of 10 datasets) while 20% exhibited moderate correlation. Thus, we can say that as the count of
substitutions increase between a pair of sequences in their outer capsid proteins, their antigenic
similarity decreases.
3.5.3.2 Correlation between r1 Values and Substitutions in Antigenic Loops in Capsid
Proteins
Here we present the results of correlation analysis between antigenic similarity (r1 values) and
the total count of amino acid substitutions in three epitope regions on capsid proteins for FMDV
and influenza A.
Figure 3.10 shows the correlation between the antigenic distance (as opposed to antigenic
similarity in the previous plots, hence higher the value the more divergent the sequences are)
and count of amino acid substitutions in three epitopes on the HA1 protein of influenza A
Phillipines. We can see a positive correlation (R=0.598, p<0.000) between antigenic distance
and substitutions in the epitopes i.e. an increase in the number of substitutions in the epitopes
gives rise to antigenically divergent virus strains.
Figure 3.10: Correlation between the amino of substitutions in the three antigenic regions
(loops) in the outer capsid proteins and their respective antigenic distances for influenza A
when INF/A/PHILLIPINES was used as the vaccine strain.
Figures 3.11a and 3.11b are correlation plots showing the correlation between antigenic
similarity and total count of amino acid substitutions in three antigenic loops in FMDV SAT1
SAR/09/81 and FMDV A Tur/20/06. In both the plots, the total count of amino acid sub-
stitutions in the three epitopes correlate strongly (R=-0.943, p<0.000 and R=-0.772, p<0.000
respectively) with antigenic similarity.
Even though the above correlation analysis does not show a clear advantage of using sub-
stitutions only in the antigenic areas or in the entire outer capsid protein, Pearson’s correlation
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(a) (b)
Figure 3.11: Correlation between the amino of substitutions in the three antigenic regions
(loops) in the outer capsid proteins and their respective r1 for FMDV when (a) SAT1 SAR/09/81
and (b) A Tur 20/06 were used as vaccine strains.
coefficient for one of the SAT1 datasets taking only the substitutions in the epitopes into consid-
eration, was the highest. The above correlation results are indicative of a negative correlation
between antigenic similarity and amino acid substitutions in the capsid protein and hence it
provides us with enough encouragement to use these as variables for further modelling work.
3.5.3.3 Correlation between r1 Values and Type of Amino Acid Substitution
An amino acid is more or less likely to mutate to another amino acid. For instance, a substi-
tution is more likely to occur between amino acids with similar biochemical properties due to
redundancy in genetic code that translates similar codons into similar amino acids [6]. Selective
pressure plays a vital role in this process as it often removes mutations that may significantly af-
fect the function and folding of the protein due to substitution of amino acids with very different
properties.
18-19 SAT1 sequences were compared with the reference vaccine and was seen that the
most frequent amino acid substitution were T (Threonine)-A (Alanine)/A-T, S (Serine)-A/A-S,
V(Valine)-I(Isoleucine)/I-V and T-V/V-T. On comparing the 19-20 SAT2 sequences with the
reference vaccine, T-A/A-T and S-A/A-S substitutions were found to be most frequent. The
heatmaps for the most commonly occurring substitutions that we noted in FMDV SAT1 and
SAT2 can be found in Appendix D. It is interesting to see that T and S which are both ‘polar’
are mutated to A which is ‘non-polar’2 and thus could be a result of selective pressure. T and S
2There are 20 amino acids in nature and their specific characteristics are defined based on the propensity of
their side chains to form hydrogen bonds with water. The hydrophobic or non-polar amino acids such as alanine
(A), valine (V), leucine (L), isoleucine (I), proline (P) and phenylalanine (F) have a low propensity to be in contact
with water. The charged amino acid such as lysine (K), arginine (R), aspartate (D) and glutamic acid (E) and the
polar amino acids such as serine (S), threonine (T), asparagine (N), glutamine (Q), histidine (H), tryptophane (W),
cysteine (C), methionine (M) and tyrosine (Y) can both (polar and charged) make energetically favourable contact
with water. Glycine (G), which does not have a side chain is neither classified as polar or non-polar [32].
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(a) (b)
Figure 3.12: Correlation between the raw count of T-A substitutions and r1 values when (a)
SAT1 KNP/196/91 was used as vaccine strain. R=0.276, p<0.001. (b) SAT2 ERI/12/89 was
used as vaccine strain. R=0.185, p<0.001.
having very similar side chain polarity, charge and negative hydropathy index are good substitu-
tions for each other. In addition, D and E have identical side chain polarity, charge and negative
hydropathy index, thus supporting the observed substitutions. Valine and isoleucine are very
similar chemically both being nonpolar, neutral and having very similar hydropathy indexes.
Interestingly, valine and threonine are not that similar with different polarity and hydropathy in-
dexes although their side chains are neutral. The chemical basis of the T-V substitution should
be investigated owing to its high frequency between SAT1 sequences.
Figures 3.12a and 3.12b show correlation plots of antigenic distance plotted against the raw
count of T-A/A-T substitutions for one dataset each of SAT1 and SAT2 respectively. Figures
3.13a and 3.13b show correlation plots of antigenic distance plotted against the raw count of
S-A/A-S substitutions for one dataset each of SAT1 and SAT2 respectively. We can see that due
to the limited number of scattered data points, it is difficult to say whether there is a correlation
and if there is, whether it is a positive or a negative one. However, from the Pearson’s correlation
coefficient values (provided in the figure captions) we can see that three out of the four plots
show a weak positive correlation (R values between 0.185 and 0.402) while one plot shows a
very negative correlation (R=-0.04).
Figures 3.14a and 3.14b show correlation of antigenic distance plotted against and the raw
count of T-V/V-T substitutions for two datasets of SAT1 while Figures 3.15a and 3.15b show
correlation of antigenic distance plotted against the raw count of V-I/I-V substitutions for two
datasets of SAT1. Like the T-A and S-A plots, it is very difficult to visualise a linear correlation
in these plots, although the Pearson’s correlation coefficient values indicate a weak positive
correlation in three plots (R values between 0.193 and 0.391) and a weak negative correlation
(R=-0.456) in the fourth.
From the above plots we can say that there is probably moderate to weak linear correlation
(as indicated by the correlation coefficient values) between the raw count of specific amino acid
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(a) (b)
Figure 3.13: Correlation between the raw count of S-A substitutions and r1 values when (a)
SAT1 KNP/196/91 was used as vaccine strain. R=0.402, p<0.001. (b) SAT2 ERI/12/89 was
used as vaccine strain. R=-0.04, p<0.001.
(a) (b)
Figure 3.14: Correlation of correlation between the raw count of T-V substitutions and r1 values
when (a) SAT1 KNP/196/91 was used as vaccine strain. R=-0.456, p<0.001. (b) SAT1 NIG/5/81
was used as vaccine strain. R=0.391, p<0.001.
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(a) (b)
Figure 3.15: Correlation between the raw count of V-I substitutions and r1 values when (a)
SAT1 NIG/5/81 was used as vaccine strain. R=0.318, p<0.001. (b) SAT1 KNP/196/91 was
used as vaccine strain. R=0.193, p<0.001.
substitutions between pairs of sequences and their r1 values.
A majority of the plots show a slight positive correlation (Pearson’s correlation coefficient)
which shows that an increase in the number of frequently occurring amino acid changes between
sequences, corresponds to a higher r1 value (the strains are antigenically not similar). This is
explained by the fact that, in nature, substitutions of an amino acid with another amino acid with
similar properties is permissible, with the overall structure/function of the protein remaining
unchanged [58].
Availability of more data could potentially improve the possibility of seeing any clustering
or pattern in the correlation plots. Considering that there were only 18-20 sample points on
the correlation plots, were not enough to show any particular linear relationship when specific
amino acid substitutions are considered. Since the datasets are small, it is difficult to say whether
there is actually a linear correlation between specific amino acid substitutions and r1 values as
indicated by low Pearson’s correlation coefficient values.
3.6 Discussion
We use a combination of graphical and tabular representations to present our datasets and also
presented the results of the statistical analysis we performed on them prior to the modelling
work that we present in the later chapters of this document. We can summarise the results as
follows:
• The frequency histograms show that five out of seven FMDV datasets and all influenza
datasets show a positively skewed distribution indicating most values clustered on the left
of the median.
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• All FMDV datasets show small standard deviations which means that most data are clus-
tered around the mean and hence the data is not spread out. In case of the influenza
datasets, the standard deviations were large indicating that the data is very spread out on
either side of the mean.
• All FMDV datasets show positive kurtosis values which is indicative of a distribution
more peaked than a normal distribution. The kurtosis values for the influenza datasets
were very small (both positive and negative) which is probably because the antigenic
distance values that we use are quite small. The weak positive skew, high values of
standard deviation, low kurtosis values together with a small sample size in the case of
influenza datasets are indicative of a non-uniform but spread out sparse dataset.
• A compound bar chart of r1 values for the seven FMDV datasets show a better represen-
tation of data in the three ranges of r1 i.e. r1 ≥ 0 ≤ 1.9, r1 ≥ 2 ≤ 3.9 and r1 ≥ 4
for SAT1 data than SAT2 and hence models trained3 of SAT1 datasets will potentially be
more accurate in prediction tasks.
• Boxplots show more intratypic variations in SAT2 than SAT1.
• Thus overall, we can say that the poor range of SAT2 data relative to SAT1 data would
potentially translate to poorer modelling performance with SAT2 data compared to SAT1
data.
• Boxplots for influenza show data mostly clustered around the lower quartile of the plot
confirming the small negative and positive skew in its distribution across all influenza
datasets.
• Both FMDV and influenza show a moderate to strong correlation between antigenic sim-
ilarity (r1 values) and the total count of amino acid substitutions in their outer capsid
proteins, across all datasets.
• Wider range of r1 values in the influenza datasets means that correlation was more visible
for the influenza datasets than in the FMDV datasets, although they both showed similar
range of correlation coefficient values.
• Antigenic similarity correlated negatively to the count of amino acid substitutions in epi-
topes on their capsid proteins for both FMDV and influenza.
• When we plot the correlation between antigentic similarity and count of specific types
of antigenic substitutions, no clear linear relationship was seen. Most plots showed a
positive correlation i.e. an increase in the number of frequently occurring amino acid
changes between sequences, corresponds to a higher r1 value (indicating that the strains
are antigenically similar). This is in line with the theory of selection pressure whereby,
3In statistical modelling, the process of using a set of data to discover and/or predict trends and relationships in
the data is called training.
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in nature, substitutions of an amino acid with another amino acid with similar properties
is permissible, with the overall structure/function of the protein remaining unchanged.
Hence substitutions between similar (biochemically) amino acids are more frequent and
consequently has little effect on the function (degree of antigenicity) of the resultant pro-
tein.
• Whether we considered the substitutions in the entire capsid protein or only in the epi-
topes on the capsid proteins, it made no significant difference to the degree of correlation
that we observed. And also, specific substitutions show no clear correlation with antigenic
similarity probably because we considered substitutions across the viral sequence. How-
ever, we know that particular types of substitutions in nature are more favoured than the
others, thus the less frequently occurring substitutions must be the less favourable ones.
Considering that there are 20 amino acids and so there are 400 different types of sub-
stitutions that can be considered for such a correlation analysis with antigenic distance,
we consider using this information to build a scoring method to score/weight amino acid
substitutions based on their biochemical properties for our modelling work presented in
the later chapters.
• The results of the correlation analysis are reassuring in terms of using antigenic similarity
and amino acid substitution data in capsid proteins, as variables for further modelling
work to understand how inter and intratypic genetic variation in virus effect their cross
reactivity.
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Chapter 4
Regression Analysis for Predicting Viral
Antigenicity
In statistics, regression is a technique for understanding the relationship between variables, how
a dependent variable changes with respect to one or more independent variables. It involves
quantitative estimation of the trend of the outcomes (dependent variable) i.e. fitting equations
of approximating curves to the raw data. This process is called curve fitting and the desired
outcome is to find the curve with the minimum deviation from the actual data.
Linear models are simple and in many cases provide an adequate understanding of the re-
lationship between variables. Non-linear models on the other hand can be used to understand
the relationship between variables that cannot be expressed as a linear combination of model
parameters or when there are complex interdependencies between one or more independent
variables [89].
4.1 Linear Regression
Linear regression is the most widely used regression technique. It aims to find the relationship
between a scalar dependent variable (y) and one or more independent variables x1, x2, x3, ..., xn.
In the case of simple regression there is only one independent variable while in multiple regres-
sion there are more. When there is more than one correlated dependent variables to be predicted
it is called multivariate regression.
Linear regression uses a linear function of coefficients and independent variables to model
the data provided in order to estimate the model parameters. It is used mainly for prediction
or to study the relationship between variables. In the first case, a predictive model is fit to
observed data x and y(being known) so that when a new xi value is provided, the value of yi
can be predicted. In the latter case, the degree of relationship between the dependent and the
independent variables can be estimated [89].
If we have an input vector XI = (x1, x2, x3, ..., xn), and want to predict the real valued
output Y. The linear regression model has the form
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f(x) = β0 + β1x1 + β2x2 + β3x3 + ...+ βnxn, (4.1)
where β0−n are the regression coefficients or unknown parameters. Although the parameters
can be estimated by various methods, the simplest and most popular method used with linear
regression is the least squares method (LSM) [353] explained in Section 4.3.1.
4.2 Non-linear Regression
Non-linear regression is conceptually similar to linear regression whereby the difference be-
tween the experimental and the calculated results is minimised. However in non-linear regres-
sion, this is done by fitting a curve rather than a line as in linear regression [289, 314]. If x
and y are the independent and the dependent variables respectively, and y is a function f(x, β)
expressed as
f(x, β) = β0 + β1x
2. (4.2)
β0 and β1 are the regression coefficients (unknown parameters). The above function is non-
linear since the dependent variable cannot be expressed as a linear relationship between the
coefficients and the independent variable. Logarithmic, polynomial, trigonometric and Gaus-
sian are a few other examples of non-linear regression [113].
Unlike linear regression non-linear regression models do not have a closed form expres-
sion for the best fitting model and different optimisation algorithms are used to estimate the
parameters by solving the problem of finding the global minima [349].
A non-linear regression model can be written asy = f(x, β) + ee ∼ N(0, σ2), (4.3)
where σ ∈ Rp (parameter space). If (x1, y1), (x2, y2), ..., (xn, yn) are the given data pairs,
then the non-linear estimation problem is to determine σˆ ∈ Rp such that Z(σˆ) 6 Z(σ) finds the
least squares or the robust estimates for all σ ∈ Rp, where
Z(σ) =
n∑
i=1
[yi − f(xi, σ)]2 (4.4)
or
Z(σ) =
n∑
i=1
| yi − f(xi, σ) |, (4.5)
show the objective functions for least squares and robust estimates respectively. Thus non-
linear parameter estimation is an optimization problem [253].
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4.3 Parameter Estimation Methods
The Least Squares Method (LSM) and the Genetic Algorithm (GA) are two widely used op-
timization methods. The LSM is a gradient search1 technique that needs a gradient objective
function. It is difficult to determine the initial solution and so the local minimum might be
reached [89]. In addition they are highly effected by noise in the data [317, 91]. Unlike the
LSM, the GA is a stochastic search technique that searches for a global minimum. It works
very well with regression since it does not require a gradient function. However a GA is slower
in execution than the LSM and works better when applied to more complex problems [157].
4.3.1 Least Squares Method
The least squares method assumes that the best fit model is the one that has the minimum
sum of errors squared between the actual data and the output of the model. Given that (x1, y1),
(x2, y2), ..., (xn, yn) are the data points, x and y are the independent and the dependent variables
respectively from which we need to estimate the parameter β. If each xi = (xi1, xi2, ..., xip)T
is a vector of feature measurements for the ith case and β = (β0, β1, ..., βp)T , the least squares
estimation method finds the best fit model by minimising the residual sum of squares (RSS)
given by
RSS(β) =
n∑
i=1
(yi − f(xi))2
=
n∑
i=1
(yi − β0 − βixi)2.
(4.6)
To illustrate how Eq. 4.6 is minimised, let X be an N x (p + 1) matrix in which each row is
an input vector with 1 in the first position. Let y be an N-vector of outputs in the training set.
The RSS can then be written as
RSS(β) = (y− Xβ)T (y− Xβ). (4.7)
This is a quadratic function of the p + 1 parameters. By differentiating Eq. 4.7 respect to β,
we get
∂RSS
∂β
= −2XT (y− Xβ), (4.8)
If the first derivative is set to zero, i.e.
XT (y− Xβ) = 0, (4.9)
1An optimisation algorithm to solve the minimisation problem where the search directions are defined by the
gradient of the function at the current point.
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by assuming that X has full column rank, the fitted solution obtained is
βˆ = (XTX)−1XTy. (4.10)
Now that the final solution is reached, the predicted values at an input vector x0 are given
by fˆ(x0) = (1:x0)T βˆ and the fitted values at the training inputs are [113]
yˆ = Xβˆ = (XTX)−1XTy. (4.11)
4.3.2 Evolutionary Algorithms
Data analysis tools used earlier in bioinformatics were mainly based on statistical techniques
such as regression and estimation. Biological data which is often noisy and incomplete has
given way to use of evolutionary algorithms (EAs), a class of randomized search and optimiza-
tion techniques guided by the principles of evolution and natural genetics, have been gaining the
attention of researchers for solving bioinformatics problems. Metaheuristic optimisation algo-
rithms like EAs have the advantage of not requiring detailed prior knowledge of the system, but
also have the flexibility to add biological information during inference [324]. As optimisation
algorithms require only evaluation of potential solutions, they are a powerful tool for modelling
complex systems in biology [368].
Evolutionary algorithms (EAs) were first developed in the early 1960s as models that sim-
ulate biological evolutionary processes for parameter optimisation [14], among other purposes.
They are biologically inspired algorithms that use operations based on natural mechanisms such
as reproduction, mutation and selection. These algorithms can be used in many applications,
however they are commonly used to solve optimisation problems. These algorithms begin with
a population of candidate solutions denoted as the parent population, which are used to create a
new set of offspring solutions via operations based on reproduction and recombination. The off-
spring solutions are also subject to mutation operations to increase variability in the solutions.
These solutions are then evaluated against an objective function, in order to simulate natural
selection by favouring the solutions that result in the best objective value. The process of pro-
ducing new a offspring solution is repeated for a number of generations in order to converge to
the optimal solution for a given problem denoted by the best solution. Although metaheuristic
searches do not always yield the global optimal solution, they can provide an acceptable so-
lution given the problem constraints. As many metaheuristics are stochastic, it is possible to
average results over numerous simulations or to the optimum solution.
Solutions can be represented as a chromosome of alleles, with each allele corresponding
to a parameter in the system. Operations in the EA are performed on the chromosome, such
as recombination where the chromosome of two candidate solutions are used to create new
solutions by mixing the chromosomes. If mutation is also used this will then be applied to each
allele in turn with a given probability of changing the parameter value.
Genetic algorithms (GAs) [141, 41, 33, 122, 123] evolutionary strategies (ES) [313] , and
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genetic programming (GP) are the major components of EAs. Of these, GAs are the most
widely used we will look at GAs in particular since we have used a GA in our work. GAs are
efficient, adaptive, and robust search processes, producing near optimal solutions, and have a
large amount of implicit parallelism. The role of GAs in bioinformatics gained significance with
the need to handle large data sets in biology in a robust and computationally efficient manner.
4.3.2.1 Genetic Algorithm
GA is a search heuristic that gradually improves the solutions in succeeding populations by
mimicking processes of natural evolution such as reproduction, crossover and mutation. Two
essential applications of GA is parameter estimation and structural optimisation [54, 197, 198].
GAs were introduced in 1975 by J.Holland [142]. A canonical GA uses binary (or Gray)
coding for representing the decision variables to be optimised. Starting from a randomly gen-
erated parent population, in which each individual represents a candidate solution, a canonical
GA performs crossover and flip mutation to generate new candidate solutions (offspring). The
offspring individuals are then evaluated to determine their fitness, and in this work, the pre-
diction error of each candidate model. Then, offspring individuals are selected according to
their fitness value as parents for the next generation. In this work, the better the fitness value
(i.e., the smaller the prediction error), the more likely an offspring individual will be selected.
The selection process simulates the principle of survival of the fittest in natural evolution. This
generations cycle continues until a termination criteria is fulfilled, e.g., when the predefined
number of generations have been processed or the global minimum solution identified.
A canonical GA uses binary (or Gray) coding for representing the decision variables to
be optimised. Starting from a randomly generated parent population, in which each individual
represents a candidate solution, a canonical GA performs crossover and flip mutation to generate
new candidate solutions (offspring).
A genetic representation of the solution domain and a fitness function (e.g. minimising
the error of each candidate model) is defined to evaluate the solution domain. The GA then
proceeds as follows [328]:
• Initialisation: Many individual solutions (search space) are randomly generated from an
initial population. Sometimes the solutions may also be ‘seeded’ where optimal solutions
may be found. The population usually contains hundreds or thousands of solutions.
• Selection: The offspring individuals are then evaluated to determine their fitness (e.g.
the prediction error of each candidate model). Then, offspring individuals are selected
according to their fitness value as parents for the next generation. The better the fitness
value (i.e., the smaller the prediction error), the more likely an offspring individual will be
selected. The selection process simulates the principle of survival of the fittest in natural
evolution.
• Genetic operators: After the initial population has been seeded throughout the search
region, operators such as mutation and crossover dynamically generate off-spring. The
70
algorithm then looks for trial solutions in new search regions
Figure 4.1: Flowchart of a canonical genetic algorithm.
of the solution space, thereby enhancing the convergence to the global optimum. This
task is performed by the mutation operator, which is controlled by a probability func-
tion. It operates on a random individual being chosen from the population and alters the
individual by a certain amount. Pairs of individuals are then randomly chosen from the
population to exchange information among them. This is called crossover and it com-
bines the parameters from two parents to produce two off-spring. The crossover operator
may randomly assume any point in the parameter string for as the crossover point and is
controlled by a crossover probability.
• Generation cycle: The off-spring generated after crossover and mutation are evaluated
for their fitness. A termination criteria is also set which can be the maximum number of
generations to process or a certain high fitness value. If the termination criterion is not
met at the end of a fitness evaluation, a new generation is created and its fitness evaluated.
• Termination: The generations cycle continues until a termination criteria is fulfilled,
e.g., when the predefined number of generations have been processed.
71
Fig. 4.1 is a flowchart summarising the process of a canonical genetic algorithm.
Many variants of the canonical GA have been developed by introducing new representation
schemes, genetic variations and selection methods to enhance the search performance of the
canonical genetic algorithms, see e.g. [14]. For example, in real-coded GAs (RCGAs), decision
variables can be directly represented using real-values [79]. Accordingly, new crossover and
mutation operators, e.g., simulated binary crossover (SBX) and new mutation operators such as
polynomial mutation have been designed for RCGAs [79].
4.3.2.2 Single and Multiple Objective Optimisation
Optimisation problems are solved by evaluating a solution, or potential solutions, by comparing
it to a predefined objective function. In a simple case an objective, say a cost, is to be minimised
by varying some parameters in the system. A common objective in biological model construc-
tion is simply to minimise the error between the model output and the data [78, 199]which can
be applied to both real and Boolean models. This is the example of a single objective optimisa-
tion problem. However, this method can lead to over-fitting and high false-positive rate which
has a potential effect on biological plausibility and practical application of the model. Some
authors have integrated prior biological information in the form of penalty terms to reduce over
fitting and increase biological plausibility [10, 261].
More complicated problems however may involve more than one objective which may con-
flict with each other, such as increasing accuracy (minimising error) and decreasing complexity
of a model. The problem of finding a function optimizing the expected value and the risk is a
multi-objective optimisation problem. Particularly in the case of conflicting objectives, f1 and
f2, it is not possible to optimise each function separately as improving one may compound the
other. Thus they must be optimised simultaneously.
Multi-objective optimisation problems can be considered as extensions of a single objective
problem with multiple objectives, or on the contrary, a single objective problem can be consid-
ered the degenerate case of a multiple objective problem where both the objectives are the same
[80]. However, there is a fundamental difference, in the case of a single objective optimisation
problem, there is a single optimal solution for a given objective, but this is not the case in a
multiple objective problem. In the latter, particularly for two conflicting objectives, there exists
many solutions that are optimal for the objectives and these cannot be directly compared. A
solution that is better in f1 but worse in f2 compared with another solution cannot be said to be
more or less optimal without further information [80].
Robustness, model error, biological probability, etc are some of the objectives that can be
optimised in biological models. Thus a multiple objective model can be used to build an accu-
rate model based on a certain set of objectives and use another objective(s) to ensure that the
model remains biologically feasible. It has been seen that multiple objectives are able to deal
with more complex models than single objectives [139]. In addition, based on user preferences,
users can also compare and select the best solutions from the Pareto front in multi-objective
optimisation.
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4.3.2.3 A Multi-objective Genetic Algorithm: NSGA-II
The non-dominate sorting genetic algorithm (NSGA-II) [81] is a genetic algorithm that can
solve real coded multi-objective (MO) optimisation problems. Due to the representation of the
genomes, many early GAs were for binary values only, however, there were also real coded
GAs available. NSGA-II suggested by Deb et al. [81] is independent of representation and can
be used to solve real valued optimisation problems. The multi-objective selection process used
in NSGA-II is as follows:
Simulated binary crossover (SBX): The standard recombination operator used in binary GAs
is the crossover operator in which segments are taken from the string of the values of the parents
to form the offspring. However, for real-coded GAs, a SBX operation can be used. Given two
parent solutions x(1,t)i and x
(2,t)
i , a random number ui, between 0 and 1 is generated at first:
βqi =
 (2ui)
1
ηc+1 if ui ≤ 0.5(
1
2(1−ui)
) 1
ηc+1 otherwise,
(4.12)
where ηc is a distribution index. As recommended in [79], ηc is typically set to 20. Two
offspring solutions, x(1,t+1)i and x
(2,t+1)
i , are then produced as follows:
x
(1,t+1)
i = 0.5
[
(1 + βqi)x
(1,t)
i + (1− βqi)x(2,t)i
]
, (4.13)
x
(2,t+1)
i = 0.5
[
(1− βqi)x(1,t)i + (1 + βqi)x(2,t)i
]
, (4.14)
Polynomial mutation: For binary coded algorithms, which can be encoded by a fixed length
string, discrete mutation operators are used [123]. These operators use a mutation probability to
determine if the value of the parameter is flipped. However, for real-coded GAs, a polynomial
mutation operator is used. For these operations, the mutation probability is based on the number
of dimensions,4, in the problem pm = 4−1. The distribution of a spread factor is defined as,
P (βmi) = 0.5 (ηm + 1) (1− |βmi|)ηm , (4.15)
where ηm is the distribution factor, and βmi is given by,
βmi =
{
(2ui)
1
ηm+1 − 1 if ui ≤ 0.5
1− (2 (1− ui))
1
ηm+1 otherwise ,
(4.16)
If a mutation in the individual occurs, the parameter value is given as
x′ = x+ (α− δ) βmi , (4.17)
where α and δ are the upper and lower bounds for the mutation values respectively.
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Non-dominated sorting for elitism: As NSGA-II is a multi-objective (MO) optimisation
algorithm, it can optimise problems based on several objective functions simultaneously. Here,
after objective evaluation, parent and offspring solutions are combined and sorted into non-
dominated fronts, where front 1 is comprised of non-dominated solutions, front 2 is comprised
of solutions that are only dominated by the solutions of front 1, etc. A solution dominates
another if it has a better value in both objectives and is said to weakly dominate another if it
is better in only one of the objective values but equal in the other. Thus a solution is defined
as non-dominated if no solution exists with a better value for each of the objectives. Next the
crowding distance operation is applied to all solutions, which is the average distance between
a solution and its nearest neighbours on the same dominated front. A new population of size
µ is then filled from the non-dominated fronts starting with the solutions on front 1, and then
from successive fronts if there are spaces in the new population. If there are more solutions on
a front than spaces in the population then the most diverse solutions, i.e. those with the largest
crowding distance, are selected. Once this population is full, two randomly selected solutions
are compared in a tournament selection, with a lower front winning the tournament. In the
case where solutions are from the same front, the solution with the higher crowding distance is
selected as the better solution to promote the diversity of the population. The resulting solutions
from the tournament selection form the mating pool for the next generation and the crossover
and the mutation operations, described above, are applied to produce the next generation of
offspring solutions. Once completed, this algorithm produces a number of solutions that form
the Pareto front 2 in the objective space. At this stage, other information or preferences need to
be used to compare solutions. Additional details of this algorithm can be found in [79].
Single objective optimisation with NSGA-II: It is possible to use NSGA-II to solve single
objective (SO) problems, which, in this case, the recombination and mutation operations remain
as described above. The difference is in the selection process, which for the single objective
set up of NSGA-II uses an elitest selection strategy. In this SO set up, there is a single opti-
mal solution as the objectives are equivalent so each solution will form a different front in the
objective space leading to one solution that dominates all others.
4.3.3 Genetic Algorithms in Bioinformatics
Genetic algorithms [122, 33, 41, 141] a biologically inspired technology, are randomized search
and optimization techniques guided by the principles of evolution and natural genetics. They
are efficient adaptive, and robust search processes, producing near optimal solutions, and have
a large degree of implicit parallelism. Therefore, the application of GAs for solving certain
problems of bioinformatics, which need optimization of computation requirements, and robust,
2If {minimse F (x) = (f1(x), ..., fm(x)) subject to x ∈ Ω} is a MO optimisation problem where Ω is the
decision (variable) space,Rm is the objective space, and F : Ω −→ Rm consists of real-valued objective functions.
Let p = (p1, ..., pm),q = (q1, ..., qm) ∈ Rm, be two vectors, p is said to dominate q if pi ≤ qi for all i = 1, ...,m
and and p 6= q. A point x∗ is called Pareto optimal if there is no x ∈ Ω such that F (x) dominates F (x∗).
The set of all the Pareto optimal points is called the Pareto set (PS). The set of all the Pareto objective vectors,
F (x) ∈ Rm|x ∈ PS is called the Pareto front [236].
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fast and close approximate solutions, appears to be appropriate and natural [33]. Moreover,
the errors generated in experiments with bioinformatics data can be handled with the robust
characteristics of GAs. To some extent, such errors may be regarded as contributing to genetic
diversity, a desirable property. The problem of integrating GAs and bioinformatics constitutes
a new research area.
Of all the evolutionarily inspired approaches, GAs seem particularly suited to implementa-
tion using DNA, protein, and other bioinformatics tasks [59]. This is because GAs are generally
based on manipulating populations of bitstrings using both crossover and pointwise mutation.
The main advantages using GAs are as follows.
• Several tasks in bioinformatics involve optimization of different criteria (such as energy,
alignment score, and overlap strength), thereby making the application of GAs more nat-
ural and appropriate.
• Problems of bioinformatics seldom need the exact optimum solution; rather, they require
robust, fast, and close approximate solutions, which GAs are known to provide efficiently.
• GAs can process, in parallel, populations billions times larger than is usual for conven-
tional computation. The usual expectation is that larger populations can sustain larger
ranges of genetic variation, and thus can generate high-fitness individuals in fewer gener-
ations.
• Laboratory operations on DNA inherently involve errors. These are more tolerable in
executing evolutionary algorithms than in executing deterministic algorithms. (To some
extent, errors may be regarded as contributing to genetic diversity which is a desirable
property.)
GAs have been applied to solve various bioinformatics problems such as alignment and
comparison of DNA, RNA, and protein sequences [257, 391, 71], gene mapping on chromo-
some [248, 130, 116], gene finding from DNA sequence [175, 195, 166], interpretation of gene
expression and micro-array data [], gene regulatory network identification [386, 348], DNA,
RNA and protein structure prediction [8, 25, 9], construction of phylogenetic trees [196, 193]
and molecular design and docking [24, 268, 356, 129, 351, 179]. Even though this list is not
exhaustive, GAs have so far not been applied to in silico vaccine prediction.
4.4 Model Setup
Figure 4.2 provides an overview of our approach. Here we assume that the efficacy (cross-
reactivity) of a vaccine is accurately measured by a serological test (HI for influenza or VN
for foot-and-mouth disease) and that this can be predicted from the alignment of amino acid
sequences for the heterologous virus (e.g. outbreak strain) and homologous virus (e.g. the
vaccine strain) pair.
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Thus, to create our training and validation data sets we use serological test results (r1 values
from VNT for FMDV/HI assay values for influenza/r values from ELISA for Ebola. For details
of how these serological titre values are generated, refer to Section 2.2.2.1) and the sequence
data from the alignment files. The serological data results are directly used as the dependent
variables for regression analysis while the sequence data from pairwise comparisons are used
with three types of scoring methods (refer to Section 4.4.1 below), outputs of which are used as
the independent variables for regression analysis.
We use a linear regression model as well as a quadratic non-linear regression model to
predict the antigenic variability of two viral strains using sequence data and r1 values. The
parameters of the linear model are estimated using the least square method, while the parameters
and the structure of the quadratic model are optimised using an evolutionary algorithm.
Figure 4.2: Flowchart of Regression Analysis.
4.4.1 Scoring Methods
Scoring methods are used to determine the difference between a pair of aligned amino acid
sequences. Using our models we compared three different scoring methods i.e. ‘no weighting’,
‘grouping’ and ‘matrix scoring’ as we described in Section 2.6.
1)“No weighting”: the basic approach of counting the number of amino acid substitutions
between a pair of aligned sequences, as previously applied in studies on FMDV [290]. 2)
“Grouping” : a weighting method applied in studies on influenza A ([202]). The 20 amino
acids are divided into seven groups, namely, non-polar aliphatic, non-polar aromatic, polar,
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positively charged and negatively charged where substitutions between groups are assigned 1
while those within a group are assigned 0.
3)“Matrix Scoring”: Use of the PAM-120 matrix, a matrix scoring the probability of one
amino acid substituted by another in closely related species [72]. The matrix was modified by
setting the diagonal values to 0 so that identical amino acids in the two sequences are not scored.
The positive values were changed to zero and the negative values to positive so that frequently
occurring substitutions are not scored while the rare substitutions are scored. In addition, all
elements in the matrix were normalised between 0 and 0.5. The scores using this approach were
calculated by totalling the values of all elements corresponding to substitutions between pairs
of sequences.
4.4.2 Linear and Non-linear Regression Models
Linear and non-linear models were constructed to predict the antigenic variability. To examine
whether there are any differences in the influence of amino acid changes in different capsids
on the r1 value, we compare two approaches for calculating amino acid changes, one report-
ing the total number of changes across the three capsids (referred to as ‘non-looped’), while
the other reporting specific-capsid changes (referred to as ‘looped’). The scoring methods de-
scribed above were used as the continuous dependent variables for prediction using regression
techniques.
4.4.2.1 Linear Regression Model
Linear regression is the most widely used regression technique. It aims to find the best line
that fits the data. When the amino acid changes in all capsid proteins are totalled, the linear
model has only one dependent variable x, and the predicted VN titre or HI assay value (y) can
be predicted as follows:
y = β0 + β1x. (4.18)
When changes are calculated for specific antigenic regions there are three dependent variables
(x1, x2, x3), and the linear regression model for predicting the VN titre or HI assay value has
the following form:
y = β0 + β1x1 + β2x2 + β3x3, (4.19)
where β0, β1, β2 and β3 are the regression coefficients that need to be estimated. The pa-
rameters are estimated by minimising the mean squared error (MSE) between the experimental
and the predicted values [113], which is known as the least squares method (LSM).
4.4.2.2 Non-linear Regression Models
In the linear regression model, it is assumed that the VN titre or HI assay value depends lin-
early on the amino acid changes. However, this may be overly simplistic and not adequate for
describing the relationship between the VN titre or HI assay value and the amino acid changes.
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A non-linear regression model, however, can describe a more complex relationship between the
dependent (VN titre or HI assay value) and the independent variables (amino acid changes).
Here, we adopted a quadratic (second-order polynomial) non-linear regression model. Similar
to that described for linear models, there is one dependent variable if the amino acid changes
in the capsid protein(s) are totalled, and three variables if the amino acid changes are counted
specifically for each of the antigenic regions (capsid proteins). In the former case, the quadratic
model is in the following form:
y = β0 + β1x+ β2x
2, (4.20)
and in the latter case, the quadratic model has the following form:
y = β0 + β1x1 + β2x2 + β3x3
+β4x1x2 + β5x1x3 + β6x2x3
+β7x
2
1 + β8x
2
2 + β9x
2
3. (4.21)
where βi, i = 1, 2, ..., 9 are the regression coefficients to be determined. Typically, these
parameters can also be estimated using the least squares method.
In this work, we not only want to estimate the coefficients in the quadratic regression model,
but also to examine if any of the terms in the non-linear model in Equation (4.21) can be re-
moved to reduce the complexity of the model. This is potentially beneficial due to the small
number of experimental data available for determining the coefficients. In the following, we
describe in more detail a method for optimising the structure and coefficients of the quadratic
regression model using an evolutionary algorithm, specifically a hybrid genetic algorithm.
4.4.3 Hybrid Evolutionary Non-linear Model
Due to the success of EAs, they are used in a wide range of fields [249, 367, 367, 220] and in
bioinformatics research [12, 283, 267, 106].
Here we use NSGA-II [79], one of the most widely used multi-objective optimisation al-
gorithms [80] that is available to handle multiple objectives, but can also be set-up for a single
objective problem [250]. NSGA-II has been successful in many real-world applications such as
in engineering and design [220, 213], aerospace [187], image feature extraction [3] and power
planning [286, 285, 221]. We optimise both the structure as well as the parameters of the
quadratic regression model in Eq. (4.21) in Section 4.3.2. By structure, we mean here which of
the 10 terms in the non-linear model should be kept for prediction. We aim to find a quadratic
model of minimum complexity that best predicts the FMDV and influenza data. Meanwhile, we
intend to optimise the coefficients of the existing terms in the non-linear regression model. In
the following, we elaborate the details of the hybrid evolutionary algorithm used for optimising
the non-linear regression model.
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4.4.3.1 Single Objective Optimisation Set-up:
In order to optimise the structure and parameters of our non-linear regression model, we use an
error minimisation objective as the objective function in the single objective set-up. The steps
in the SO optimisation implementation are as follows:
Representation: A binary chromosome and a real-valued chromosome are used to repre-
sent the structure and coefficients of the non-linear regression model, respectively. The binary
chromosome has 10 bits of a value ‘0’ or ‘1’, where a ‘1’ means that the corresponding term
of the model in Eq. (4.21) is kept in the model and a ‘0’ indicates that the corresponding term
is deleted. The real-valued chromosome directly encodes the coefficients. For example, the
following individual
1 0 0 0 1 0 1 0 0 1
0.1 1.2 -1.5 0.5 2.2 0.3 -0.8 0.1 1.8 3.2
defines the following non-linear regression model:
y = 0.1 + 2.2x1x2 − 0.8x2x3 + 3.2x23. (4.22)
Population: In this work, the population size is set to 100, with each individual representing
a candidate non-linear regression model specified by two chromosomes. The initial parent
population is generated randomly, the value of the binary chromosome is set to ‘0’ or ‘1’ at
with a probability of 0.5, respectively, whereas the the value of the real-valued chromosome is
set to a uniformly distributed random number between [-0.1, 0.1].
Fitness function: The fitness of the individuals is determined by calculating the MSE be-
tween the predicted and the experimental r1 values:
MSE =
1
N
N∑
i=1
(
yi − ydi
)2
, (4.23)
where yi and ydi are the r1 value predicted by the model and the experimental value of the i-th
training data pair, respectively, i = 1, 2, ..., N , N is the number of training samples.
The selection strategy adopted in this work is an elitism strategy. Before selection, the
offspring population is combined with the parent population, forming a population of 200 indi-
viduals. Then, the best 100 individuals are selected as the parents for the next generation.
Reproduction: The binary tournament selection is adopted to select individuals from the
parent population to generate offspring, one at a time. Each time, two individuals in the parent
population are randomly selected and the fitter is chosen as a parent. This is repeated to choose
a second parent individual.
Crossover and mutation are applied to the two parents to generate two offspring individuals.
As each individual has two different types of chromosome, different crossover and mutation
operators are applied to the binary and real-valued chromosomes. For the binary chromosome,
uniform crossover and flip mutations are employed. For the real-valued chromosome, SBX and
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polynomial mutation are used. The probability for crossover and mutation are specified to be
0.9 and 0.1, respectively. This process repeats until 100 offspring are generated.
Selection As in NSGA-II [81], parent populations are combined with the offspring popula-
tion before selection. The 200 individuals are sorted based first on the individuals’ front number
in a decreasing order and then on the crowding distance in an increasing order. Finally, the first
100 individuals are selected as the parents of the next generation. In this work, 500 generations
are run before the evolutionary optimisation is terminated.
4.4.3.2 Multi-objective Optimisation Set-up:
NSGA-II is one of the most efficient multi-objective evolutionary algorithms [77]. It generates
a Pareto optimal solution set, rather than a single solution, via comparison of the qualities of
different solutions by using an elitist approach (i.e., a fast non-dominated sorting and crowding-
distance estimation procedure. The use of multiple objectives can improve success rates and can
solve complex problems. Our previous regression modelling results show that the sensitivity
and specificity of the models were quite low for some models and increase in one, resulted in
decrease of the other. Moreover, training models based on small datasets are particularly prone
to type II (false positives). Type II errors are closely linked to type I errors (refer to Section
2.12 for more details) and the task of optimizing the performance (high sensitivity and low
false-positive rate) of the model, is a multiobjective problem i.e. to simultaneously increase
the sensitivity and reduce the false-positive rate of the system. We therefore describe the two
objectives by a single objective function, which is commonly created by taking a weighted sum
of the sensitivity and false-positive rate.
In our MO setup of NSGA-II we use the same chromosome representation, population size,
mutation and crossover probabilities as our SO setup above (refer to Section 4.4.3.1 for de-
tails). We define our MO optimisation problem in terms of two deciding components of model
performance i.e. minimisation of false positive rate (FPR) (1-specificity) and maximisation of
true positive rate (TPR) (sensitivity). To formally define our fitness function: If TP = true posi-
tive (positive correctly classified),TN = true negative (negative correctly classified), FP = false
positive (negative classified as positive), FN = false negative (positive classified as negative).
TPR = TP/(TP + FN)
FPR = FP/(TN + FP )
TPR = Sensitivity
FPR = 1− Specificity
If ~w∗ and ~w are two parameter vectors, with ~g∗ = [g∗1, g
∗
2, ..., g
∗
n] =
~f(~w∗) and ~g =
[g1, g2, ..., gn] = ~f(~w). The parameter vector ~w is said to dominate ~w∗ if ~gi ≤ ~g∗i ; i = 1, ..., n;
and ~gi < ~g∗i for at least one i ∈ 1, ..., n. The solution to the multi-objective problem is the
Pareto-optimal set, comprised of all non-dominated vectors { ~w∗}. The objective vector ~f(~w∗)
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in our setup is compromised of the two components
f1(~w) = −Sens(~w;D),
f2(~w) = FPR(~w;D) (4.24)
where D ⊂ S denotes the set of input vectors {~x} that are used to compute ~f(~x). The
optimisation task is to minimise the set of equations in Eq. 4.24. The Pareto-optimal set contains
the vectors ~w that provide the limiting tradeoffs between Sens(~w;D) and FPR(~w;D). In other
words, for a given FPR(~w;D) value the Pareto-optimal solution will correspond to the solution
possessing the largest possible Sens(~w;D) value.
The practical implementation of NSGA-II in our MO setup can be summarized as follows:
1. The maximum number of generations was set at 500 and the number of chromosomes
(individuals) N in each population was fixed at 10. Each chromosome codes a solution
by G = 10 real-valued genes, where the total number of parameters (weights and biases)
is 10 in the non-linear regression : thus, each chromosome represents the model as in
Eq. (4.21). Set the generation number n = 1. Initialize the first population Pn of size
N , by randomly generating N chromosomes (corresponding to the non-linear regression
model).
2. For each input vector x in the training set, compute the outputs of N for the non-linear
regression model.
3. Evaluate the two objectives −Sens(~w;D) and FPR(~w;D) for the N non-linear regres-
sion models; then, one pair of values−Sens(~w;D) and FPR(~w;D) is associated to each
of the N chromosomes in the population Pn.
4. Rank the chromosomes (vectors of G values) in the population Pn by running the fast non-
dominated sorting algorithm with respect to the pairs of objective values, and identify the
ranked non-dominated fronts F1, F2, ..., Fk where F1 is the best front, F2 is the second
best front and Fk is the least good front.
5. Apply to Pn binary tournament selection based on the crowding distance as described in
Section 4.3.2.3, for generating an intermediate population Sn of size N .
6. Apply the crossover and mutation operators to Sn, to create the offspring population of
size N .
7. Apply step 2 to Qn and obtain outputs.
8. Evaluate the two objectives in correspondence of the solutions in Qn, as in step 3.
9. If the maximum number of generations is reached, stop and return Pn . Select the first
Pareto front F1 as the optimal solution set. Otherwise, go to 10.
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10. Combine Pn and Qn to obtain a union population Rn = Pn ∪ Pn.
11. Apply steps 2 to 4 to Rn and obtain a sorted union population.
12. Select the N (set as 10 here) best solutions from the sorted union to create the next parent
population Pn+1.
13. Apply steps 5 to 8 to Pn+1 to obtain Qn+1. Set n = n+ 1; and go to step 9.
14. Finally, the best front in terms of ranking of non-dominance and diversity of the individual
solutions is chosen.
Here, we evaluate a set of model parameters in Eq. 4.21 using both objectives in Eq. 4.24
producing a Pareto front of possible solutions for the problem. In general for multi-objective
optimisation problems the objectives are conflicting resulting in trade-off solutions that cannot
be compared without user preference or system constraints [80]. In this case however, the
problem is actually a single objective problem with the goal of creating a weighted sum of the
sensitivity and false-positive rate. Therefore we can select one solution from the front as the
best solution based on one of its objective values and do not have to add additional preferences
or constraints.
To select the best solutions, we search the Pareto front to obtain the best parameter values.
As defined in Eq. 4.24, the two objectives are determined through the minimisation of false
positive rate (FPR) (1-specificity) and maximisation of true positive rate (TPR) (sensitivity)
for each combination of input variables (number of amino acid substitutions in whole capsid
or a particular antigenic loop) in our model. Thus by retaining the FPR and TPR for each
individual combination of input variables, we are able to search the Pareto front to obtain the
solution (parameter set) that corresponds to the lowest FPR and (-sensitivity). Each solution on
the Pareto front has two objective values each of which corresponds to sequence of individual
combination of input variables i.e. amino acid substitution values (produced from a specific
parameter set), Eq. 4.24. As this is a two objective problem, for each combination of amino acid
substitutions, we determine the best overall solution, i.e. optimal parameter sets for the whole
model, by obtaining the best set for each combination of amino acid substitutions by searching
the front. As illustrated in Figures 4.3a and 4.3b, the best parameter set for a given model is
determined as the set that produce the lowest FPR and (-sensitivity). For each combination of
amino acid substitutions in turn, the front is searched to obtain the solution corresponding to
the lowest FPR from f1 or the lowest (-sensitivity) from f2.
To ensure fairness of the comparison of the SO and the MO set-ups the same crossover
and mutation operators were used in both cases. In the MO evolutionary algorithm, elitist non-
dominated sorting operations are used, see Section 4.3.2.3. Like in the SO set-up in the MO
set-up, we use a population size of 100 and run for 500 generations with a crossover probability
of 0.9 and mutation probability of 0.1.
We also study two methods for weighting the importance of amino acid changes, one based
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(a) (b)
Figure 4.3: Pareto front (a) of non-dominated solutions (b) of multi-objective problem in Eq.
4.24. Illustrated here is a front of n solutions for the model of N (10 here) combinations of
amino acid substitutions. The overall best solution, so, is selected by taking the sum of the N
f oi values. The f
o
i values are selected for the Nth combination of amino acid substitutions by
evaluating the minimum of xfa (minimising FPR) and yf b (minimising -sensitivity), where x
and y are the solution number (1 to n) that yields the lowest xfa and yf b respectively.
on the characteristics and structure of amino acids and the other based on amino acid substitu-
tion scores (PAM/BLOSUM)3.
In addition to the two weighted approaches, a non-weighted approach was also adopted,
where all amino acid changes were counted equally. The weighted and non-weighted amino
acid changes were used as the continuous dependent variables for prediction using regression
techniques.
4.5 Results and Discussions
In the following we compare the prediction performance of the linear and non-linear regression
models, where in one case the amino acid changes on the entire three capsid proteins are totalled
(herein referred to as ‘no loops’), and in the other case, the changes in the three antigenic regions
are counted separately (referred to as ‘loops’).
4.5.1 Datasets
Three datasets comprising serological and amino acid sequence data for outbreak-vaccine strain
pairs for three different viruses were used to train and cross-validate our models: (1) 22 FMDV
SAT2 outbreak-vaccine strain pairs, taken from Reeve et al.; (2) 52 outbreak-vaccine strain
pairs for FMDV A, taken from Upadhyaya et al.[352]; and (3) 54 outbreak-vaccine strain pairs
for influenza A H3N2, taken from Liao et al.[202].
3PAM matrices are used to score alignments between closely related protein sequences using global alignments
while BLOSUM matrices are used to score alignments between evolutionarily divergent protein sequences using
local alignments. For details refer to [246]
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Amino acid sequences for FMDV and influenza A were either downloaded from GenBank
(http://www.ncbi.nlm.nih.gov/genbank/)[30] or provided by Mana Mahapatra, personal com-
munication. Accession numbers of all sequences can be found in Appendix A and C. The
sequences of a particular viral serotype were harmonised to the same length (743 residues for
SAT2 comprising viral proteins (VP) 1-3, 735 residues for A similarly comprising (VP) 1-3
and 349 residues for HA1 gene of H3N2) by obtaining a multiple sequence alignment using
ClustalW [343]. The alignment files for FMDV SAT2 and influenza H3N2 can be found in
Appendix F. This alignment was used to identify substitutions between the pairs of sequences
for which the serological data was available. We have used two different approaches to build
the models. In one we have used substitutions only from specific antigenic regions, two regions
in VP1 and one in VP2 [290] for FMDV (SAT2 and A) and three regions in H3N2 HA1 [192].
In the other setup, we have used substitutions in all three capsid proteins (VP1, VP2 and VP3)
for SAT2 and A, and the entire HA1 sequence for H3N2.
4.5.2 Comparison of Linear Regression, Non-Linear Regression with LS
and Non-Linear Regression with GA Models
In the following we compare the prediction performance of the linear and non-linear regression
models, where in one case the amino acid changes on the capsid protein(s) are totalled (herein
referred to as ‘no loops’), and in the other case, the changes in the three antigenic regions are
counted separately (referred to as ‘loops’). The agreement rates for the two FMDV serotypes
SAT2, A and influenza A are shown in Table 4.1. The MSEs for the same datasets are presented
in Figures 4.4, 4.5 and 4.6 respectively. From the figures, we can see that better prediction
results can be achieved when the amino acid changes in different capsid proteins are treated as
different independent variables. The agreement rates for models with immunodominant posi-
tions (a total of 39) or ‘loops’ were at least similar or better than those containing amino acid
positions for the capsid protein(s). In addition, the MSEs for the models with antigenic loops
are lower than those without loops except the “scoring model”, whose MSEs are almost the
same, refer to Figures 4.4, 4.5 and 4.6. It is noteworthy that the non-linear grouped model op-
timised using the GA obtained the best performance. The results from the three datasets for
FMDV SAT 2, two datasets for FMDV A and two datasets for influenza are consistent across
serotypes. SAT2 results presented here are for SAT2 sequence RWA/2/01, A sequence TUR02
and influenza Phyllipines/02/82/01.
Even though the capsid protein(s) are directly involved in determining the antigenicity of
the virus, from the modelling point of view, it is only the specific antigenic areas (loops) that
are most relevant. However, when the changes in capsid(s) are summarised, useful information
for prediction purposes may be lost, resulting in poor prediction performance. Indeed, certain
positions within the capsid proteins, not included in the antigenic loops may be essential for im-
proving the prediction quality. Thus a way to weigh each position to extract the most significant
ones will greatly improve the model based on antigenically relevant residues.
When we compare scoring methods, the grouping method performs the best out of the three.
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The grouping method had agreement rates between 73% and 100% while the matrix scoring
method between 26% and 85%. For the non-weighted approach, it was between 62% and
90% across all datasets. The lower rates correspond to models involving residues in the capsid
protein(s). Table 4.1 shows the performance of the weighted and the non-weighted linear and
non-linear models.
We know that, in nature, substitutions of an amino acid with another amino acid with sim-
ilar properties is permissible, with the overall structure/function of the protein remaining un-
changed. The grouping method exploits this phenomenon by scoring substitutions with similar
biochemical properties as 0 and substitutions that may change the structure and/or functions of
the resultant proteins as 1. The non-weighted approach that considers all substitutions regard-
less of structural relevance, includes frequent substitutions that are of little significance to the
model; the overall result of this is a poor quality model.
The grouping method that classifies amino acids based on their biochemical properties dis-
tinguishes between amino acid substitutions based on their relevance to the overall protein struc-
ture and thus would be expected to enhance the regression models. The 20 amino acids have
different properties and not all substitutions are equally important for measuring antigenic vari-
ability. It is also known that certain amino acid substitutions are more common than others
[32].
The prediction power of the matrix scoring method was unexpectedly low. Even though the
modified PAM matrix (positive values being removed for regression, the values in the matrix for
very different types of substitutions (originally different positive values) were the same. Thus,
the effects of frequently occurring substitutions, were replaced by 0 and negative values being
made positive) was normalised to relay some information about they may be of very different
types, were added with the same probability, resulting in similar, if not identical, scores for very
different amino acid changes between viruses.
Referring to the correlation analysis we performed earlier (refer to Section 3.5.3 for details)
for the type of amino acid substitutions and antigenic similarity between virus, some commonly
occurring substitutions have no correlation or are slightly positively correlated to antigenic sim-
ilarity. Pearson’s correlation coefficient for T-A/A-T and S-A/A-S substitutions is 0.179 and
0.312, respectively. The correlation obtained was weak due to the limited amount of data avail-
able for the analysis. This is contrary to the expectation that the number of amino acid substi-
tutions must be negatively correlated to antigenic similarity. However, for some less frequently
occurring substitutions the correlation was seen to be weakly negative. This is explained by the
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fact that, in nature, substitutions of one amino acid with another of similar properties is
permissible, with the overall structure/function of the protein remaining unchanged [58]. The
grouping method exploits this phenomenon by scoring substitutions with similar biochemical
properties as 0 and substitutions that may change the structure and/or functions of the resultant
proteins as 1. The non-weighted approach that considers all substitutions regardless of structural
relevance, includes frequent substitutions that are of little significance to the model; the overall
result of this is a poor quality model.
There was not much difference between the results of the non-linear regression model with
LSM and the one optimised using a GA although in most cases the performance of the latter is
slightly better. From Figs. 4.4 to 4.6 and Table 4.1, it can be seen that there is no clear trend of
increasing or decreasing MSE or agreement rates between the two types of models.
However, the performance of the non-linear models was consistently better than the linear
models across all virus datasets, scoring methods and antigenic regions (i.e, loops/non-loops).
Eqs. (4.25) and (4.26) detail are the two best performing quadratic models; a grouped with
loops and a non-weighted with loops model, respectively for SAT2.
f(x) = 0.09 + 0.07x1 + 0.09x2 + 0.03x1x2 − 0.07x2x3
− 0.03x21 + 0.09x22 − 0.06x23. (4.25)
f(x) = 0.07− 0.01x1 + 0.07x2 + 0.006x3 + 0.05x1x2
− 0.002x1x3 − 0.06x2x3 + 0.0865243x22 − 0.1x23. (4.26)
These regression models have a much larger number of terms than their linear counterparts.
In other words, the non-linear models have a much higher complexity than that of the linear
models.
In the cases where the GA-optimised non-linear regression models have performed worse
than the linear models, the non-linear models were found to be much simpler, refer to the
Tables 4.2 and 4.3 for details. This implies that the relationship between the variables may be
highly non-linear and there is a complex additive effect of two or more types of amino acid
substitutions, which can be better explained by quadratic terms.
Liao, et al. have used a multiple regression model to predict the antigenic similarity between
influenza sequences, and have reported an agreement rate of 91.67% for their best model [202]
while Reeve, et al. have reported 98% and 77% (for different serotypes of FMDV) agreement
rate for their linear mixed effects model [290]. Compared to these models which have also
used cross-reactivity essay and sequence data, our best model (multiple regression with EA)
has achieved a higher agreement rate (100%). Thus evolutionary optimisation techniques might
be an important tool in improving our models considering that cross-reactivity values might be a
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complex function of the effects of many interlinked amino acid substitutions making parameter
estimation a challenge. However, due to the lack of serological data, the results reported here
are still preliminary. Although, even with the limited data we have achieved results that make
good biological sense. These results are promising, indicating that nature-inspired optimisation
techniques may be applied to solve challenging biological problems.
Figure 4.4: The MSEs of the linear and non-linear regression models using different weighting
methods for antigenic regions and whole capsid proteins for FMDV serotype SAT2. Key: L-
with loops, NL-no loops, NW-Non-weighted, G-grouped, MS-matrix scored.
Figure 4.5: The MSEs of the linear and non-linear regression models using different weighting
methods for antigenic regions and whole capsid proteins for FMDV serotype A. Key: L-with
loops, NL-no loops, NW-Non-weighted, G-grouped, MS-matrix scored.
We also calculated the 95% confidence interval for all model coefficients to find out the
statistically significant ones which supports the above and are reported in Table 4.1. This implies
that the relationship between the variables may be highly non-linear and there is a complex
additive effect of two or more types of amino acid substitutions, which can be better explained
by quadratic terms.
88
Figure 4.6: The MSEs of the linear and non-linear regression models using different weighting
methods for antigenic regions and whole capsid proteins for influenza A. Key: L-with loops,
NL-no loops, NW-Non-weighted, G-grouped, MS-matrix scored.
Table 4.2: Parameters of the linear models. Key: NW-Non-weighted, G-Grouped, S-Scored,
L-Looped, NL-No loop.
Parameter no. NW-L NW-NL G-L G-NL-L S-L S-NL
1 0.0881336 0.160372 0.111151 0.149279 0.091411 0.443188
2 0.00388561 0.00503442 -0.0491645 0.00754729 -0.0839796 -0.176372
3 0.0916292 -0.0171631 -0.0190458 0.0617458 0.332496 0.0689416
4 -0.0169663 0.0069817 -0.0189816 -5.07695e-005 0.0350038 0.1
Table 4.3: Parameters of the non-linear models using GA. Key: NW-Non-weighted, G-
Grouped, S-Scored, L-Looped, NL-No loop.
Parameter no. NW-L NW-NL G-L G-NL-L S-L S-NL
1 0.074526 0.0958093 0.1 0.0999509 0.1 -0.0108597
2 -0.0116088 0 -0.000142357 0.00312726 -0.0235289 0
3 0.0794772 0 0.251453 -0.00425561 0 0.1
4 0.00613178 0.00434499 -0.0294078 0 0.0350038 0.1
5 0.0591156 0 0.0981995 0 -0.1 -0.0144461
6 -0.00214484 0 0.0535674 0 0.1 -0.0644223
7 -0.0601213 0 0 0 0.1 0
8 0 6.69795e-005 -0.0593979 0 -0.1 0
9 0.0865243 -0.000370123 0.069961 0 -0.1 0
10 -0.1 0 0 0 0.1 0.1
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4.5.3 Comparison of SO and MO Non-Linear Regression Models
In the following we compare the prediction performance of the non-linear regression models
optimised by a single objective and two objectives. Some of our single objective models (par-
ticularly the unloopd models) gave a high a number of type II errors which was the motivation
behind trying to minimise the probability of type I and type II errors using a MO approach. Here
we present the results obtained with three datasets (FMDV serotype SAT2, FMDV serotype
A and influenza A). For details of the datasets, refer to Section 4.5.1. We considered three
datasets for which the SO set-up gave the worst results, to see whether the MO set-up made
any improvements on them and we present only the results of the best scoring method i.e. the
grouping method since the matrix scoring and the unweighted methods gave consistently worse
results than the grouped method across the learning algorithms and for all datasets. Refer to
Table 4.4 for these results.
The error rates of the two models with grouping method for the three datasets are given
in Figures 4.8, 4.9 and 4.10. From the figures, we can see that the MO optimisation set-up
improves the overall error rate of the models by 1 − 13% if we consider all the datasets. From
Table 4.4, we can also see that the proportion of type II error was reduced by 4 − 12% in the
models using the MO optimisation compared to the SO optimisation set-up.
The MO set-up gave slightly better results than the SO set-up because MO optimisation
increases generalisation ability particularly when the dataset is very small. The MO set-up has
the potential to conduct a better search of the parameter space by providing diverse solutions
(Pareto front) rather than a single optimal solution as in the SO set-up.
Table 4.4: Performance results of SO and MO models for FMDV and influenza data. Key: Sn-
Sensitivity, Sp-Specificity, Agg. rate-Agreement rate, G-L-Grouped looped, G-NL-Grouped no
loop.
Analysis Weighting FMDV SAT2 (N=22) INFLUENZA (N=54) FMDV A (N=54)
Sn Sp Ag rate Sn Sp Ag rate Sn Sp Ag rate
NLR G-L 100 95 98 100 78 95 95 80 95
(SO) G-NL 57 80 75 55 79 72 60 80 75
NLR G-L 100 99 99 99 98 99 98 99 98
(MO) G-NL 65 86 85 64 82 85 67 87 77
Figure 4.7 shows the Pareto front approximation of the non-dominated solutions to the
MO problem. We also plot the best solution for our SO problem to compare it with the non-
dominated solutions of our MO Pareto front. To select the best solution we search the Pareto
front to obtain the best parameter values with respect to the two objective functions i.e. min-
imising the FPR and maximising sensitivity. From the front of non-dominated solutions, we
choose the one that is a good trade-off between the two objectives. Due to the nature of the aim
of our modelling work i.e. in silico prediction of a vaccine, the number of false positives have
a critical effect on the quality of the model as a wrongly predicted non-vaccine as a vaccine
could have serious implications in the application stage. Thus when selecting the best solution,
we give a higher weight to minimising the false positive rate than maximising the sensitivity
of the model. We also plot the best solution for our SO problem by plotting the sensitivity and
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FPR for the model with the lowest MSE (which was our objection function for the SO setup).
From the figure we can see that the best solution for our SO problem is very close to the Pareto
front of the MO problem. Although we can see that for our vaccine prediction model, two other
solutions on the Pareto front to the left of the best SO solution would be a better trade-off in
terms of overall performance (minimising FPR and maximising sensitivity) of the model.
Figure 4.7: Pareto front approximation of MO model for grouped looped model using FMDV
serotype A. The non-dominated solutions to the MO problem are shown as red diamonds and
the best solution for our SO problem for the same dataset using the same weighting method.
When we looked at the parameters of our SO and MO models with our best scoring method
i.e. grouped, we saw that they both retained most of the parameters of the non-linear model.
Both the models were similar in complexity across the datasets, although the MO setup reduced
one to two parameters compared to the SO setup for both the looped and the unlooped mod-
els. Table 4.5 presents the coefficients of the MO and SO for an FMDV serotype A dataset.
This could be because MO has the potential to conduct a better search of the parameter space
by providing diverse solutions due to the nature of the MO problem. The MO optimisation
process removes the need for the direct optimisation of just the MSE (as in the SO setup) and
therefore reduces the number of parameters in the optimisation problem. Reducing the number
of parameters reduces the search space and could therefore enhance convergence to the global
optimum.
The MO optimisation set-up takes into account the performance (FPR and sensitivity) of the
models and obtains comparable or slightly better) results than the SO optimisation set-up (that
optimises on a global error), carrying out the trade-off between objectives.
We also compared the results of SO optimisation and MO optimisation on two other datasets
for which the results for the two set-ups were very similar ( and as such we haven’t presented the
results here). We think this is because those datasets were slightly bigger (72 and 75 samples)
than the ones we have presented here and also the spread of the data was more diverse allowing
more generalisation even in the SO optimisation set-up.
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Table 4.5: Coefficients of the non-linear models using SOO and MOO FMDV serotype A. Key:
SO-Single objective, MO-Multi objective, G-Grouped, L-Looped, NL-No loop.
Coefficient M0(G-L) MO(G-NL) SO(G-L) SO(G-NL)
β0 0.046 0.086 0.023 0.076
β1 -0.034 0 0.054 0
β2 0 0.054 0.043 -0.056
β3 0.016 0.078 0 -0.041
β4 -0.089 0.045 0.032 0.075
β5 0.078 0 0.067 -0.043
β6 0.026 -0.047 0.084 0.036
β7 0.043 -0.056 0.039 0.047
β8 0 0.056 -0.098 0.054
β9 0.043 0 0.057 0.048
Figure 4.8: The error rates of the non-linear regression models using SOO and MOO with the
grouped weighting method for antigenic regions and whole capsid proteins for FMDV serotype
A. Key: L-with loops, NL-no loops, G-grouped.
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Figure 4.9: The error rates of the non-linear regression models using SOO and MOO with the
grouped weighting method for antigenic regions and whole capsid proteins for FMDV serotype
SAT2. Key: L-with loops, NL-no loops, G-grouped.
Figure 4.10: The error rates of the non-linear regression models using SOO and MOO with
the grouped weighting method for antigenic regions and whole capsid proteins for influenza A.
Key: L-with loops, NL-no loops, G-grouped.
4.5.4 Hypothesis Testing
We carried out statistical analysis to assess whether our best model (non-linear regression with
GA using the grouped looped scoring method) performed better than the linear, non-linear re-
gression with LS and cubic models using the same scoring methods. The result of the test
was;
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For the linear model, the r2 (coefficient of determination of the regression line) was 0.186
and p value (probability of obtaining the observed sample results when the null hypothesis is
true) was 0.10. For the non-linear model with LS r2 was 0.326 and p was 0.05; for the cubic
model r2 was 0.467; p was 0.02. However, for our non-linear model with GA r2 was 0.787; p
was 0.0002. The above results show that even though there are improvements in both r2 and p
values from one to the next higher degree model, our method using a quadratic model with GA
performs better than a cubic model. Thus we can confidently reject the null hypothesis that our
non-linear regression with GA does not perform better than the linear and the cubic models.
4.5.5 Test Results with Unseen Data
We also used five additional pairwise comparisons of FMDV A sequences (provided by The
Pirbright Institute) to test our best model (grouping method with non-linear regression using
GA). The model was able to achieve an 80% agreement rate with the actual serological data.
Both the non-linear using LS and the linear models achieved 60% agreement rate on the actual
data. It was generally seen that the sequences for which the test results did not match the
actual serological data, the input variables for testing were outside the range of the data that
was used for training the models. Consequently, we think that the availability of more data for
training would have helped us achieve better agreement rates to the actual data. Table 4.6 gives
a summary of the results. These results are highly encouraging, considering that a very limited
amount data was available for training the models. Our results clearly indicate that nature-
inspired optimisation techniques are competitive for solving challenging biological problems.
4.5.6 Discussion
We compared three types of regression models, namely, linear, quadratic with parameter op-
timisation using LSM, and quadratic with both the structure and parameters being optimised
with a hybrid GA. All of these models were further compared based on the presence/absence of
specific antigenic loops for FMDV and influenza. The looped models performed ∼ 20% better
than the unlooped models.
Better prediction results are achieved when amino acid changes in the capsid(s) were treated
as different independent variables. Models with substitutions in the antigenic areas performed
better than ones that took the entire exposed viral capsid protein(s) i.e. only the specific anti-
genic regions on the capsid protein(s) are most relevant for modelling. When substitutions in
the capsid(s) are summarised, important information for prediction may be overlooked resulting
in poor results.
MSEs for looped models are lower than their unlooped counterparts except the scoring
model for which the MSEs are almost the same. Comparing the weighted and the non-weighted
methods, the grouping method performed best among the three, which is probably because the
grouping method classifies amino acids based on their biochemical properties that enhances
the models. The non-weighted approach did not perform as well as the grouping method per-
haps because it considers all substitutions regardless of structural relevance, thereby including
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Table 4.6: Comparison of predicted and actual r1 values using our grouping method with the
three types of regression models. Key: St 1-vaccine strain 1 (IRQ/24/64), St 2-vaccine strain 2
(TUR/20/06).
Challenge Model Predicted Actual
Strain St 1 St 2 St 1 St 2
IRN/07/13 NLR
with GA
0.17 0.29 0.15 0.25
NLR
with LS
0.11 0.15
LR 0.09 0.16
IRN/35/12 NLR
with GA
0.15 0.39 0.18 0.45
NLR
with LS
0.18 0.22
LR 0.08 0.18
TUR/05/12 NLR
with GA
0.53 0.25 0.24 0.28
NLR
with LS
0.32 0.44
LR 0.15 0.36
IRN/01/13 NLR
with GA
0.20 0.29 0.095 0.221
NLR
with LS
0.30 0.15
LR 0.21 0.40
SAU/23/86 NLR
with GA
0.56 0.11 0.1 0.14
NLR
with LS
0.22 0.17
LR 0.46 0.02
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frequent substitutions of little significance to the model. The prediction power of the scoring
method was unexpectedly low which is probably because a significant amount of biological data
was lost when the substitution matrix was normalised to penalise only the non-frequent substitu-
tions. Overall, the models that combined the scoring method based on biochemical properties of
amino acids with non-linear regression for the specific antigenic areas on the capsid protein(s)
gave best results.
We used a GA to optimise the structure and parameters to fit the non-linear model. GA is a
much more robust optimisation method than LSM as LSM cannot find the optimal solution of
coefficients if the initially guessed solution is not sufficiently close to the ideal solution. Hence,
GAs are able to work well with noisy biological data, which is reflected in our results as the
non-linear regression models using the GA performed consistently better (throughout datasets)
than the linear and the non-linear models whose parameters are estimated using the LSM.
We use the hybrid GA model in two set-ups namely SO and MO and we get slightly better re-
sults with the two objective set-up rather than the single objective one. The MO set-up achieves
better generalisation than in the SO optimisation case because of a more diverse search space.
Some of the results of both the MO and SO set-ups were very similar and on close inspection of
the dataset, we saw that those datasets were more balanced and thus had a better spread of data.
The predictive ability of any model heavily depends on the data used to build them. Thus
the quality and availability of data has a profound effect on the efficiency and the predictive
ability of the method. Consequently, due to lack of serological data, the results reported in
this report could still potentially be improved. Nevertheless, considering that we have achieved
similar results across six datasets for two different viruses (FMDV and influenza), it would not
be unreasonably optimistic to say that similar models can perhaps be deployed for other viruses
when working towards developing an in silico vaccine predictor.
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Chapter 5
Classification Models for Vaccine
Prediction
Classification tasks are carried out in a wide range of human activities. Most generally speaking,
the term can mean some decision made on the basis of currently available information, and a
classification procedure is then some formal method for repeatedly making such judgements in
new situations. It is the construction of a procedure that will be applied to a continuing sequence
of cases, in which each new case must be assigned to one of a set of pre-defined classes on the
basis of observed attributes or features.
More formally, classification is the problem of identifying to which of a set of categories a
new observation belongs, on the basis of a training set of data containing observations whose
category membership is known. An example would be sorting mail based on postcodes or
suggesting immediate treatment to a patient based on preliminary diagnosis of a disease [235].
An algorithm that implements classification is known as a classifier. Often, the individual
observations are analyzed into a set of quantifiable properties, known as observed attributes or
features. This features can be in the form of real, integer, categorical or ordinal data. Other
classifiers may use similarity or distance function to compare new observations to previous
ones.
In machine learning, classification is considered an instance of supervised learning, i.e.
learning where a training set of correctly identified observations is available. The corresponding
unsupervised procedure is known as clustering, and involves grouping data into categories based
on some measure of inherent similarity or distance [5].
Even though most learning models and systems in artificial intelligence apply inductive
inference, transductive modelling has been seen to work better with sparse high dimensional
biological data [159, 339].
5.1 Inductive vs. Transductive Learning
The main aim of learning classifiers is to assign labels to the working set i.e unlabelled data
using the training set i.e labelled data. In the case of supervised learning, the working set is
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empty while in the case of unsupervised learning the training set is empty and many clustering
approaches exist in such situations. When both training set and working set are non-empty,
transductive and semi-supervised learning can be implemented where both both sets are used
for learning phase of classifiers.
The transductive approach’s main goal is to label the working set while inductive approach
tries to classify the whole problem space. The latter learn a decision rule based on training set
and then apply it to working set.
The inductive approach estimates a function based on data from the whole problem space
and uses this function to predict output values for a new input values, which can be any point
in this space. In contrast, the transductive learning methods estimates the function only for a
single point of the space by using additional information related to this point [359, 160]. Fig. 5.1
illustrates separation using only training data which may not seem like a perfect solution when
the size of training data is relatively small. Fig. 5.2 shows the hyperplane separator when
transductive approach is applied. The output of transductive methods only labels working sets,
not the classifier.
Figure 5.1: Separator hyperplane by SVM for positive, negative and unlabelled (solid circles)
data.
Figure 5.2: Separator hyperplane by TSVM for positive, negative and unlabelled (solid circles)
data.
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5.1.1 Inductive Support Vector Machines
The start of this century saw support vector machines (SVMs) being widely used for pattern
recognition in computational biology. They have found application in protein homology de-
tection, prediction of protein-protein interactions, analysis of microarray gene expression data,
identification of translation start sites and functional classification of promoter regions [359].
There are two main reasons underlying the use of SVMs in computational biology. One
being that biological data can be noisy and high-dimensional, with which SVMs are known to
deal better compared to other machine learning techniques. The other being that unlike most
machine learning methods, kernel methods like SVM can handle non-vector inputs which are
common in biological data such as variable length sequences.
SVMs are a class of supervised learning algorithms first introduced by Vapnik [359]. If
there is a set of positive and negative labelled training vectors, SVMs learn a linear decision
boundary to separate the two classes. The resultant linear classifier can be used to classify new
test examples.
For a typical learning task P (x, y) = P (y|x)P (x) , an inductive SVM learner aims to build
a decision function fL : x −→ −1,+1 based on a training set St1 , which is
fL = L(St1)
where : St1 = (x1, y1), (x2, y2), ...., (xn, yn), (5.1)
The computation of fL is carried out by minimizing the empirical risk, as:
R =
1
l
N∑
i=1
|f(xi)− yi| (5.2)
where N and f represent the size of examples and the classification decision function respec-
tively, l is a constant for normalization. SVM tries to determine an optimal separating hyper-
plane that gives a low generalization error. Usually, the classification decision function in the
linearly separable problem is represented by
fw,b = sign(w.x+ b) (5.3)
SVM determines the optimal separating hyperplane by drawing the largest margin of sepa-
ration between classes. The following minimisation constraint is met by bisecting the shortest
line between the convex hulls of the two classes:
min
1
2
wTw
where : yi(w.x+ b) ≥ 1. (5.4)
For the linearly non-separable case, the minimization problem is modified to allow misclas-
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sified data points. This modification results in a soft margin classifier that allows but penalizes
errors by introducing a new set of variables ξli=1 as the measurement of violation of the con-
straints.
min
1
2
wTw + C(
L∑
i=1
ξi)
where : yi(w.φ(x) + b) ≥ 1− ξi. (5.5)
where C and k are used to weight the penalizing variables ξli=1, and ξ(.) is a nonlinear
function which maps the input space into a higher dimensional space. Minimizing the first term
in Eq.5.5 corresponds to minimizing the dimension of the learning machine and minimizing the
second term in Eq.5.5 controls the empirical risk. Therefore, in order to solve problem Eq.5.5,a
set of functions are constructed, and classical risk minimization is implemented on the set of
functions. Using a Lagrangian method is used to solve the above problem Eq.5.5 can be written
as:
minF (Λ) = Λ.1− 1
2
Λ.D.Λ,
where : Λ.y = 0; Λ ≤ C; Λ > 0 (5.6)
where Λ = (λ1, ...., λl) , D = yiyjxi.xj for binary classification and the decision function
Eq.5.2 can be rewritten as:
f(x) = sign(
l∑
i=1
λ∗i (x · φ(x1)) + b∗) (5.7)
5.1.2 Transductive Support Vector Machines
Transductive support vector machines (TSVMs) is an extension of the standard SVM using
unlabelled data. It does not put a boundary in the high density regions and thereby builds a con-
nection between the decision boundary and the partially labelled data. In a standard SVM only
the labelled data is used, and the goal is to find a maximum margin linear boundary. In a TSVM
the unlabelled data is also used. The TSVM labels the unlabelled data, so that a linear bound-
ary has the maximum margin on both the original labelled data and the unlabelled data (later
labelled). The decision boundary has the smallest generalization error bound on unlabelled
data [359]. Intuitively, unlabelled data guides the linear boundary away from dense regions. In
TSVM, margin maximization in the presence of unlabelled examples can be interpreted as an
implementation of the cluster assumption.
Unlike traditional SVM, TSVM training procedure includes the information of test set St2
thus the learning function Eq.5.1 of inductive SVM can be written as,
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fL = L(St1, St2)
where : St1 = (x∗1, y
∗
1), (x
∗
2, y
∗
2), ...., (x
∗
n, y
∗
n), (5.8)
Consequently, in a linearly separable data case, to find a labelling y∗1, y
∗
2, ..., y
∗
n of the test
data, the hyperplane < w, b > should separate both training and test data with maximum mar-
gin:
min(y∗1, y
∗
2, ..., y
∗
3, w, b) :
1
2
wTw (5.9)
where : yt(w.xt + b) ≥ 1
y∗j (w
∗
j .x+ b) ≥ 1
The TSVM training procedure can be written as the following optimization problem, in
order to handle non-separable data:
min(y∗1, y
∗
2, ..., y
∗
3, w, b)ξ1, ..., ξn, ξ
∗
1 , ..., ξ
∗
k :
1
2
wTw + C(
L∑
i=1
ξi)
k + C(
K∑
j=1
ξ∗j )
k (5.10)
where : yi(w.φ(xi) + b) ≥ 1− ξi
y∗j (w.φ(x
∗
j) + b) ≥ 1− ξ∗j
Where C∗ is the effect factor of the test examples, and C∗ξ∗i is the effect term of the ith test
example in the above objective function [159].
5.2 Model Setup
The task of vaccine selection can also be seen as a classification problem. To this effect, we
apply both an inductive (SVM) and a transductive (TSVM) learning method to improve our
previous regression predictions. To enable comparison of results from our previous regression
analysis, we use sequence data as our input features in our SVM and TSVM models. We convert
the r1 values for viral strain pairs to labels depending on whether the r1 value denotes significant
antigenic similarity between the stain or the absence of it. Figure 5.3 provides an overview of
our approach.
101
Figure 5.3: Flowchart of Classification.
5.2.1 Scoring Methods
Scoring methods are used to determine the difference between a pair of aligned amino acid
sequences. Using our models we compared three different scoring methods i.e. ‘no weighting’,
‘grouping’ and ‘matrix scoring’ as we described in Sections 2.6 and 4.4.1.
5.2.2 Inductive Support Vector Machines
We used a modified finite Newton algorithm which was developed by Keerthi and DeCoste in
2005 [165] for Linear SVMs and is ideally suited for sparse datasets.
Given a binary classification problem with l labelled examples {xi, yi}li=1
where the input patterns xiRd and the labels yi{+1,−1}, to obtain a linear classifier y =
w · x+ b, this Newton modified L2-SVM algorithm solves the following primal problem:
w∗ = argminwRd
1
2
l∑
x=1
l2(y1w
Tx1) +
λ
2
|w|2 (5.11)
where l2 is the loss given by l2(z) = max(0, 1 − z)2, λ is a real-valued regularization pa-
rameter and w∗Tx is the final classifier. This modified version of the L2-SVM algorithm uses
the square of the hinge loss (quadratic soft margin loss function) as the loss function which
makes the objective function continuously differentiable, allowing easier applicability of gradi-
ent techniques and regularises the bias term “b”. The above equation implicitly assumes that an
additional component in the weight vector and a constant feature in the example vectors have
been added to incorporate the bias indirectly. This formulation combines the simplicity of a
least squares aspect with algorithmic advantages associated with SVMs.
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If w is a candidate solution, rewriting Eq. 5.11 in terms of support vector set j(w) =
i : yi(w
Txi) < 1, gives the following objective function
min
w
=
1
2
∑
ij(w)
cil2(y1w
Tx1) +
λ
2
|w|2 (5.12)
where ci is the cost of the loss associated with the ith.
And the gradient of f at w is given by:
5 f(w) = λw + CTj(w)Xj(w)[Xj(w)w − Yj(w)]
where Xj(w) is a matrix whose rows are the feature vectors of training points corresponding
to the index set j(w), Yj(w) is a column vector containing labels for these points, and Cj(w) is a
diagonal matrix that contains the costs ci for these points along its diagonal.
Mangasarian’s finite newton method [219] does iterations of the form
wk+1 = wk + δknk (5.13)
where the step size δkR, the search direction nk is based on a second order approximation
of the objective function at wk:
nk = −H(wk)−1Of(wk). Since f is not twice differentiable at w where at least one of the
di is zero, H(w) is taken to be the generalized Hessian defined by H(w) = λJ +CTDC where
J is the nxn identity matrix, C is a matrix whose rows are (xTi , 1) and D is a diagonal matrix
whose diagonal elements are given by:
Dii =

1 if tiyi(w)<1
some specific element of [0,1] if tiyi(w)=1
0 if tiyi(w)>1,
(5.14)
The overall efficiency of the method is improved by the condition that ensures indices satis-
fying tiyi(w) > 1 do not affect H(w) and nk. To ensure convergence the step size δk is found
by applying a halving method of line search in the [0,1] interval. Mangasarian (2002) showed
that if C in (1) is sufficiently small then the fixed step size, δk = 1 suffices for convergence.
The modified finite Newton algorithm (L2-SVM-MFN) has four main steps and they are as
follows:
• Initialisation: The simplest starting point is w0 = 0. For this point yi = 0 for all i and
so I0 = 1, ...,m. With a zero initialization as the above, the w obtained is exactly the
solution in Eq. 5.11.
If we have a w˜ for the weight vector w and if w˜ comes from an inexpensive classification
method, it is necessary to rescale w˜ and also choose aw0 that is good for starting the SVM
solution. So w0 is set to (γw˜, w0) and choose suitable values for γ and w0. Assuming
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that I, a guess of the optimal set of active indices, is available, γ and w0 are chosen to
minimize the cost
1
2
∑
iI
[γw˜ · xi + b0 − ti]2 + λ
2
[γ2‖w˜‖2+b20] (5.15)
The resulting γ and w0 are as follows:
γ = (p22q1 − p12q2)/d and b0 = (p11q2 − p12q1)/d.
where p11 = λ‖w˜‖2+
∑
iI(w˜ · xi)2, p22 = λ+ |I|, p12 =
∑
iI w˜ · xi, q1 =
∑
iI tiw˜ · xi,
q2 =
∑
iI ti and d = p11p22 − (p12)2. Once γ and w0 are obtained as above, b0 is set to
(γw˜, b0) and the algorithm is started.
• Checking Convergence: To check whether an optimal solution has been reached, the
algorithm first calculates yi(wk) and di(wk) for all i, determines the active index set Ik
and then checks whether ‖OfIk(wk)‖= 0 where OfIk(wk) is the gradient vector.
• Regularised Least Squares Solution: The solution of the objective function is ap-
proached using an iterative conjugate gradient method.
If X is a matrix whose rows are (xTi , iI
k; and t be a vector whose elements are ti, iIk
then the objective function becomes a regularised least squares problem
min
w
fIk(w) =
λ
2
‖w‖2+1
2
‖Xw − t‖2. (5.16)
which gives a solution of the normal form,
(λI +XTX)w = XT t. (5.17)
This implementation of L2-SVM uses a CGLS algorithm by Frommer and Maass 1999
[114] to solve Eq. 5.16 as follows:
Let w0 = wk. Compute z0 = t−Xw0, r0 = XT z0−λw0, set p0 = r0 and for j = 0, 1, ..
compute the following
qj = Xpj
γj = ‖rj‖2/(‖qj‖2 + λ‖pj‖2)
wj+1 = wj + γjpj
zj+1 = zj − γjqj
rj+1 = XT zj+1 − λwj+1
If rj+1 = 0 stop with wj+1 as the solution.
ωj = ‖rj+1‖2/‖rj‖2
pj+1 = rj+1 + ωjpj
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This algorithm takes at most l iterations to converge where l is the rank of X . l ≤
min{m,n} where m is the number of examples and n is the number of features.
The algorithm terminates when the negative gradient vector rj+1 is close to zero up
to some relative precision. If ‖rj+1‖≤ ‖X‖‖zj+1‖+‖λ‖wj+1‖ is used as the bound,
‖rj+1‖≤ (ρ‖zj+1‖+λ‖wj+1‖) where ρ = ‖X‖ is a good stopping criterion. Since X
varies at different major iterations of the L2-SVM-MFN algorithm, ρ is taken as ‖Xˆ‖
where Xˆ is the entire mxn data matrix. For all normalised data, the data matrix are in the
unity range and in such cases ‖X‖≤ √n. This algorithm takes a conservative approach
and maintains a stopping criterion
‖rj+1‖≤ ‖zj+1‖. (5.18)
where  is a relative tolerance parameter and its value is set to 10−6 by default as suggested
by Keerthi and DeCoste 2005 [165]. Termination of L2-SVM-MFN occurs when, after
the least squares solution exact line search gives wk+1 = w(i.e., δ∗ = 1), and the active
set remains unchanged, i.e., I(wk) = I(w) = I(wk+1).
• Exact Line Search: Let w(δ) = wk + δ(w − wk). To determine the minimiser of the
function, φ(δ) = f(w(δ)) the points at which the second derivative jumps, are computed.
For any given i, let: δi = (ti − yki )/(yi − yki ), where yi = yi(w) and yki = yi(wk). The
jump points for above are given by,
∆ = ∆1 ∪∆2, (5.19)
where
∆1 = δi : i ∈ Ik, ti(yi − yki ) > 0and∆2 = δi : i /∈ Ik, ti(yi − yki ) < 0. (5.20)
For ∆1, iwith ti(yi−yki ) ≤ 0 is not used because they do not cause switching at a positive
δ; similarly, for ∆2, i with ti(yi − yki ) ≥ 0 is not used. Take one δi ∈ ∆1. When δ across
δi is increased, the index i leaves I(w(δ)) and the term d2i /2 is left out of the objective
function for all δ > δi. Similarly, for δi ∈ ∆2, when δ across δi is increased, the index i
enters I(w(δ)) and the term d2i /2 is included in the objective function for all δ > δi. The
slope, φ´(δ) is a continuous piecewise linear function that changes its slope only at one of
the δi’s. The optimal point δ∗ is the point at which φ´(δ) crosses 0 and to determine this
point all δi’s in ∆ are sorted in non-decreasing order. If we assume that δi, i = 1, 2, ...
denotes that ordering and we know that between δi and δi+1, φ´(δ) is a linear function.
We extend this line on both sides to meet the δ = 0 and δ = 1 vertical lines and call the
ordinate values at the two meeting points li and ri respectively. As indices get dropped
and added to the active set of indices, it is very easy to keep track of the changes in li and
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li. Starting from δ = 0, we move from left to right to find the zero crossing of φ´(δ) and
between δ0 and δ1, Ik is the active set. From the definition of phi(δ),
l0 = λw
k · (w − wk) +
∑
i∈Ik
(yki − ti)(yi − yki ) (5.21)
and
r0 = λw · (w − wk) +
∑
i∈Ik
(yi − ti)(yi − yki ) (5.22)
Using the approximate termination as in Eq. 5.18 r0 is computed using Eq. 5.22. From
the above, the point where the line joining (0, l0) and (1, r0) points on the (δ, φ´) plane
crosses zero is found. If the zero crossing point of this line is between 0 and δ1 then that
point is δ∗. If not, the line search is moved between δ1 and δ2. Once the search moves,
l1 and r1 need to be computed which is done by updating over l0 and r0 since only the
term d2i /2 enters or leaves. Thus, for a general situation where li, ri is already computed
for the interval δi to δi+1 and li+1, ri+1 for the interval δi+1 to δi+2 needs to be computed.
This is done by using the formula
li+1 = li+s(y
k
i − ti)(yi − yki )
and
ri+1 = ri+s(y
k
i − ti)(yi − yki ) (5.23)
where s = −1 if δi ∈ ∆1 and s = 1 if δi ∈ ∆2. The line search keeps moving to the right
until reaching a zero that satisfies the condition that the root determined by interpolating
(0, li) and (1, ri) lies between δi and δi+1.
5.2.3 Transductive Support Vector Machines
We use an extension of the standard L− 2-SVM with the capability of handling unlabelled data
as implemented by Keerthi and DeCoste in 2005 [165] based on the algorithm proposed by
Joachims in 1999 [153].
If there are l labelled examples xi, yili=1 and u unlabelled examples {x´j}uj=1 with xi, x´j ∈ Rd
and yi ∈ −1,+1. Using the unlabelled data where l  u typically, TSVM constructs a linear
classifier sign(wTx).
This TSVM algorithm wraps around an SVM training procedure. The TSVM adds and
extra term to the SVM objective function to drive the classification hyperplane towards low
data density regions as follows:
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min
w,{y´j}uj=1
λ
2
‖w‖2+ 1
2l
l∑
i=1
l(yiw
Txi) +
λ´
2u
u∑
j=1
l(y´jw
T x´j)
subject to:
1
u
u∑
j=1
max[0.sign(wT x´j)] = r (5.24)
where the hinge loss function is given by l(z) = l1(z) = max(0, 1 − z) and the unlabelled
data, y´1...y´u, have values +1,−1. The SVM objective function is minimised when the TSVM
draws a hyperplane w and labels the unlabelled data considering that at least a fraction r of the
unlabelled data are classified positive. An initial estimate of r can be made from the fraction
of labelled examples that belong to the positive class but based on validation performance fine
tuning can be done. This optimization first uses an inductive SVM to label the unlabelled
data and then iteratively switches labels and retrains SVMs (discussed below) to improve the
objective function. In addition, this implementation of TSVM also switches more than one pair
of labels in each iteration.
In TSVM, margin maximisation can be looked at as being done by cluster assumption. In
Eq. 5.24, λ´ is a user-provided parameter to control the influence of unlabelled data such that,
if the data has distinct clusters with a large margin, but the cluster assumption does not hold,
then λ´ can be set to 0 and the standard SVM is retrieved. The L2-SVM-MFN retraining steps
in the inner loop of TSVM are typically executed extremely fast by using seeding techniques
(discussed below).
5.2.3.1 TSVM as an extension of L2-SVM-MFN
This TSVM implementation with L2-SVM-MFN, uses a TSVM objective function with the L2-
SVM loss function, l = l2.
min[l2(w
Tx), l2(−wTx)] = max[0, 1− |wTx|]2
Here, the absolute value of the output of the classifier on the unlabelled example x is rewrit-
ten in terms of the value of the label variable y that minimizes the loss on x.
The implementation of TSVM algorithm with L2-SVM-MFN is as follows:
• Run L2-SVM-MFN on just the labelled examples to obtain a classifier.
• Assign temporary labels to unlabelled data by thresholding the soft outputs of this claas-
sifier so that the fraction of the total number of unlabelled examples that are temporarily
labelled positive equals the parameter r.
• Gradually bring in the unlabelled data by starting from a small value of λ´, and then
increasing λ´ by a certain factor in the outer loop. This control over the influence of the
unlabelled data is a way to prevent TSVM from being immediately trapped in a local
minimum.
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• Use inner loop to identify pairs of unlabelled exam- ples with positive and negative tem-
porary labels such that switching these labels would decrease the objective function.
• Retrain L2-SVM-MFN with the switched labels.
5.2.3.2 Multiple Switching
Earlier versions of the TSVM algorithm [28, 153] involve switching a single pair of labels at
a time but this variant switches upto S pairs to improve the objective function. Keerthi and
Sindhwani,2006 [321] show that the multi-pair switching heuristic is remarkably effective in
speeding up TSVM training while maintaining generalization performance.
Here, S is a user controlled parameter. When it is set to 1, the TSVM algorithm is recovered,
while setting S = u/2 switches as many pairs as possible in the inner loop of TSVM. The multi-
switching is implemented as follows:
• Unlabelled examples with active indices(positive labels) are identified and corresponding
outputs are sorted in a list L+ in ascending order.
• Unlabelled examples with active indices(negative labels) are identified and corresponding
outputs are sorted in a list L− in descending order.
• Pairs of elements are picked, one each from the top of each list, until either a pair is found
such that the output from L+ is greater than the output from L−, or if S pairs have been
picked.
• Current labels of these pairs are switched.
5.2.3.3 Seeding
The efficiency of this algorithm is enhanced from seeding w in the re-training steps, after
switching labels or after increasing λ´. The complexity of the Transductive L2-SVM-MFN is
O(nswitchestmfntcglsn0), where n switches is the number of label switches. And, the value of
nswitches depends on the data set and on the number of labelled examples.
5.3 Results and Discussions
This section presents the results of comparing the performance of SVM and TSVM models with
those obtained from our best regression model i.e non-linear regression with GA in the previous
chapter. To create training and validation data sets we use serological test results (r1/HI assay
values) and the sequence data from the alignment files. The serological data results are con-
verted to classification labels (using the serological gold standard value as the threshold as the
margin to label the data) for classification while the sequence data from pairwise comparisons
are used with three types of scoring methods (refer to Section 2.6 for details), outputs of which
are used as the features. For the features, two setups are considered (directly comparable to
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the input variables of the regression models. In one case the amino acid changes on the capsid
protein(s) are totalled (herein referred to as ‘no loops’), and in the other case, the changes in the
three antigenic regions are counted separately (referred to as ‘loops’).
5.3.1 Datasets
For supervised learning we used the same FMDV and influenza datasets (refer to Section 4.5.1
for details) that we used in our regression models and also used Ebola [155] data in addition.
For semi-supervised learning with TSVM we used complete genome sequences downloaded
from the GenBank website (http://www.ncbi.nlm.nih.gov/genbank/)[30]. Accession numbers
of all sequences can be found in Appendix A and C. The proportion of labelled to unlabelled
are as follows: 1) For FMDV Serotype SAT2, we used 22 labelled and 51 unlabelled data. 2)
For FMDV Serotype SAT1, we used 19 labelled and 55 unlabelled data. The labelled data for
SAT1 and SAT2 was taken from taken from Reeve et al. [290]. 3) For Ebola Zaire, we used
24 labelled and 104 unlabelled data. The labelled was taken from MacNeil et al. [216]. 4) For
influenza, we used 54 labelled and 99 unlabelled data. The labelled data was taken from taken
from Liao et al. [202].
Amino acid sequences of a particular viral serotype were harmonised to the same length
(743 residues for SAT2 comprising viral proteins (VP) 1-3, 735 residues for A similarly com-
prising (VP) 1-3, 349 residues for HA1 gene of H3N2 and 684 residues for Ebola nucleoprotein
NP.) by obtaining a multiple sequence alignment using ClustalW [343]. The alignment files
for FMDV SAT2 and influenza H3N2 can be found in Appendix F. This alignment was used to
identify substitutions between the pairs of sequences for which the serological data was avail-
able.
We have used two different approaches to build the models. In one we have used substitu-
tions only from specific antigenic regions, two regions in VP1 and one in VP2 [290] for FMDV
(SAT2 and A), three regions in H3N2 HA1 [192] and for Ebola we use two set-ups, in one we
use three most antigenically reactive regions (peptides FLS, RLM and KLT) and in the other,
we include two other regions (peptides AMN and YOG) that are low reactive epitopes [337] in
Ebola Zaire NP (For details of Ebola and its antigenic regions, refer to Section 2.1.4. We com-
pare the results of only the dataset where we consider three highly antigenic regions of Ebola
for all models (LR, NLR with LS and GA, SVM and TSVM). While we include the results
with the five antigenic regions in Ebola, to compare the results of TSVM using three antigenic
regions. In the other approach, we have used substitutions in all three capsid proteins (VP1,
VP2 and VP3) for SAT2 and A, the entire HA1 sequence for H3N2 and the entire NP sequence
of Ebola Zaire. These substitutions were the input features for our SVM and TSVM models.
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5.3.2 Comparison of SVM, TSVM and GA Optimised Non-Linear Re-
gression Models
Table 5.1 presents a comparison of the performance results for SVM and TSVM from our
analysis and also compares them with the results of the best regression model all using the
same six scoring methods (for details refer to Section 2.6).
• FMDV serotype SAT2: Both TSVM and NLR with GA gave the smallest error rate
of 0 for FMDV SAT2 using the grouping methods with loops. TSVM gave the lower
error rates than SVM and NLR with GA for five out of the six scoring methods. SVM
performed the worst out of the three. SVM did worse than the quadratic regression models
with GA when it came to the giving fewer false positives than false negatives. The other
two models improved on the SVM model reducing the number of false positives across
all the scoring matrices and in particular giving no false positives for the models with the
grouping method (looped).
• FMDV serotype SAT1: TSVM gave the smallest error rate of 1 for FMDV SAT1 using
the grouping methods with loops. TSVM gave lower error rates than SVM and NLR with
GA for all the six scoring methods while SVM performed the worst of the three models.
While SVM gave one model for which the number of false positives was less than the
number of false negatives, TSVM and NLR with GA both gave two models each that
produced no false positives.
• Ebola: Both TSVM and NLR with GA gave the smallest error rate of 2 for Ebola using
the grouping methods with loops. However, the TSVM model had high specificity and
sensitivity than the NLR with GA. TSVM gave lower error rates than all the six SVM
models and for five out six NLR with GA models.
The proportion of false positives were greater than the false negatives for all the SVM
models while TSVM and NLR with GA both gave two models with lower false positives
than false negatives.
• Influenza A: TSVM gave the smallest error rate of 2 for influenza A using the grouping
methods with loops. TSVM gave lower error rates than SVM and NLR with GA for all
the six scoring methods while SVM performed the worst of the three models. While SVM
gave one model for which the number of false positives was less than the number of false
negatives, TSVM and NLR with GA both gave two models each that produced less false
positives than false negatives.
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Figure 5.4: Comparison of accuracy of SVM, TSVM and non-linear regression model with GA
(NLR-GA) using different weighting methods for antigenic regions and whole capsid proteins
for Ebola. Key: L-with loops, NL-no loops, NW-Non-weighted, G-grouped, MS-matrix scored.
Figure 5.5: Comparison of accuracy of SVM, TSVM and non-linear regression model with GA
(NLR-GA) using weighting methods for antigenic regions and whole capsid proteins for FMDV
SAT2. Key: L-with loops, NL-no loops, NW-Non-weighted, G-grouped, MS-matrix scored.
The grouping method performs the best out of the three. The grouping method had an
accuracy of at least 20% greater than the matrix scoring method and at least 10% greater than
the non-weighted approach across all datasets. The lower rates correspond to models involving
residues in the capsid protein(s). The grouping method that classifies amino acids based on their
biochemical properties distinguishes between amino acid substitutions based on their relevance
to the overall protein structure and thus would be expected to enhance the classification rate.
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Figure 5.6: Comparison of accuracy of SVM, TSVM and non-linear regression with GA (NLR-
GA) using weighting methods for antigenic regions and whole capsid proteins for influenza A.
Key: L-with loops, NL-no loops, NW-Non-weighted, G-grouped, MS-matrix scored.
The 20 amino acids have different properties and not all substitutions are equally important for
measuring antigenic variability. It is also known that certain amino acid substitutions are more
common than others [32] (also refer to Section 3.5.3.3 for more details).
Figures 5.4,5.5 and 5.6 show the accuracy of SVM, TSVM and NLR with GA for Ebola,
FMDV SAT2 and influenza A using the six different scoring methods. For all the datasets, it
can be seen that the accuracy is enhanced by the use of unlabelled data.
TSVM has been seen to outperform inductive SVM models with small to medium size
datasets [160] and these results demonstrate the same. TSVM has been seen to perform well
even with small amounts of labelled data [138] which is supported by these results considering
that all of our datasets have small a number of labelled data. Genomic data is also known
to be sparse and generalization from this sparse data space often leads to over-fitting. Over-
fitting arises in areas where number of training patterns is relatively small due to the number
of features. In semi-supervised learning, the informal decision in labelling samples can lead
to better generalization. In our study, the transductive SVM model performs better than the
inductive SVM in all of the six experimental setups and across all datasets. And comparing
the performance of SVM against the semi-supervised TSVM, the benefit of unlabelled data for
boosting generalization performance is evident on all datasets. It indicates that TSVM exploits
the unlabelled data distribution for better classification. Adding every unlabelled sample to the
training set shifts and rotates the hyperplane slightly, and this extra information leads the current
hyperplane to the optimal solution.
5.3.3 Comparison of TSVM Models Using Three and Five Antigenic Re-
gions
Since our TSVM results with the Ebola dataset was not as good as the ones with the other
datasets, we decided to use additional antigenic areas in the NP in our TSVM model, to see
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whether they would contribute to a better model. In our previous TSVM model we used three
active binding epitopes on the Ebola NP, namely FLS, KLT and RLM reported by Sundar et al.
[337]. And in this part, we add two other epitopes (AMN and YQG) that have been reported as
generating strong antibody response but were non-binding. We consider only the looped models
since the unlooped models sum up the substitutions in the entire NP and hence is not relevant
in terms of testing the effect of including additional antigenic epitopes in our model.
We report the results of our comparison as accuracy of the models and present them in Fig-
ure 5.7. We can see from the figure that the performance of TSVM models for three and five
antigenic epitopes was almost identical. For the grouped model, the five epitope model per-
formed 2% better and for the non-weighted and the matrix scored methods, the three epitopes
model performed 1% and 2% better than their comparative five epitopes model.
Even though our TSVM results with Ebola are promising, we think that the Ebola dataset
does not perform as well compared to the other datasets because the substitutions in the anti-
genic epitopes that we use in our models might not be best representative of the antigenic regions
that are correlates of the r values and also probably because of the quality of the labelled data
that we have used. On close inspection of the dataset, it was seen that out of the 24 sequences,
only three had r values above 0.2 and none above 0.4. This poor spread of data could have
resulted in a relatively lower performance of the TSVM algorithm with Ebola data. In addition,
there has been no in vivo tests that yet confirms the antigen binding ability of these peptide
motifs [102, 316]. Other factors that could be the length of the antigenic peptide and hence
the number of the substitution or the inclusion other amino acids which may act as secondary
anchor residues [90, 297, 394].
Figure 5.7: A comparison of accuracy of TSVM models using three and five different antigenic
regions with different weighting methods for Ebola. Key: L:-with loops, NW:-Non-weighted,
G:-grouped, S:-matrix scored, TSVM-3A:-TSVM with three epitopes and TSVM-5A:-TSVM
with five epitopes.
We think that the additional two peptides in our five epitope model failed to make much
difference to the performance of TSVM because the substitutions in these two epitopes were
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probably not significant in terms of relaying any effect on the antigenic values which we use as
our labels. The FLS, RLM and KLT epitopes used in our three epitope model, have been shown
to correlate to high human leukocyte antigen stabilisation while AMN and YOG epitopes used
additionally in the five epitope model, were seen to be non-binders when synthetic peptides
were evaluated in vitro even though they were predicted to be antigentically relevant in in silico
prediction [337].
5.3.4 Hypothesis Testing
We carried out a statistical test to see whether our best model (TSVM) performed better than
the SVM and the non-linear regression with GA using the same scoring methods. The result of
the test was;
For the SVM model, the r2 (coefficient of determination of the regression line) was 0.686
and p value (probability of obtaining the observed sample results when the null hypothesis is
actually true) was 0.005 and for the non-linear model with GA r2 was 0.787 and p was 0.00023.
However, for our TSVM model r2 was 0.801; p was 0.00012. The above results show that
TSVM has both r2 and p values better than the SVM and the quadratic regression model with
GA. Thus we reject the null hypothesis that the TSVM model performs better than the SVM
and the quadratic regression with GA models even though the results of the TSVM and the
quadratic regression with GA are very similar. Even though the modelling results for TSVM
and quadratic regression with GA were very similar in many cases, the results of hypothesis
testing has clearly established TSVM as the better performing.
5.3.5 Test Results with Unseen Data
We tested our SVM and TSVM models with the five additional pairwise comparisons of FMDV
A sequences (provided by The Pirbright Institute) that we had tested our regression models with
and compared the results. The TSVM model was able to correctly classify 9 out of 10 for the 10
strains we used for testing. Thus we can say that it achieved an accuracy of 90% on the actual
serological data and thereby exceeded the performance of the non-linear regression with GA
model by 10%. The SVM model performed similarly to the non-linear regression model using
LS and the linear model as it correctly classified six out of the 10 unseen sequences (refer to
Section 4.5.5 for complete results of regression models).
It was seen that for the TSVM model, the r1 value for the sequence that was misclassified
was actually very close to the threshold that we define for labelling the data and thus using
more labelled data that would provide a greater range of inputs would probably improve the
performance of our TSVM model. Similarly for the SVM model, it was seen that the four
misclassifications were again for r1 values that were very close to the class margin. No such
association between incorrect prediction and closeness of the actual r1 value to the regression
threshold was seen in the linear regression and the non-linear regression with LS models. This
also makes us believe that more labelled
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Table 5.2: Comparison of predicted and actual r1 values using our grouping method with SVM,
TSVM and the NLR with GA. Key: St 1-Vaccine strain 1 (IRQ/24/64), St 2-Vaccine strain 2
(TUR/20/06). For the regression model we report the predicted value and for the classification
models we report the predicted label.
Challenge Model Predicted Actual
Strain St 1 St 2 St 1 St 2
IRN/07/13 NLR-GA 0.17 0.29 0.15 0.25
TSVM 0 0
SVM 0 1
IRN/35/12 NLR-GA 0.15 0.39 0.18 0.45
TSVM 0 1
SVM 0 1
TUR/05/12 NLR-GA 0.53 0.25 0.24 0.28
TSVM 0 1
SVM 1 1
IRN/01/13 NLR-GA 0.20 0.29 0.095 0.221
TSVM 0 0
SVM 0 0
SAU/23/86 NLR-GA 0.56 0.11 0.1 0.14
TSVM 0 0
SVM 0 0
data would enable us to achieve better results with SVM than the linear regression and the
non-linear regression with LS models.
Table 5.2 gives a summary of the results. These results clearly demonstrate that the addi-
tion of unlabelled data enhances the predictive power of models when labelled data is limited.
However, it will also be interesting to see how much of an improvement, availability of more
labelled data would make to the TSVM model.
5.3.6 Discussion
We compared two different classification models namely, SVM and TSVM and also compared
their results with those of the best performing model (NLR with GA) from our regression anal-
ysis in the previous chapter.
All of these models were further compared based on the presence/absence of specific anti-
genic loops for FMDV, influenza and Ebola. The looped models performed in the range of
10 − 40% better than the unlooped models in six out of nine pairs of ‘looped and unlooped’
models presented in the previous section. Of the remaining three pairs, one pair performed the
same while in the other two, the unlooped performed marginally better (in the range of 2− 5%)
than the unlooped. These three models used no scoring method to weigh the amino acid substi-
tutions, unlike the other six models which either used the grouped or the matrix scored methods.
The looped models used amino acid changes in different antigenic areas as different features
while the unlooped models summed up the substitutions across the entire capsid protein and in
116
the process may have lost important biologically significant information that could lead to poor
results.
The classification accuracy of the grouped looped models was best among all the weighted
and the non-weighted models. The grouped model which assigns weights to the amino acid
substitutions based on biochemical properties has a clear advantage over the non-weighted ap-
proach where all substitutions regardless of their functional significance were added. The scor-
ing method did not perform well as we think that the normalisation of the PAM-120 matrix to
penalise only the non-frequent substitutions may have over complicated the scoring setup. We
also think that using a more suitable PAM evolutionary matrix (discussed in future work in the
next chapter) might improve the results with matrix scoring.
Serological data is difficult and expensive to obtain and remains a bottleneck in obtaining
robust and accurate classifiers using such data. Our labelled datasets being quite small, we used
available unlabelled data to build a semi-supervised model implementing a TSVM. An induc-
tive SVM with a small dataset finds it difficult to create a global model (function) that would
be valid for the whole problem space and thus the use of additional information in iterative
retraining of the TSVM greatly enhances the model performance of a TSVM compared to an
SVM particularly when labelled data is limited which is reflected in our results as the TSVM
model outperforms the SVM. The SVM models perform worse that the TSVM models because
of the small training data which can result in over-fitting as model variance has been seen to be
inversely proportional to sample size [45].
Our three and five epitope TSVM models perform almost identically, as the substitutions
in the additional two epitopes in the latter model, provide no additional information for better
prediction. These two epitopes were seen to be non-binding in in vitro tests even though they
were predicted as antigenically relevant in in silico prediction. Even though the results of TSVM
were promising for Ebola, further in vivo studies in non-human primates are needed to confirm
their ability to confer protection.
Semi-supervised algorithms are valuable in applied scenarios where sparse classification
problems arise frequently, labelled data is scarce and plenty of unlabelled data is easily avail-
able. Even in situations where a good number of labelled examples are available, utilizing
unlabelled data to obtain a semi-supervised solution using these algorithms can be worthwhile.
For one thing, the semi- supervised solutions never lag behind purely supervised solutions in
terms of performance. The presence of a mix of labelled and unlabelled data can provide added
benefits such as reducing performance variability and stabilizing the linear classifier weights.
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Chapter 6
Discussion and Future Work
In this report we have analysed and discussed the relationship between antigenic similarity and
amino acid substitutions to find any existing patterns (linear/non-linear relationship) in Chap-
ter 3 before using that information to extract further regularities/relationship using linear and
non-linear regression models in Chapter 4, to explore their potential to predict actual antigenic
similarity values. Predicting the output as the exact antigenic similarity (r1) value is not essen-
tial as prediction of a class label would be indicative enough of whether a vaccine strain would
provide protection against a wild viral strain. Hence, we convert our vaccine prediction problem
to a classification problem in Chapter 5. Below we discuss the theoretical motivations behind
our choosing the various analysis and modelling methods that we employed and implemented
to extend our understanding and contribute towards advancing in silico vaccine prediction tech-
niques. We also discuss our contributions and future work that we think could be taken up to
further advance the field of computational vaccine prediction.
6.1 Antigenic Similarity Correlated to Amino Acid Substitu-
tions in External Capsid Proteins
Many studies have been carried out to clarify the manner by which viruses escape antibody
pressure. Mechanisms by which the viral capsid molecule escapes neutralization by neutralis-
ing antibodies has been studied in several studies [269, 387, 303, 319, 176, 97]. Amino acid
substitutions in the viral capsid protein can result in escape from neutralising antibodies, affect
viral fitness, and change receptor preference. In influenza, Wilson and Cox [382] and Plotkin
et al. [276] reported that multiple antigenic sites have changed in recent H3 virus epidemic
strains. Bush et al. [50], Suzuki and Gojobori [338], and Plotkin and Dushoff [275] stressed the
positive selection of certain amino acid residues in the H3HA protein. This seems to explain
the accumulation of amino acid changes in restricted regions. In FMDV serotypes O, A and
C, antigenic sites in VP2 were shown to be immunologically important [210, 269, 303] and
mutations within these sites were able to affect antigenicity of these viruses.
We explored the correlation between antigenic similarity and amino acid substitutions in
the capsid proteins of FMDV (SAT1 and SAT2 serotypes) and influenza type A. Both FMDV
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and influenza showed a moderate to strong negative correlation between antigenic similarity
(r1 values) and the total count of amino acid substitutions in their outer capsid proteins i.e as
the number of substitutions increase in the outer capsid proteins between a pair of sequences,
their antigenic similarity reduces. These results were in line with the findings reported in the
above mentioned literature. We also had a setup to check the correlation between antigenic
similarity and the number of amino acid substitutions only in the antigenic areas (that we used
for modelling in the Chapters 4 and 5) on the capsid proteins. We wanted to see whether
choosing only the antigenic areas would result in a stronger correlation. However, the results
did not indicate any stronger correlation between amino acid substitutions only in the antigenic
areas compared to when substitutions in the entire capsid were considered. The correlation
coefficient values that we obtained were very similar which we think were because there are
probably more non-linear relationships between amino acid combinations that could not be
detected by the correlation plots.
Studies also suggest that synonymous mutations1 in FMDV play a major role in the evo-
lution of this virus [61, 304, 224]. A study done on FMDV type C found that the antigenic
variation attained over 6 decades was due to fluctuations among limited combinations of amino
acid residues without net accumulation of amino acid replacements over time [224]. When we
plot the correlation between antigentic similarity and count of specific types of antigenic substi-
tutions, no clear linear relationship was seen. Most plots showed a weak positive correlation i.e.
an increase in the number of frequently occurring amino acid changes between sequences, cor-
responding to a higher r1 value (indicating that the strains are antigenically similar). This is in
line with the theory of selection pressure whereby, in nature, substitutions of an amino acid with
another amino acid with similar properties is permissible, with the overall structure/function of
the protein remaining unchanged. Hence substitutions between similar (biochemically) amino
acids are more frequent and consequently has little effect on the function (degree of antigenic-
ity) of the resultant protein. This could also mean that there are non-linear relationships between
such substitutions that were not picked up by our correlation studies.
In addition to the above correlation analyses, we also carried out some initial analysis where
we considered substitutions across the entire viral sequence (not just the external capsid protein)
and the results showed no clear linear correlation (the correlation plots can be found in Appendix
E) which is probably because the entire viral sequence would have accumulated substitutions
which have no effect on the antigenicity of the virus.
The results from our correlation analysis definitively showed a correlation between amino
acid substitutions in the capsid proteins and antigenic similarity. These were encouraging
enough for us to employ linear and non-linear modelling methods to extract regularities/patterns
to give us more biological insight.
1A synonymous substitution alters the amino acid sequence of a protein while a non-synonymous substitution
does not alter the amino acid sequence [308].
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6.2 Linear and Evolutionary Non-linear Modelling for Se-
lecting Vaccines
As the correlation results above demonstrated amino acid substitutions in the capsid proteins as
direct correlates of antigenic similarity, our fist modelling step was to implement a simple linear
regression model using least squares estimation to predict vaccine efficacy against a field strain.
However, our correlation results also indicated possible interactions between amino acids that
were not linear. To date, in silico approaches for predicting vaccine efficacy have focussed on
the use of linear and logistic regression techniques ( Reeve et al. [290] use linear mixed effects
models to relate estimated antigenic differences to sequence variation in FMDV and Liao et al.
[202] use stepwise and logistic regression to predict antigenic variants in influenza). However,
as vaccine efficacy relies on the interaction of amino acid residues within or outside an antigenic
site (loop) [194] that may results in unusual (non-linear) patterns in antigenic distance [191] it
is likely that non-linear models, that can handle complex interdependencies between variables,
will be better suited. We also know that the structure of a protein is effected not just by the
neighbouring amino acids in its 2D conformation but also its neighbours as a results of how the
protein folds in 3D and hence we naturally progressed to fit our data into a non-linear model.
We chose regression as our first step to model our vaccine prediction data because of the nature
of our serological data which were continuous values. We found that the performance of the
non-linear models was consistently better than the linear models. These regression models
have a much larger number of terms than their linear counterparts. In other words, the non-
linear models have a much higher complexity than that of the linear models. This implies
that the relationship between the variables may be highly non-linear and there is a complex
additive effect of two or more types of amino acid substitutions, which can be better explained
by quadratic terms.
In addition to least squares estimation, we also use GA to optimise the parameters of the
quadratic regression model. Liao et al. have used a multiple regression model to predict the anti-
genic similarity between influenza sequences, and have reported an agreement rate of 91.67%
for their best model [202] while Reeve et al. have reported 98% and 77% (for different serotypes
of FMDV) agreement rate for their linear mixed effects model [290]. Compared to these mod-
els which have also used cross-reactivity essay and sequence data, our non-linear model with
GA has achieved a higher agreement rate (100%). Thus evolutionary optimisation techniques
might be an important tool in improving our models considering that cross-reactivity values
might be a complex function of the effects of many interlinked amino acid substitutions making
parameter estimation a challenge. We show that our model is an improvement to the approaches
previously taken and this is also the first time an evolutionary algorithm has been used to predict
vaccine efficacy.
In the above set-up, we used the NSGA-II algorithm in a SO setup with minimisation of
the mean squared error as the objective function. We noticed that some of our less performing
models (unlooped models) had a higher number of type II error (false positives) compared to
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type I errors (false negatives) and this resulted in us implementing a MO optimisation setup
with two objectives, i.e. minimising both the probability of type I and type II errors. In our
MO optimisation setup we see an overall error rate improvement of 1-13% and type II error
reduction of 4-12% compared to the SO optimisation set-up. In our case, where we worked
with small datasets, our results show that MO optimisation increases generalisation as it has
the potential to conduct a better search of the parameter space by providing diverse solutions
(Pareto front) by carrying out the trade-off between objectives rather than optimising on a global
error as in the single objective setup.
In all of the above linear and non-linear models, to examine whether there are differences in
the influence of amino acid changes in different capsid proteins on the Virus Neutralisation (VN)
titre/Haemagglutination inhibition (HI) assay value we compare two approaches for calculating
amino acid changes, one reporting the total number of changes across all capsid proteins (three
capsid proteins in FMDV and one in influenza) i.e. the ‘unlooped’ model, while the other
reporting specific-capsid changes i.e. the ‘looped’ model. Our lopped models performed better
than our unlooped models for all linear and non-linear models which show that only the specific
antigenic regions on the capsid protein(s) are most relevant for modelling. When substitutions in
the capsid(s) are summarised, important information for prediction may be overlooked resulting
in poor results.
Finally, we studied two methods for weighting the importance of amino acid changes, one
based on the characteristics and structure of amino acids and the other based on amino acid sub-
stitution scores (PAM/BLOSUM). The implementation of the scoring methods was an extension
of the correlation analysis that we carried out for specific types of amino acid substitutions. As
we know that in nature, certain types of substitutions are favoured above others, we wanted to
weigh the amino acid substitutions in the capsid proteins based on their biochemical proper-
ties to add a biological dimension to our models. Out of the weighted and the non-weighted
methods, the grouping method performed best among the three, which is probably because the
grouping method classifies amino acids based on their biochemical properties that enhances
the models. The non-weighted approach considers all substitutions and regardless of structural
relevance includes frequent substitutions of little significance to the model. The matrix scoring
method performed unexpectedly low probably because a significant amount of biological data
was lost when the substitution matrix was normalised to penalise only the non-frequent sub-
stitutions. We used a PAM 120 matrix for our matrix scoring method while a range of other
PAM matrices (PAM 40, PAM 140, PAM 250 etc) are available, where the lower PAM matrices
will tend to find short alignments of highly similar sequences, and higher PAM matrices will
find longer, weaker local alignments. We also think that our choice of PAM matrix might have
been restrictive in terms of penalising even the slightest of substitutions and hence the use of
the other PAM matrices could be explored in future.
121
6.3 Semi-supervised Classification for Vaccine Prediction
Our vaccine selection problem is not limited to predicting exact antigenic similarity (r1) values.
Our problem definition requires predicting whether a field strain is antigenically similar enough
(or not) to the vaccine strain based on a cutoff value, which meant that we could also explore
classification methods to model our variables.
We use support vector machines (SVMs) [43] as our choice of classifier. SVM has been
very broadly applied within the field of computational biology, in secondary protein structure
prediction [369], microarray gene expression studies [47], detection of protein structural and
evolutionary relationships [201], recognition of translation initiation sites [396], interpretation
of peptide tandem mass spectrometry data in proteomics [7] and prediction of protein-protein
binding sites [44]. SVMs deal better with high dimensional noisy data than other statistical
or machine learning methods and hence to work well when applied to biological problems
[256]. In addition, unlike other machine learning methods they are flexible in modelling with
diverse sources of data such as variable length sequences and other non-vector inputs [256]. We
compare the results of SVM with those obtained in the previous part of our work. We see that,
even though the overall agreement rates of our SVM models is very similar to our non-linear
regression with GA models, the type II errors of our SVM models is higher than our non-linear
models with GA.
As biological data can be noisy and/or viral strains partially labelled (dataset contains only
sequence data but not serological data) [17, 200], a predictor that can be trained with imperfect
data is needed. Studies show that the use of unlabelled data in conjunction with labelled data
improves the learning performance [124, 318, 57]. Semi-supervised learning techniques have
been effective used in solving biological problems such as sequence segmentation and labelling
of genetic data [152], gene expression measurement [63], protein classification [373], peptide
identification from shotgun proteomics [156], extraction of protein interaction sentences [95],
prediction of transcription factor-gene interactions [96] and cancer diagnostics based on gene
profiling [15, 177] to name a few. Semi-supervised learning methods exploit unlabelled data in
addition to labelled data to improve the learning process of a machine learning algorithm [56].
Unlabelled training samples are fairly easily available from databases like GenBank while la-
belled data is expensive to obtain since this case are dependent on having access to VN data.
We use FMDV, influenza and Ebola sequences from GenBank as partially labelled data in a
TSVM model to alleviate the problem of limited labelled data. Our TSVM models outperform
our SVM models for all our datasets i.e. FMDV, influenza and Ebola. TSVM has been seen to
outperform inductive SVM models with small to medium size datasets and these results demon-
strate the same. Genomic data is also know to be sparse and generalization from this sparse data
space often leads to over fitting. Over fitting arises in areas the number of training patterns is
relatively small due to the number of features. In semi-supervised learning, the informal deci-
sion in labelling samples can lead to better generalization. Comparing the performance of SVM
against the semi-supervised TSVM, the benefit of unlabelled data for boosting generalization
performance is evident on all datasets. It indicates that TSVM exploits unlabelled data distribu-
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tion for better classification. Adding every unlabelled sample the training set shifts and rotates
the hyperplane slightly, and this extra information leads the current hyperplane to the optimal
solution. We also modified our TSVM setup to include two additional epitopes of Ebola. How-
ever, the inclusion of additional sequence positions had no effect on the prediction ability of the
model. We think that this is because the additional two peptides were probably not significant
in terms of relaying any effect on the antigenic values which we use as our labels.
Even though adding additional epitopes made no noticeable improvement to the TSVM
model in the Ebola dataset, we think that adding additional antigenic regions (supported by
review of literature) could be used as a way to improve the specificity of our TSVM models.
The probability of a success with influenza and FMDV data is probably higher owing to the fact
that their epitopes are better characterised and verified than for Ebola.
Another future direction for this work could be the application of heterogeneous ensemble
techniques with a combination of the models to form an integrated model. Ensemble learning
involves generating the base learners from the training data and then combining them to form
the composite predictor [113]. Studies addressing classification problems have demonstrated
that ensembles perform much better than any single base learner [133, 86, 83] since the main
purpose of these classification methods is to achieve strong generalisation by using multiple
base learners [395]. This will be particularly useful in in silico vaccine selection the case of
highly variable viruses like FMDV and influenza where model performance could vary for
different datasets of the same virus. Thus a ensemble could be a step towards designing a broad
spectrum vaccine.
The progress made here signifies a step towards successfully selecting vaccines with very
limited serological data. However, much investigation is still needed to understand the biolog-
ical complexity of the mechanisms used by viruses to escape antibody neutralisation. There
also needs to be more initiatives in the direction of developing more reliable preclinical animal
models to test vaccines.
An additional approach is to combine your model with knowledge of three bases that then
to change irrespective of antibody selective pressure. So if there is a change which has a low
probability of being involved then this is scored lower than another with a high probability of
being linked to selective pressure. There is a current project in progression at the Pirbright
institute to establish the ‘background’ changes in FMDV and those changes that occur in the
virus to escape immunopressure.
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Appendix A: GenBank Accession
Numbers of FMDV Sequences
Table A.1: GenBank Accession numbers for all SAT1 sequences.
Serotype Virus strain GenBank Accession No.
SAT1 KNP/196/91 AF283429
SAT1 KNP/148/91 GU194495
SAT1 ZIM/HV/3/9 GU194496
SAT1 ZIM/GN/13/90 GU194497
SAT1 KNP/41/95 GU194498
SAT1 SAR/9/81 DQ009715
SAT1 NAM/307/98 AY770519
SAT1 ZIM/6/94 GU194500
SAT1 TAN/37/99 DQ009718
SAT1 ZAM/2/93 DQ009719
SAT1 ZIM/25/90 GU194499
SAT1 MOZ/3/02 DQ009720
SAT1 KEN/5/98 DQ009721
SAT1 UGA/3/99 DQ009722
SAT1 UGA/1/97 AY043300
SAT1 NIG/5/81 DQ009723
SAT1 SUD/3/76 DQ009725
SAT1 NIG/15/75 DQ009724
SAT1 NIG/8/76 GU194503
SAT1 NIG/6/76 GU194502
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Table A.2: GenBank Accession numbers for all SAT2 sequences.
Serotype Virus strain GenBank Accession No.
SAT2 KNP/19/89 DQ009735
SAT2 KNP/2/89 GU194488
SAT2 KNP/51/93 GU194489
SAT2 ZIM/1/88 GU194491
SAT2 SAR/16/83 DQ009734
SAT2 ZIM/14/90 DQ009728
SAT2 ZIM/17/91 DQ009727
SAT2 ZIM/GN/10/91 GU194493
SAT2 RHO/1/48 AJ251475
SAT2 ZIM/7/83 AF540910
SAT2 ZIM/34/90 GU194490
SAT2 ZIM/8/94 GU194492
SAT2 KEN/8/99 AY254730
SAT2 GHA/8/91 DQ009732
SAT2 SEN/5/75 DQ009738
SAT2 SEN/7/83 DQ009733
SAT2 SAU/6/00 AY297948
SAT2 ERI/12/89 GU194494
SAT2 RWA/2/01 DQ009730
SAT2 ANG/4/74 DQ009736
SAT2 UGA/2/02 DQ009731
SAT2 ZAI/1/74 DQ009737
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Appendix B: Datasets of FMDV Sequences
Table B.3: Dataset for pairs of SAT2 sequences when sequence RWA/2/01 was taken as vaccine.
Field virus strain r1 value
ANG/4/74 0.027676568
ERI/12/89 0.29564168
GHA/8/91 0.279337725
GN/10/91 0.077194134
KEN/8/99 0.024408438
KNP/19/89 0.052054422
KNP/2/89 0.150665333
KNP/51/93 0.098774863
RHO/1/48 0.395387164
RWA/2/01 1
SAR/16/83 0.069651168
SEN/5/75 0.024408438
SEN/7/83 0.497844012
UGA/2/02 0.043663142
ZAI/1/74 0.099570155
ZIM/1/88 0.098716931
ZIM/14/90 0.061886687
ZIM/17/91 0.224639099
ZIM/7/83 0.167155492
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Table B.4: Dataset for pairs of SAT2 sequences when sequence KNP/19/89 was taken as vac-
cine.
Field virus strain r1 value
ANG/4/74 0.05762371
ERI/12/89 0.294457523
GHA/8/91 0.071855511
GN/10/91 0.062678127
KEN/8/99 0.053178442
KNP/19/89 1
KNP/2/89 0.126558043
KNP/51/93 0.076321413
RHO/1/48 0.090675525
RWA/2/01 0.082963004
SAR/16/83 0.037321891
SAU/6/00 0.046302066
SEN/5/75 0.044022925
SEN/7/83 0.223391841
UGA/2/02 0.035655886
ZAI/1/74 0.049219127
ZIM/1/88 0.073614681
ZIM/14/90 0.07537143
ZIM/17/91 0.052410708
ZIM/34/90 0.116784584
ZIM/7/83 0.309894849
ZIM/8/94 0.050050536
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Table B.5: Dataset for pairs of SAT2 sequences when sequence ERI/12/89 was taken as vaccine.
Field virus strain r1 value
ANG/4/74 0.031033801
ERI/12/89 1
GHA/8/91 0.174364199
GN/10/91 0.065456919
KEN/8/99 0.034438871
KNP/19/89 0.247830365
KNP/2/89 0.09310118
KNP/51/93 0.110084977
RHO/1/48 0.208111223
RWA/2/01 0.160496064
SAR/16/83 0.051919876
SAU/6/00 0.311198863
SEN/5/75 0.02736924
SEN/7/83 0.319434343
UGA/2/02 0.049136851
ZAI/1/74 0.077584502
ZIM/1/88 0.097943066
ZIM/14/90 0.09263428
ZIM/17/91 0.110084977
ZIM/7/83 0.137685294
Table B.6: Dataset for pairs of SAT1 sequences when sequence KNP/196/91 was taken as
vaccine.
Field virus strain r1 value
KEN/5/98 0.318239955
KNP/148/91 0.318127774
KNP/196/91 1
KNP/41/95 0.350225449
MOZ/3/02 0.364650797
NAM/307/98 0.195951536
NIG/15/75 0.169181412
NIG/5/81 0.20000972
NIG/6/76 0.110620614
NIG/8/76 0.339047027
SAR/9/81 0.387432146
SUD/3/76 0.225139968
TAN/37/99 0.339047027
UGA/1/97 0.240893781
UGA/3/99 0.240707214
ZAM/2/93 0.114729899
ZIM/25/90 0.116359972
ZIM/6/94 0.310643014
ZIM/GN/13/90 0.529683336
ZIM/HV/3/90 0.456516834
128
Table B.7: Dataset for pairs of SAT1 sequences when sequence NIG/5/81 was taken as vaccine.
Field virus strain r1 value
KEN/5/98 0.305384043
KNP/148/91 0.3481485
KNP/196/91 0.202080256
KNP/41/95 0.197000992
MOZ/3/02 0.433547045
NAM/307/98 0.269740406
NIG/15/75 0.161557217
NIG/5/81 1
NIG/6/76 0.223656929
NIG/8/76 0.238419088
SAR/9/81 0.313873911
SUD/3/76 0.602938064
TAN/37/99 0.332934137
UGA/1/97 0.267246304
UGA/3/99 0.424269876
ZAM/2/93 0.103008819
ZIM/6/94 0.148700561
ZIM/GN/13/90 0.213263946
ZIM/HV/3/90 0.266560644
129
Appendix C: Datasets of Influenza
Sequences with GenBank Accession
Numbers
Table C.8: Dataset for pairs of influenza H3N4 sequences when sequence A/PORT
CHALMERS/1/1973 was taken as vaccine.
GenBank Acc. No. Field virus strain r1 value
CY021093 A/Albany/20/1974 1.072
AY661018 A/Bilthoven/5146/74 3.06
AY661042 A/Bilthoven/5930/74 1.072
AY661017 A/Bilthoven/5931/74 1.072
AY661027 A/Bilthoven/7398/74 2.281
AY661005 A/Bilthoven/9459/74 1.072
CY003496 A/Hong Kong/14/74 1.072
CY006907 A/Hong Kong/49/74 1.072
CY006715 A/Memphis/101/74 1.072
CY006819 A/Memphis/102/74 1.072
CY006827 A/Memphis/103/74 1.072
CY021077 A/Albany/42/1975 1.072
CY006044 A/Beijing/39/75 2.406
AY661043 A/Bilthoven/2600/75 2.281
AY661028 A/Bilthoven/2813/75 2.281
EF626614 A/England/864/1975 3.552
CY003728 A/Hong Kong/43/75 2.406
EF626616 A/Mayo Clinic/1/1975 3.042
EF626621 A/Singapore/4/1975 3.774
EF626622 A/Tokyo/1/1975 3.294
EF626609 A/Victoria/ A/3/1975 2.829
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Table C.9: Dataset for pairs of influenza H3N4 sequences when sequence A/VICTORIA/3/1975
was taken as vaccine.
GenBank Acc. No. Field virus strain r1 value
CY021941 A/Albany/1/1976 0.423
CY021829 A/Albany/15/1976 0.423
AY661006 A/Bilthoven/1761/76 0.423
AY661007 A/Bilthoven/2271/76 2.795
AY661008 A/Bilthoven/5029/76 0.423
AY661009 A/Bilthoven/5657/76 0.423
AY661044 A/Bilthoven/628/76 2.795
AY661010 A/Bilthoven/6545/76 0.423
CY006883 A/Memphis/103/76 0.423
CY012192 A/Memphis/104/1976 0.423
CY009060 A/Memphis/105/76 0.423
CY008692 A/Memphis/106/76 0.423
CY008700 A/Memphis/108/76 0.423
CY006835 A/Memphis/110/76 0.423
CY006723 A/Memphis/137/76 0.423
CY021101 A/Albany/4/1977 0.423
AY661045 A/Amsterdam/1609/77 0.423
AY661011 A/Bilthoven/3895/77 0.423
X05907 A/England/321/77 1.797
CY006731 A/Memphis/1/77 1.797
CY008115 A/Memphis/2/77 1.797
CY006739 A/Memphis/3/77 1.797
CY008123 A/Memphis/4/77 1.797
CY006843 A/Memphis/5/77 1.797
CY006763 A/Nanjing/49/77 2.473
AY661012 A/Rotterdam/5828/77 1.632
AY661013 A/Rotterdam/8179/77 0.423
EF626623 A/Texas/1/1977 1.797
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Table C.10: Dataset for pairs of influenza H3N4 sequences when sequence
A/PHILLIPINES/2/1982 was taken as vaccine.
GenBank Acc. No. Field virus strain r1 value
AF008870 A/Texas/18733/84 1.211
AF008901 A/Bangkok/25/85 0.716
AF008899 A/Bangkok/85 1.116
AF405211 A/Baylor5B/85 2.299
AF008908 A/Cheng-mei/4/85 0
AF008895 A/Christchurch/1/85 1.116
AF008896 A/Christchurch/4/1985 1.116
AF008876 A/Fukuoka/C29/85 2.216
AY661051 A/Guildford/V728/85 0.716
AF008900 A/Gumma/346/85 1.116
CY003520 A/Hong Kong/24/85 1.116
CY003504 A/Hong Kong/6/85 1.116
CY003536 A/Hong Kong/7/85 1.116
M57631 A/Houston/24269/85 3.478
CY011472 A/Memphis/12/1985 1.116
CY009068 A/Memphis/2/85 0.716
CY008668 A/Memphis/25/85 0.716
CY008452 A/Memphis/5/85 0.716
CY008708 A/Memphis/7/85 0.716
AF008872 A/Michigan/1/85 0.716
AF008893 A/Mississippi/1/85 1.116
AY661049 A/Netherlands/330/85 0.716
AF008873 A/New Jersey/4/85 0.716
AY661052 A/Stockholm/10/85 0.716
AF008865 A/Stockholm/4/85 1.116
AF008898 A/Stockholm/8/85 0.716
AF008874 A/Texas/24752/85 0.716
AF008891 A/Texas/24753/85 1.788
AF008892 A/Texas/25784/85 0.716
AF008866 A/Texas/25887/85 0.716
AF008906 A/Tonga/23/85 1.116
AF008864 A/USSR/26/85 0.716
AF092063 A/Wellington/4/85 0.716
AF008902 A/Yamagata/96/85 0.716
AF008877 A/Yamaneshi/497/85 3.901
AF008904 A/Yokohama/C5/85 1.116
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Table C.11: Dataset for pairs of influenza H3N4 sequences when sequence
A/SHANGHAI/11/1987 was taken as vaccine.
GenBank Acc. No. Field virus strain r1 value
AY661071 A/Atlanta/211/89 0.998
D49962 A/Bangkok/235/89 1.759
D43786 A/Beijing/352/89 2.505
DQ508833 A/Beijing/353/1989 3.161
L19000 A/Beijing/4/89 1.398
AF008662 A/Beijing/57/89 0.998
AF008672 A/Czechoslovakia/19/89 1.398
AF008664 A/England/648/89 2.207
AY661057 A/Geneva/5007/89 0.998
AF008667 A/Guangdong/16/89 0.998
L19004 A/Guangdong/39/89 0.998
AF008665 A/Guizhou/54/1989 0.998
D49960 A/Hokkaido/20/89 1.398
AY661059 A/Hong Kong/1/89 1.952
AY661067 A/Netherlands/620/89 0.998
AY661068 A/Netherlands/650/89 1.398
ISDN13403 A/Netherlands/738/89 1.821
D49964 A/OMS/7026/89 0.298
AF386605 A/Seoul/16/89 4.049
AF008669 A/Shanghai/1/89 0.998
AF008668 A/Shanghai/16/89 0.998
AF008663 A/Sichuan/18/89 0.998
L20114 A/Singapore/12/89 0.998
L20118 A/Singapore/13/89 0.998
AY661060 A/Singapore/34/89 0.998
AY661061 A/Singapore/35/89 0.998
AY661062 A/Singapore/36/89 0.998
AY661063 A/Singapore/40/89 0.998
AY661064 A/Singapore/53/89 0.998
AY661065 A/Victoria/1/89 0.4
AF008673 A/Victoria/5/89 3.782
AY661058 A/Wellington/5/89 0.998
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Appendix D: Heatmaps of Specific Amino
Acid Substitutions in FMDV Serotypes
SAT1 and SAT2
Two-dimensional hierarchical clustering of viruses and the count of specific antigenic substitu-
tions for SAT1 and SAT2. Viruses were clustered according to the number of substitutions of a
particular type (red for the least frequent while white for the most frequent) along the vertical
axis. Simultaneously, the type of substitutions were arranged along the horizontal axis. The
color key for neutralization data points is shown in the histogram in the top left of each plot
along with the frequency of count of the specific amino acid substitution.
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Figure 6.1: Heat map of specific amino acid substitutions for SAT1 KNP/196/91.
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Figure 6.2: Heat map of specific amino acid substitutions for SAT1 NIG/5/81.
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Figure 6.3: Heat map of specific amino acid substitutions for SAT2 ERI/12/89.
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Figure 6.4: Heat map of specific amino acid substitutions for SAT2 KNP/19/89.
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Appendix E: Correlation of All Amino
Acid Substitutions in FMDV Serotype A
Figure 6.5: Correlation of all amino acid substitutions for FMDV A TUR20/06. The Pearson’s
correlation coefficient was -0.248 with a p-value of 0.079 (not statistically significant).
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Figure 6.6: Correlation of all amino acid substitutions for FMDV A IRQ24/64. The Pearson’s
correlation coefficient was -0.238 with a p-value of 0.092 (not statistically significant).
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Appendix F: Multiple Alignment of FMDV
SAT2 and Influenza H3N2
Figure 6.7: Multiple Alignment of FMDV SAT2 sequences-Part I. The antigenic areas that we
consider in this study are highlighted within a black outlined box.
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Figure 6.8: Multiple Alignment of FMDV SAT2 sequences-Part II. The antigenic areas that we
consider in this study are highlighted within a black outlined box.
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Figure 6.9: Multiple Alignment of FMDV SAT2 sequences-Part III. The antigenic areas that we
consider in this study are highlighted within a black outlined box.
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Figure 6.10: Multiple Alignment of FMDV SAT2 sequences-Part IV. The antigenic areas that
we consider in this study are highlighted within a black outlined box.
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Figure 6.11: Multiple Alignment of FMDV SAT2 sequences-Part V. The antigenic areas that
we consider in this study are highlighted within a black outlined box.
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Figure 6.12: Multiple Alignment of FMDV SAT2 sequences-Part VI. The antigenic areas that
we consider in this study are highlighted within a black outlined box.
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Figure 6.13: Multiple Alignment of influenza H3N2 sequences-Part I. The antigenic areas that
we consider in this study are highlighted within a black outlined box.
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Figure 6.14: Multiple Alignment of influenza H3N2 sequences-Part II. The antigenic areas that
we consider in this study are highlighted within a black outlined box.
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Figure 6.15: Multiple Alignment of influenza H3N2 sequences-Part III. The antigenic areas that
we consider in this study are highlighted within a black outlined box.
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Figure 6.16: Multiple Alignment of influenza H3N2 sequences-Part IV. The antigenic areas that
we consider in this study are highlighted within a black outlined box.
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Figure 6.17: Multiple Alignment of influenza H3N2 sequences-Part V. The antigenic areas that
we consider in this study are highlighted within a black outlined box.
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Figure 6.18: Multiple Alignment of influenza H3N2 sequences-Part VI. The antigenic areas
that we consider in this study are highlighted within a black outlined box.
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Figure 6.19: Multiple Alignment of influenza H3N2 sequences-Part VII. The antigenic areas
that we consider in this study are highlighted within a black outlined box.
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Figure 6.20: Multiple Alignment of influenza H3N2 sequences-Part VIII. The antigenic areas
that we consider in this study are highlighted within a black outlined box.
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